ZA200606597B - Substituted heteroaryl-and phenylsulfamoyl compounds - Google Patents
Substituted heteroaryl-and phenylsulfamoyl compounds Download PDFInfo
- Publication number
- ZA200606597B ZA200606597B ZA200606597A ZA200606597A ZA200606597B ZA 200606597 B ZA200606597 B ZA 200606597B ZA 200606597 A ZA200606597 A ZA 200606597A ZA 200606597 A ZA200606597 A ZA 200606597A ZA 200606597 B ZA200606597 B ZA 200606597B
- Authority
- ZA
- South Africa
- Prior art keywords
- yield
- benzoic acid
- halo
- methyl
- phenyl
- Prior art date
Links
- -1 phenylsulfamoyl compounds Chemical class 0.000 title claims description 118
- 150000001875 compounds Chemical class 0.000 claims description 298
- 125000005843 halogen group Chemical group 0.000 claims description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 62
- 239000002253 acid Substances 0.000 claims description 58
- 150000003839 salts Chemical class 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- 229910052799 carbon Inorganic materials 0.000 claims description 40
- 125000003545 alkoxy group Chemical group 0.000 claims description 32
- 239000003981 vehicle Substances 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 21
- 229910052717 sulfur Chemical group 0.000 claims description 16
- 125000004414 alkyl thio group Chemical group 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000000335 thiazolyl group Chemical group 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 13
- 125000002971 oxazolyl group Chemical group 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 125000002837 carbocyclic group Chemical group 0.000 claims description 7
- 239000011593 sulfur Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 229910052792 caesium Inorganic materials 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 2
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 229960004365 benzoic acid Drugs 0.000 description 156
- 239000005711 Benzoic acid Substances 0.000 description 155
- 238000005481 NMR spectroscopy Methods 0.000 description 116
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
- 238000000034 method Methods 0.000 description 95
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 94
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 79
- 239000000203 mixture Substances 0.000 description 63
- 239000000126 substance Substances 0.000 description 63
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 59
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 51
- 235000010233 benzoic acid Nutrition 0.000 description 50
- 150000004702 methyl esters Chemical class 0.000 description 49
- 239000003112 inhibitor Substances 0.000 description 48
- 229940002612 prodrug Drugs 0.000 description 48
- 239000000651 prodrug Substances 0.000 description 48
- 150000002148 esters Chemical class 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 37
- 230000000694 effects Effects 0.000 description 37
- 238000011282 treatment Methods 0.000 description 36
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 239000000460 chlorine Chemical group 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 29
- 235000021588 free fatty acids Nutrition 0.000 description 29
- 230000002829 reductive effect Effects 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 29
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- 102000004877 Insulin Human genes 0.000 description 26
- 108090001061 Insulin Proteins 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 26
- 229940125396 insulin Drugs 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- 241000282849 Ruminantia Species 0.000 description 25
- 239000007787 solid Substances 0.000 description 25
- 150000003626 triacylglycerols Chemical class 0.000 description 25
- 241000283690 Bos taurus Species 0.000 description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 23
- 235000013336 milk Nutrition 0.000 description 23
- 239000008267 milk Substances 0.000 description 23
- 210000004080 milk Anatomy 0.000 description 23
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 239000008103 glucose Substances 0.000 description 22
- 229910052757 nitrogen Inorganic materials 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 20
- 239000002585 base Substances 0.000 description 20
- 150000002632 lipids Chemical class 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 235000012000 cholesterol Nutrition 0.000 description 19
- 206010012601 diabetes mellitus Diseases 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 19
- 239000003826 tablet Substances 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 201000001320 Atherosclerosis Diseases 0.000 description 17
- 102000004366 Glucosidases Human genes 0.000 description 17
- 108010056771 Glucosidases Proteins 0.000 description 17
- 108010010234 HDL Lipoproteins Proteins 0.000 description 17
- 102000015779 HDL Lipoproteins Human genes 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 15
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- 238000010992 reflux Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 239000007858 starting material Substances 0.000 description 15
- 239000012267 brine Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 229910000027 potassium carbonate Inorganic materials 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 238000012289 standard assay Methods 0.000 description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 14
- 208000006011 Stroke Diseases 0.000 description 13
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 13
- 239000002775 capsule Substances 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 12
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 239000000556 agonist Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 150000002576 ketones Chemical class 0.000 description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 150000001448 anilines Chemical class 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- 238000010979 pH adjustment Methods 0.000 description 9
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 208000001145 Metabolic Syndrome Diseases 0.000 description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 8
- 239000003392 amylase inhibitor Substances 0.000 description 8
- 229940030600 antihypertensive agent Drugs 0.000 description 8
- 239000002220 antihypertensive agent Substances 0.000 description 8
- 235000013365 dairy product Nutrition 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 108020001756 ligand binding domains Proteins 0.000 description 8
- 235000001968 nicotinic acid Nutrition 0.000 description 8
- 239000011664 nicotinic acid Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- 208000005189 Embolism Diseases 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 229960000528 amlodipine Drugs 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 229920000609 methyl cellulose Polymers 0.000 description 7
- 239000001923 methylcellulose Substances 0.000 description 7
- 235000010981 methylcellulose Nutrition 0.000 description 7
- 229960003512 nicotinic acid Drugs 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 230000036284 oxygen consumption Effects 0.000 description 7
- 230000032696 parturition Effects 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 6
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 6
- 208000004930 Fatty Liver Diseases 0.000 description 6
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 102000005720 Glutathione transferase Human genes 0.000 description 6
- 206010019708 Hepatic steatosis Diseases 0.000 description 6
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 6
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 6
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 6
- 102100027441 Nucleobindin-2 Human genes 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229960004005 amlodipine besylate Drugs 0.000 description 6
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000010706 fatty liver disease Diseases 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 150000002828 nitro derivatives Chemical class 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 5
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 5
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 5
- 229940122816 Amylase inhibitor Drugs 0.000 description 5
- 229940127291 Calcium channel antagonist Drugs 0.000 description 5
- 208000002249 Diabetes Complications Diseases 0.000 description 5
- 206010012655 Diabetic complications Diseases 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000002705 Glucose Intolerance Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 208000018262 Peripheral vascular disease Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 description 5
- 229940123464 Thiazolidinedione Drugs 0.000 description 5
- 206010046793 Uterine inflammation Diseases 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000003288 aldose reductase inhibitor Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000000480 calcium channel blocker Substances 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 5
- 238000003305 oral gavage Methods 0.000 description 5
- 238000002638 palliative care Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 description 5
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 4
- FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 description 4
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 4
- VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical compound NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 4
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 4
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 4
- 102000007592 Apolipoproteins Human genes 0.000 description 4
- 108010071619 Apolipoproteins Proteins 0.000 description 4
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- 229940122498 Gene expression inhibitor Drugs 0.000 description 4
- 108010000775 Hydroxymethylglutaryl-CoA synthase Proteins 0.000 description 4
- 102100028888 Hydroxymethylglutaryl-CoA synthase, cytoplasmic Human genes 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 208000007976 Ketosis Diseases 0.000 description 4
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 4
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 4
- 229940119502 Squalene cyclase inhibitor Drugs 0.000 description 4
- 229940123185 Squalene epoxidase inhibitor Drugs 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- YVPOVOVZCOOSBQ-AXHZAXLDSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2s)-2-methylbutanoate;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 YVPOVOVZCOOSBQ-AXHZAXLDSA-N 0.000 description 4
- 229960002632 acarbose Drugs 0.000 description 4
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 108010004469 allophycocyanin Proteins 0.000 description 4
- 239000000883 anti-obesity agent Substances 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 229940125710 antiobesity agent Drugs 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 229920000080 bile acid sequestrant Polymers 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000009109 curative therapy Methods 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 229940125753 fibrate Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 125000002346 iodo group Chemical group I* 0.000 description 4
- 239000003456 ion exchange resin Substances 0.000 description 4
- 229920003303 ion-exchange polymer Polymers 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 230000004140 ketosis Effects 0.000 description 4
- 230000006651 lactation Effects 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 229960004844 lovastatin Drugs 0.000 description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 4
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 4
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 201000009104 prediabetes syndrome Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 239000003087 receptor blocking agent Substances 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical class SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- AXBVSRMHOPMXBA-UHFFFAOYSA-N 4-nitrothiophenol Chemical compound [O-][N+](=O)C1=CC=C(S)C=C1 AXBVSRMHOPMXBA-UHFFFAOYSA-N 0.000 description 3
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 3
- 101710095342 Apolipoprotein B Proteins 0.000 description 3
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 3
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 3
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 3
- 238000006751 Mitsunobu reaction Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 239000004100 Oxytetracycline Substances 0.000 description 3
- 101150014691 PPARA gene Proteins 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
- 208000003142 Retained Placenta Diseases 0.000 description 3
- 206010038758 Retained placenta or membranes Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 229930186167 Trestatin Natural products 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 239000003529 anticholesteremic agent Substances 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 229960005370 atorvastatin Drugs 0.000 description 3
- 229960001770 atorvastatin calcium Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000003935 benzaldehydes Chemical class 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 229960005110 cerivastatin Drugs 0.000 description 3
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 230000001906 cholesterol absorption Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000016097 disease of metabolism Diseases 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 3
- 229960000588 flunixin Drugs 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 229960003765 fluvastatin Drugs 0.000 description 3
- 238000001640 fractional crystallisation Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 3
- 229960000991 ketoprofen Drugs 0.000 description 3
- 208000030175 lameness Diseases 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 235000021243 milk fat Nutrition 0.000 description 3
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229960000625 oxytetracycline Drugs 0.000 description 3
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 3
- 235000019366 oxytetracycline Nutrition 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229960002965 pravastatin Drugs 0.000 description 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 3
- 229960003015 rimonabant Drugs 0.000 description 3
- 229960000672 rosuvastatin Drugs 0.000 description 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 235000016804 zinc Nutrition 0.000 description 3
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 2
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- FOZFSEMFCIPOSZ-SPCKQMHLSA-N (2r,3r,4r,5s)-2-(hydroxymethyl)-1-[[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl]piperidine-3,4,5-triol;trihydrate Chemical compound O.O.O.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 FOZFSEMFCIPOSZ-SPCKQMHLSA-N 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 description 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical class NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- BNRRWFHXFMJHDW-UHFFFAOYSA-N 1-benzylsulfanyl-2-nitrobenzene Chemical class [O-][N+](=O)C1=CC=CC=C1SCC1=CC=CC=C1 BNRRWFHXFMJHDW-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- IQOMYCGTGFGDFN-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 IQOMYCGTGFGDFN-UHFFFAOYSA-N 0.000 description 2
- WEDWQCPYKKZMDF-UHFFFAOYSA-N 2-[5-[5-[5-[3,4-dihydroxy-6-methyl-5-[[4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydro Chemical compound OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC(C(C1O)O)C(CO)OC1OC(C(C1O)O)C(CO)OC1OC1OC(CO)C(O)C(O)C1O WEDWQCPYKKZMDF-UHFFFAOYSA-N 0.000 description 2
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 description 2
- CGMMPMYKMDITEA-UHFFFAOYSA-N 2-ethylbenzoic acid Chemical compound CCC1=CC=CC=C1C(O)=O CGMMPMYKMDITEA-UHFFFAOYSA-N 0.000 description 2
- TWBPWBPGNQWFSJ-UHFFFAOYSA-N 2-phenylaniline Chemical class NC1=CC=CC=C1C1=CC=CC=C1 TWBPWBPGNQWFSJ-UHFFFAOYSA-N 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
- XZYQBYQGHHGXBC-UHFFFAOYSA-N 4-(1,3-benzoxazol-2-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=NC2=CC=CC=C2O1 XZYQBYQGHHGXBC-UHFFFAOYSA-N 0.000 description 2
- FHOZTGQNSUZCIN-UHFFFAOYSA-N 4-(4-tert-butylphenoxy)aniline Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C(N)C=C1 FHOZTGQNSUZCIN-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- PBKSPEYJKHLFKC-UHFFFAOYSA-N 4-[[4-(trifluoromethoxy)phenyl]methylsulfanyl]aniline Chemical compound C1=CC(N)=CC=C1SCC1=CC=C(OC(F)(F)F)C=C1 PBKSPEYJKHLFKC-UHFFFAOYSA-N 0.000 description 2
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 2
- FIIDVVUUWRJXLF-UHFFFAOYSA-N 4-phenylmethoxyaniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=CC=C1 FIIDVVUUWRJXLF-UHFFFAOYSA-N 0.000 description 2
- SGIZECXZFLAGBW-UHFFFAOYSA-N 5-benzylidene-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1=CC1=CC=CC=C1 SGIZECXZFLAGBW-UHFFFAOYSA-N 0.000 description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 102000016912 Aldehyde Reductase Human genes 0.000 description 2
- 108010053754 Aldehyde reductase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 2
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 2
- 102000006410 Apoproteins Human genes 0.000 description 2
- 108010083590 Apoproteins Proteins 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 108010051479 Bombesin Proteins 0.000 description 2
- 102000013585 Bombesin Human genes 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 101710150887 Cholecystokinin A Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010021024 Hypolipidaemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 108010007859 Lisinopril Proteins 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 2
- 102100034028 Membrane-bound transcription factor site-1 protease Human genes 0.000 description 2
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- FOVOSQIGVKWZFK-UHFFFAOYSA-N OBO.C1=CC=CC=C1 Chemical class OBO.C1=CC=CC=C1 FOVOSQIGVKWZFK-UHFFFAOYSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 229920002065 Pluronic® P 105 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000011191 Pulmonary vascular disease Diseases 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- OCTNNXHKAOLDJL-BMGYQPLYSA-N Salbostatin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)OC[C@@H]1N[C@@H]1[C@H](O)[C@@H](O)[C@H](O)C(CO)=C1 OCTNNXHKAOLDJL-BMGYQPLYSA-N 0.000 description 2
- OCTNNXHKAOLDJL-UHFFFAOYSA-N Salbostatin Natural products OC1C(O)C(CO)OCC1NC1C(O)C(O)C(O)C(CO)=C1 OCTNNXHKAOLDJL-UHFFFAOYSA-N 0.000 description 2
- 102000005782 Squalene Monooxygenase Human genes 0.000 description 2
- 229940123495 Squalene synthetase inhibitor Drugs 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229930194936 Tylosin Natural products 0.000 description 2
- 239000004182 Tylosin Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000009982 Ventricular Dysfunction Diseases 0.000 description 2
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 2
- VXDSGTRNDFHIJB-QQPOVDNESA-N [(1s,4ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 description 2
- 210000003165 abomasum Anatomy 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 2
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 230000003555 analeptic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000001986 anti-endotoxic effect Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002253 anti-ischaemic effect Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940127226 anticholesterol agent Drugs 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 229940124537 antidiarrhoeal agent Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 2
- PERZMHJGZKHNGU-JGYWJTCASA-N bambermycin Chemical compound O([C@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H]([C@H](O1)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1NC(C)=O)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@H](O1)C(=O)NC=1C(CCC=1O)=O)O)C)[C@H]1[C@@H](OP(O)(=O)OC[C@@H](OC\C=C(/C)CC\C=C\C(C)(C)CCC(=C)C\C=C(/C)CCC=C(C)C)C(O)=O)O[C@H](C(O)=O)[C@@](C)(O)[C@@H]1OC(N)=O PERZMHJGZKHNGU-JGYWJTCASA-N 0.000 description 2
- 229940050390 benzoate Drugs 0.000 description 2
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
- 229960002802 bromocriptine Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 229950001261 camiglibose Drugs 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 2
- 229960004475 chlortetracycline Drugs 0.000 description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 2
- 235000019365 chlortetracycline Nutrition 0.000 description 2
- 230000003081 coactivator Effects 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- USVZFSNDGFNNJT-UHFFFAOYSA-N cyclopenta-1,4-dien-1-yl(diphenyl)phosphane (2,3-dichlorocyclopenta-1,4-dien-1-yl)-diphenylphosphane iron(2+) Chemical compound [Fe++].c1cc[c-](c1)P(c1ccccc1)c1ccccc1.Clc1c(cc[c-]1Cl)P(c1ccccc1)c1ccccc1 USVZFSNDGFNNJT-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 229950003040 dalvastatin Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- VXDSGTRNDFHIJB-UHFFFAOYSA-N dihydrocompactin Natural products C12C(OC(=O)C(C)CC)CCCC2C=CC(C)C1CCC1CC(O)CC(=O)O1 VXDSGTRNDFHIJB-UHFFFAOYSA-N 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 208000010515 dystocia Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 229950000269 emiglitate Drugs 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960003580 felodipine Drugs 0.000 description 2
- NYPJDWWKZLNGGM-UHFFFAOYSA-N fenvalerate Chemical compound C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960003760 florfenicol Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 229960004427 isradipine Drugs 0.000 description 2
- 229960004340 lacidipine Drugs 0.000 description 2
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 2
- 229960004294 lercanidipine Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- GPSDUZXPYCFOSQ-UHFFFAOYSA-N m-toluic acid Chemical compound CC1=CC=CC(C(O)=O)=C1 GPSDUZXPYCFOSQ-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 2
- 229960003963 manidipine Drugs 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 229960001929 meloxicam Drugs 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 229950009116 mevastatin Drugs 0.000 description 2
- 229960004438 mibefradil Drugs 0.000 description 2
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 2
- 229960001110 miglitol Drugs 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229960001783 nicardipine Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 229960000715 nimodipine Drugs 0.000 description 2
- 229960000227 nisoldipine Drugs 0.000 description 2
- 229960005425 nitrendipine Drugs 0.000 description 2
- 229940036132 norvasc Drugs 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000000590 parasiticidal effect Effects 0.000 description 2
- 239000002297 parasiticide Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000003614 peroxisome proliferator Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 101150075122 ppard gene Proteins 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical group N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 229960003401 ramipril Drugs 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000003169 respiratory stimulant agent Substances 0.000 description 2
- 229940066293 respiratory stimulants Drugs 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 238000001877 single-ion monitoring Methods 0.000 description 2
- 108010048078 site 1 membrane-bound transcription factor peptidase Proteins 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000004059 squalene synthase inhibitor Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 108091008672 sterol hormone receptors Proteins 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 108010037401 tendamistate Proteins 0.000 description 2
- 230000035924 thermogenesis Effects 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 239000003749 thyromimetic agent Substances 0.000 description 2
- 230000000929 thyromimetic effect Effects 0.000 description 2
- 231100000621 toxification Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 229960004059 tylosin Drugs 0.000 description 2
- 235000019375 tylosin Nutrition 0.000 description 2
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000006815 ventricular dysfunction Effects 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229960001729 voglibose Drugs 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- 238000011680 zucker rat Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KAATUXNTWXVJKI-NSHGMRRFSA-N (1R)-cis-(alphaS)-cypermethrin Chemical compound CC1(C)[C@@H](C=C(Cl)Cl)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-NSHGMRRFSA-N 0.000 description 1
- NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
- VCIPQQCYKMORDY-KBYFLBCBSA-N (2r,3r,4s,5s,6r)-2-(hydroxymethyl)-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]piperidine-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)N[C@@H]1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCIPQQCYKMORDY-KBYFLBCBSA-N 0.000 description 1
- PYVAAPGPTLLDGV-AGKSRYJLSA-N (2r,3r,4s,5s,6r)-2-[(2r,3r,4r,5s,6r)-5-[(2r,3r,4r,5s,6r)-5-[(2r,3r,4r,5s,6r)-5-[(2r,3r,4s,5s,6r)-5-[[(1s,4r,5r,6s)-4-[(2s,3r,4r,5s,6r)-5-[(2r,3r,4s,5s,6r)-3,4-dihydroxy-6-methyl-5-[[(1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino] Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@H](C)[C@H]([C@@H]([C@H]1O)O)N[C@@H]1[C@H](O)[C@@H](O)[C@@H](C(=C1)CO)O[C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYVAAPGPTLLDGV-AGKSRYJLSA-N 0.000 description 1
- AMNXBQPRODZJQR-DITALETJSA-N (2s)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-n-[(1r)-2-hydroxy-1-phenylethyl]acetamide Chemical compound C1([C@@H](C=2C=CC=C(C=2)CN2C3=CC=CC=C3C3=C(C)C=C(N=C32)C)C(=O)N[C@@H](CO)C=2C=CC=CC=2)CCCC1 AMNXBQPRODZJQR-DITALETJSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- FXAAOALUHHXBSO-ILDUYXDCSA-N (3,3,5-trimethylcyclohexyl) (2s)-5-oxopyrrolidine-2-carboxylate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)[C@H]1NC(=O)CC1 FXAAOALUHHXBSO-ILDUYXDCSA-N 0.000 description 1
- IQWWTJDRVBWBEL-UHFFFAOYSA-N (3,5-dimethylphenyl)methanol Chemical compound CC1=CC(C)=CC(CO)=C1 IQWWTJDRVBWBEL-UHFFFAOYSA-N 0.000 description 1
- UGZUUTHZEATQAM-UHFFFAOYSA-N (4-butylphenyl)boronic acid Chemical compound CCCCC1=CC=C(B(O)O)C=C1 UGZUUTHZEATQAM-UHFFFAOYSA-N 0.000 description 1
- QJLPWVUZFKETMK-LLVKDONJSA-N (5r)-1,5,7,9,11,14-hexahydroxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carboxylic acid Chemical compound O=C1C2=C(O)C=C(O)C=C2C(=O)C2=C1C(O)=C1C[C@@H](O)C(C=C(C(=C3O)C(O)=O)C)=C3C1=C2O QJLPWVUZFKETMK-LLVKDONJSA-N 0.000 description 1
- FMZXNVLFJHCSAF-DNVCBOLYSA-N (6R,7R)-3-[(4-carbamoyl-1-pyridin-1-iumyl)methyl]-8-oxo-7-[(1-oxo-2-thiophen-2-ylethyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CC=3SC=CC=3)[C@H]2SC1 FMZXNVLFJHCSAF-DNVCBOLYSA-N 0.000 description 1
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- XFDJYSQDBULQSI-QFIPXVFZSA-N (R)-doxapram Chemical compound C([C@H]1CN(C(C1(C=1C=CC=CC=1)C=1C=CC=CC=1)=O)CC)CN1CCOCC1 XFDJYSQDBULQSI-QFIPXVFZSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- BPALXSWPHQNCAA-RLJNYRALSA-N (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e)-2-[2-(phenoxymethyl)-1,3-dioxolan-2-yl]ethenyl]cyclopentyl]hept-5-enoic acid Chemical compound OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C1(COC=2C=CC=CC=2)OCCO1 BPALXSWPHQNCAA-RLJNYRALSA-N 0.000 description 1
- TZNOWAJJWCGILX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OC(=O)\C=C/C(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl TZNOWAJJWCGILX-BTJKTKAUSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- JPBLHOJFMBOCAF-UHFFFAOYSA-N 1,3-benzoxazol-2-amine Chemical compound C1=CC=C2OC(N)=NC2=C1 JPBLHOJFMBOCAF-UHFFFAOYSA-N 0.000 description 1
- RQIOWTFXBGZVAC-UHFFFAOYSA-N 1,3-difluoro-5-[(4-nitrophenyl)sulfanylmethyl]benzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1SCC1=CC(F)=CC(F)=C1 RQIOWTFXBGZVAC-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
- 125000005851 1-(N-(alkoxycarbonyl)amino)ethyl group Chemical group 0.000 description 1
- 125000005848 1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- MCHDHQVROPEJJT-UHFFFAOYSA-N 1-(chloromethyl)-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CCl)C=C1 MCHDHQVROPEJJT-UHFFFAOYSA-N 0.000 description 1
- PZBPKYOVPCNPJY-UHFFFAOYSA-N 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=C)CN1C=NC=C1 PZBPKYOVPCNPJY-UHFFFAOYSA-N 0.000 description 1
- SUHKSQTXXZQEBH-UHFFFAOYSA-N 1-benzothiophen-2-ylmethanol Chemical compound C1=CC=C2SC(CO)=CC2=C1 SUHKSQTXXZQEBH-UHFFFAOYSA-N 0.000 description 1
- 125000005847 1-methyl-1-(alkanoyloxy)-ethyl group Chemical group 0.000 description 1
- NVEPPWDVLBMNMB-SNAWJCMRSA-N 1-methyl-2-[(e)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4h-pyrimidine Chemical compound CN1CCCN=C1\C=C\C1=C(C)C=CS1 NVEPPWDVLBMNMB-SNAWJCMRSA-N 0.000 description 1
- ZYWSXGRMDPBISP-UHFFFAOYSA-N 1-nitro-2-phenylmethoxybenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1OCC1=CC=CC=C1 ZYWSXGRMDPBISP-UHFFFAOYSA-N 0.000 description 1
- SPUFVZLEVVIBFY-UHFFFAOYSA-N 1-nitro-3-[[4-(trifluoromethyl)phenyl]methoxy]benzene Chemical compound [O-][N+](=O)C1=CC=CC(OCC=2C=CC(=CC=2)C(F)(F)F)=C1 SPUFVZLEVVIBFY-UHFFFAOYSA-N 0.000 description 1
- XMECSHAHCONFFP-UHFFFAOYSA-N 1-nitro-4-(4-propoxyphenyl)benzene Chemical group C1=CC(OCCC)=CC=C1C1=CC=C([N+]([O-])=O)C=C1 XMECSHAHCONFFP-UHFFFAOYSA-N 0.000 description 1
- ZWOYWHYRFBLDEV-UHFFFAOYSA-N 1-tert-butyl-4-(4-nitrophenoxy)benzene Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C([N+]([O-])=O)C=C1 ZWOYWHYRFBLDEV-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical compound C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 description 1
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical compound N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 description 1
- VWQDSJKIOPTEMM-UHFFFAOYSA-N 2-(4-tert-butylphenyl)-5-nitro-1,3-benzoxazole Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=NC2=CC([N+]([O-])=O)=CC=C2O1 VWQDSJKIOPTEMM-UHFFFAOYSA-N 0.000 description 1
- JHDSVVPTMIYVGV-UHFFFAOYSA-N 2-(chloromethyl)-1-benzothiophene Chemical compound C1=CC=C2SC(CCl)=CC2=C1 JHDSVVPTMIYVGV-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- VLZVIIYRNMWPSN-UHFFFAOYSA-N 2-Amino-4-nitrophenol Chemical compound NC1=CC([N+]([O-])=O)=CC=C1O VLZVIIYRNMWPSN-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- ASXBYYWOLISCLQ-APUVXCOVSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2s,3s,4s,5r)-3-[(2r,3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@H]1[C@@](CO)(O)[C@@H](C)O[C@@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-APUVXCOVSA-N 0.000 description 1
- HQSRVYUCBOCBLY-XOOFNSLWSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2s,4r)-2-(4-chlorophenyl)-2-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CSC=4N(C=NN=4)C)(OC3)C=3C=CC(Cl)=CC=3)=CC=2)C=C1 HQSRVYUCBOCBLY-XOOFNSLWSA-N 0.000 description 1
- JLWMMYZWEHHTFF-UHFFFAOYSA-N 2-[6-(3-carbamimidoylphenoxy)-4-[di(propan-2-yl)amino]-3,5-difluoropyridin-2-yl]oxy-5-(2-methylpropylcarbamoyl)benzoic acid Chemical compound OC(=O)C1=CC(C(=O)NCC(C)C)=CC=C1OC1=NC(OC=2C=C(C=CC=2)C(N)=N)=C(F)C(N(C(C)C)C(C)C)=C1F JLWMMYZWEHHTFF-UHFFFAOYSA-N 0.000 description 1
- WCBVUETZRWGIJQ-UHFFFAOYSA-N 2-[[(methoxycarbonylamino)-(2-nitro-5-propylsulfanylanilino)methylidene]amino]ethanesulfonic acid Chemical compound CCCSC1=CC=C([N+]([O-])=O)C(NC(NC(=O)OC)=NCCS(O)(=O)=O)=C1 WCBVUETZRWGIJQ-UHFFFAOYSA-N 0.000 description 1
- ZMXYNJXDULEQCK-UHFFFAOYSA-N 2-amino-p-cresol Chemical compound CC1=CC=C(O)C(N)=C1 ZMXYNJXDULEQCK-UHFFFAOYSA-N 0.000 description 1
- UHGULLIUJBCTEF-UHFFFAOYSA-N 2-aminobenzothiazole Chemical compound C1=CC=C2SC(N)=NC2=C1 UHGULLIUJBCTEF-UHFFFAOYSA-N 0.000 description 1
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 1
- RUSPGVKKJOXAHZ-UHFFFAOYSA-N 2-methyl-5-[[4-(4-propoxyphenyl)phenyl]sulfamoyl]benzoic acid Chemical compound C1=CC(OCCC)=CC=C1C(C=C1)=CC=C1NS(=O)(=O)C1=CC=C(C)C(C(O)=O)=C1 RUSPGVKKJOXAHZ-UHFFFAOYSA-N 0.000 description 1
- ZOPPPZYLBABVSW-UHFFFAOYSA-N 2-phenyl-5-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(C(F)(F)F)=CC=C1C1=CC=CC=C1 ZOPPPZYLBABVSW-UHFFFAOYSA-N 0.000 description 1
- BANZVKGLDQDFDV-UHFFFAOYSA-N 2-propan-2-ylbenzoic acid Chemical compound CC(C)C1=CC=CC=C1C(O)=O BANZVKGLDQDFDV-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004011 3 membered carbocyclic group Chemical group 0.000 description 1
- MKMRZZJJDIBAJF-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)aniline Chemical compound NC1=CC=CC(C=2SC3=CC=CC=C3N=2)=C1 MKMRZZJJDIBAJF-UHFFFAOYSA-N 0.000 description 1
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 1
- RTZZCYNQPHTPPL-UHFFFAOYSA-N 3-nitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1 RTZZCYNQPHTPPL-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001845 4 membered carbocyclic group Chemical group 0.000 description 1
- WKRCOZSCENDENK-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=NC2=CC=CC=C2S1 WKRCOZSCENDENK-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZNDJDQOECGBUNK-UHFFFAOYSA-N 4-(4-nitrophenyl)phenol Chemical group C1=CC(O)=CC=C1C1=CC=C([N+]([O-])=O)C=C1 ZNDJDQOECGBUNK-UHFFFAOYSA-N 0.000 description 1
- CZGCEKJOLUNIFY-UHFFFAOYSA-N 4-Chloronitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1 CZGCEKJOLUNIFY-UHFFFAOYSA-N 0.000 description 1
- ZQXKHDGATBRXAC-UHFFFAOYSA-N 4-[(3,4-dimethylphenyl)methylsulfanyl]aniline Chemical compound C1=C(C)C(C)=CC=C1CSC1=CC=C(N)C=C1 ZQXKHDGATBRXAC-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- DJKBDSDXSVPSPW-UHFFFAOYSA-N 4-[(4-butoxyphenyl)methoxy]aniline Chemical compound C1=CC(OCCCC)=CC=C1COC1=CC=C(N)C=C1 DJKBDSDXSVPSPW-UHFFFAOYSA-N 0.000 description 1
- QXVCMXMHZFXHSG-UHFFFAOYSA-N 4-[(4-chlorophenyl)methylsulfanyl]aniline Chemical compound C1=CC(N)=CC=C1SCC1=CC=C(Cl)C=C1 QXVCMXMHZFXHSG-UHFFFAOYSA-N 0.000 description 1
- BWAMEPIGBSGVCX-UHFFFAOYSA-N 4-[(4-fluorophenyl)methylsulfanyl]aniline Chemical compound C1=CC(N)=CC=C1SCC1=CC=C(F)C=C1 BWAMEPIGBSGVCX-UHFFFAOYSA-N 0.000 description 1
- IIFMNSKJZMFVJD-UHFFFAOYSA-N 4-[(4-phenylphenyl)methylsulfanyl]aniline Chemical compound C1=CC(N)=CC=C1SCC1=CC=C(C=2C=CC=CC=2)C=C1 IIFMNSKJZMFVJD-UHFFFAOYSA-N 0.000 description 1
- XBOQCMUTODSZFA-UHFFFAOYSA-N 4-[(4-tert-butylphenyl)methylsulfanyl]aniline Chemical compound C1=CC(C(C)(C)C)=CC=C1CSC1=CC=C(N)C=C1 XBOQCMUTODSZFA-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- DAISNZDCSZJLRW-UHFFFAOYSA-N 4-[4-(trifluoromethoxy)phenyl]aniline Chemical compound C1=CC(N)=CC=C1C1=CC=C(OC(F)(F)F)C=C1 DAISNZDCSZJLRW-UHFFFAOYSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- YGFDUTWNERHOGF-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methylsulfanyl]aniline Chemical compound C1=CC(N)=CC=C1SCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YGFDUTWNERHOGF-UHFFFAOYSA-N 0.000 description 1
- DEXWLMMROPAVAX-UHFFFAOYSA-N 4-[[4-(trifluoromethyl)phenyl]methoxy]aniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=C(C(F)(F)F)C=C1 DEXWLMMROPAVAX-UHFFFAOYSA-N 0.000 description 1
- DNQUBMOQOOTMDY-UHFFFAOYSA-N 4-[[4-(trifluoromethyl)phenyl]methylsulfanyl]aniline Chemical compound C1=CC(N)=CC=C1SCC1=CC=C(C(F)(F)F)C=C1 DNQUBMOQOOTMDY-UHFFFAOYSA-N 0.000 description 1
- PECKLIXQHBFLKD-UHFFFAOYSA-N 4-amino-5h-1,3-thiazol-2-one Chemical compound NC1=NC(=O)SC1 PECKLIXQHBFLKD-UHFFFAOYSA-N 0.000 description 1
- WCDSVWRUXWCYFN-UHFFFAOYSA-N 4-aminobenzenethiol Chemical compound NC1=CC=C(S)C=C1 WCDSVWRUXWCYFN-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-M 4-methoxybenzoate Chemical compound COC1=CC=C(C([O-])=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-M 0.000 description 1
- KXLZZEPFQYGUPZ-UHFFFAOYSA-N 4-nitrobenzoyl bromide Chemical compound [O-][N+](=O)C1=CC=C(C(Br)=O)C=C1 KXLZZEPFQYGUPZ-UHFFFAOYSA-N 0.000 description 1
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- YCNQUFFOZVXQJM-UHFFFAOYSA-N 4-tert-butyl-n-(2-hydroxy-5-nitrophenyl)benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NC1=CC([N+]([O-])=O)=CC=C1O YCNQUFFOZVXQJM-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
- MIUOBAHGBPSRKY-UHFFFAOYSA-N 5-(4-nitrophenyl)-2h-tetrazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NNN=N1 MIUOBAHGBPSRKY-UHFFFAOYSA-N 0.000 description 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- FMWIOAWRARBKDQ-UHFFFAOYSA-N 5-chlorosulfonyl-2-methylbenzoic acid Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1C(O)=O FMWIOAWRARBKDQ-UHFFFAOYSA-N 0.000 description 1
- BIMKTWSTDJXSGY-UHFFFAOYSA-N 5-nitro-2-[4-(trifluoromethoxy)phenyl]-1,3-benzoxazole Chemical compound N=1C2=CC([N+](=O)[O-])=CC=C2OC=1C1=CC=C(OC(F)(F)F)C=C1 BIMKTWSTDJXSGY-UHFFFAOYSA-N 0.000 description 1
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 description 1
- ZPWUAVXLBCNQMC-UHFFFAOYSA-N 6-methyl-2-propan-2-yl-1,3-benzothiazole Chemical compound C1=C(C)C=C2SC(C(C)C)=NC2=C1 ZPWUAVXLBCNQMC-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- 102000054930 Agouti-Related Human genes 0.000 description 1
- 101710127426 Agouti-related protein Proteins 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 239000005877 Alpha-Cypermethrin Substances 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 101150102415 Apob gene Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 101100220066 Arabidopsis thaliana CDA4 gene Proteins 0.000 description 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 1
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 229940124802 CB1 antagonist Drugs 0.000 description 1
- NOBDFDFOFOLGHA-UHFFFAOYSA-N CN(C1=CC=NC=C1)C.C(C)(C)(C)C1=CC=C(C(=O)NC2=C(C=CC(=C2)[N+](=O)[O-])O)C=C1.C(C)(C)(C)C1=CC=C(C=C1)C=1OC2=C(N1)C=C(C=C2)[N+](=O)[O-] Chemical compound CN(C1=CC=NC=C1)C.C(C)(C)(C)C1=CC=C(C(=O)NC2=C(C=CC(=C2)[N+](=O)[O-])O)C=C1.C(C)(C)(C)C1=CC=C(C=C1)C=1OC2=C(N1)C=C(C=C2)[N+](=O)[O-] NOBDFDFOFOLGHA-UHFFFAOYSA-N 0.000 description 1
- 101100027969 Caenorhabditis elegans old-1 gene Proteins 0.000 description 1
- 101100534223 Caenorhabditis elegans src-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 229940126559 Compound 4e Drugs 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000289527 Cordyline terminalis Species 0.000 description 1
- 235000009091 Cordyline terminalis Nutrition 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 101150073133 Cpt1a gene Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 description 1
- 206010051153 Diabetic gastroparesis Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 206010012758 Diastolic hypertension Diseases 0.000 description 1
- ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- OIJXLIIMXHRJJH-KNLIIKEYSA-N Diprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)C(C)(C)O)OC)CN2CC1CC1 OIJXLIIMXHRJJH-KNLIIKEYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010013971 Dyspnoea exertional Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 241000490229 Eucephalus Species 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- HMCCXLBXIJMERM-UHFFFAOYSA-N Febantel Chemical compound C1=C(NC(NC(=O)OC)=NC(=O)OC)C(NC(=O)COC)=CC(SC=2C=CC=CC=2)=C1 HMCCXLBXIJMERM-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 102400001370 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010016122 Ghrelin Receptors Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 229940122069 Glycosidase inhibitor Drugs 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 description 1
- LJIZUXQINHXGAO-ITWZMISCSA-N HR 780 Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 LJIZUXQINHXGAO-ITWZMISCSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 208000024659 Hemostatic disease Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000928179 Homo sapiens Agouti-related protein Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 239000005795 Imazalil Substances 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical class CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- BPFYOAJNDMUVBL-UHFFFAOYSA-N LSM-5799 Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- VCIPQQCYKMORDY-UHFFFAOYSA-N MDL 25637 Natural products OC1C(O)C(O)C(CO)NC1COC1C(O)C(O)C(O)C(CO)O1 VCIPQQCYKMORDY-UHFFFAOYSA-N 0.000 description 1
- 108010000410 MSH receptor Proteins 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 1
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 1
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 102000030937 Neuromedin U receptor Human genes 0.000 description 1
- 108010002741 Neuromedin U receptor Proteins 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229940123730 Orexin receptor antagonist Drugs 0.000 description 1
- 241001282736 Oriens Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 101150085511 PEDS1 gene Proteins 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102100037592 Plasmanylethanolamine desaturase Human genes 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- QJLPWVUZFKETMK-UHFFFAOYSA-N Pradimicin Q Natural products O=C1C2=C(O)C=C(O)C=C2C(=O)C2=C1C(O)=C1CC(O)C(C=C(C(=C3O)C(O)=O)C)=C3C1=C2O QJLPWVUZFKETMK-UHFFFAOYSA-N 0.000 description 1
- 108010080283 Pre-beta High-Density Lipoproteins Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 1
- 239000004189 Salinomycin Substances 0.000 description 1
- SZKKRCSOSQAJDE-UHFFFAOYSA-N Schradan Chemical compound CN(C)P(=O)(N(C)C)OP(=O)(N(C)C)N(C)C SZKKRCSOSQAJDE-UHFFFAOYSA-N 0.000 description 1
- 229940083324 Selective androgen receptor modulator Drugs 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- UNZIDPIPYUMVPA-UHFFFAOYSA-M Sulpyrine Chemical compound O.[Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 UNZIDPIPYUMVPA-UHFFFAOYSA-M 0.000 description 1
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 206010042957 Systolic hypertension Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- PYVAAPGPTLLDGV-UHFFFAOYSA-N Trestatin A Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC(C(=C1)CO)C(O)C(O)C1NC(C(C1O)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC(C(C1O)O)C(CO)OC1OC(C(C1O)O)C(CO)OC1OC1OC(CO)C(O)C(O)C1O PYVAAPGPTLLDGV-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 108010059705 Urocortins Proteins 0.000 description 1
- 102000005630 Urocortins Human genes 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HUOFUOCSQCYFPW-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)(F)F)C=C1 HUOFUOCSQCYFPW-UHFFFAOYSA-N 0.000 description 1
- 229950008167 abamectin Drugs 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940034653 advicor Drugs 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- VXTGHWHFYNYFFV-UHFFFAOYSA-N albendazole S-oxide Chemical compound CCCS(=O)C1=CC=C2NC(NC(=O)OC)=NC2=C1 VXTGHWHFYNYFFV-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- 229960004607 alfuzosin Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 229960002587 amitraz Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940036589 antiprotozoals Drugs 0.000 description 1
- 201000006800 aortic valve disease 1 Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 208000028922 artery disease Diseases 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229940030850 avar Drugs 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 229950007118 bambermycin Drugs 0.000 description 1
- AIOWJIMWVFWROP-UHFFFAOYSA-N baquiloprim Chemical compound C12=CC=CN=C2C(N(C)C)=C(C)C=C1CC1=CN=C(N)N=C1N AIOWJIMWVFWROP-UHFFFAOYSA-N 0.000 description 1
- 229950004557 baquiloprim Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical group CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 150000005524 benzylchlorides Chemical class 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229950005357 bervastatin Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940072020 calcium borogluconate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- SSKRIDIHZLFJCG-UHFFFAOYSA-L calcium;2,3-dihydroxy-3-[2-hydroxy-5-(hydroxymethyl)-1,3,2-dioxaborolan-4-yl]propanoate Chemical compound [Ca+2].OCC1OB(O)OC1C(O)C(O)C([O-])=O.OCC1OB(O)OC1C(O)C(O)C([O-])=O SSKRIDIHZLFJCG-UHFFFAOYSA-L 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- 229950009592 cefquinome Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229940106265 charcoal Drugs 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229910052801 chlorine Chemical group 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960004409 cloprostenol Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229950002753 crilvastatin Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004385 danofloxacin Drugs 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000001904 diabetogenic effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 description 1
- 229960002222 dihydrostreptomycin Drugs 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960001342 dinoprost Drugs 0.000 description 1
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 1
- 229950002494 diprenorphine Drugs 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- TUOSYWCFRFNJBS-BHVANESWSA-N dirlotapide Chemical compound O=C([C@@H](NC(=O)C=1N(C2=CC=C(NC(=O)C=3C(=CC=CC=3)C=3C=CC(=CC=3)C(F)(F)F)C=C2C=1)C)C=1C=CC=CC=1)N(C)CC1=CC=CC=C1 TUOSYWCFRFNJBS-BHVANESWSA-N 0.000 description 1
- 229960002551 dirlotapide Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 1
- 229960003997 doramectin Drugs 0.000 description 1
- 229960002955 doxapram Drugs 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002125 enilconazole Drugs 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 description 1
- 229960002346 eprinomectin Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- AWKLBIOQCIORSB-UHFFFAOYSA-N etamiphylline Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCN(CC)CC AWKLBIOQCIORSB-UHFFFAOYSA-N 0.000 description 1
- 229960000505 etamiphylline Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZADJRRFMOOACHL-WQICJITCSA-N ethyl (e,3s,5r)-7-[4-(4-fluorophenyl)spiro[chromene-2,1'-cyclopentane]-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C12=CC=CC=C2OC2(CCCC2)C(/C=C/[C@H](O)C[C@H](O)CC(=O)OCC)=C1C1=CC=C(F)C=C1 ZADJRRFMOOACHL-WQICJITCSA-N 0.000 description 1
- IOLQWGVDEFWYNP-UHFFFAOYSA-N ethyl 2-bromo-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)Br IOLQWGVDEFWYNP-UHFFFAOYSA-N 0.000 description 1
- GYUCVQSNZFRDRL-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylbutanoate Chemical compound CCOC(=O)C(CC)P(=O)(OCC)OCC GYUCVQSNZFRDRL-UHFFFAOYSA-N 0.000 description 1
- YQBRPZBLROENTD-UHFFFAOYSA-N ethyl 3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OCC)CCCC2=C1 YQBRPZBLROENTD-UHFFFAOYSA-N 0.000 description 1
- 229950011035 etiproston Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 229960005282 febantel Drugs 0.000 description 1
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 description 1
- 229960005473 fenbendazole Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019374 flavomycin Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 229960003704 framycetin Drugs 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 125000005643 gamma-butyrolacton-4-yl group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229950000806 glenvastatin Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229950010772 glucose-1-phosphate Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 150000002336 glycosamine derivatives Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 239000003316 glycosidase inhibitor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 108010077119 high density lipoprotein-1 Proteins 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 102000055839 human AGRP Human genes 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002396 hypoinsulinemic effect Effects 0.000 description 1
- 229940121380 ileal bile acid transporter inhibitor Drugs 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 229960001195 imidapril Drugs 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- SCEVFJUWLLRELN-UHFFFAOYSA-N imidocarb Chemical compound C=1C=CC(C=2NCCN=2)=CC=1NC(=O)NC(C=1)=CC=CC=1C1=NCCN1 SCEVFJUWLLRELN-UHFFFAOYSA-N 0.000 description 1
- 229960004683 imidocarb Drugs 0.000 description 1
- 229950005809 implitapide Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229960002056 indoramin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical class C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 229960002531 marbofloxacin Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- WVWZECQNFWFVFW-UHFFFAOYSA-N methyl 2-methylbenzoate Chemical compound COC(=O)C1=CC=CC=C1C WVWZECQNFWFVFW-UHFFFAOYSA-N 0.000 description 1
- SXIPOHPNRRSUKP-UHFFFAOYSA-N methyl 5-chlorosulfonyl-2-methylbenzoate Chemical compound COC(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C SXIPOHPNRRSUKP-UHFFFAOYSA-N 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 230000000407 monoamine reuptake Effects 0.000 description 1
- 229960005121 morantel Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 description 1
- 229960004816 moxidectin Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- JVRMUFJCFLXSMJ-UHFFFAOYSA-N n,2-diphenylbenzamide Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1C(=O)NC1=CC=CC=C1 JVRMUFJCFLXSMJ-UHFFFAOYSA-N 0.000 description 1
- WIDKTXGNSOORHA-CJHXQPGBSA-N n,n'-dibenzylethane-1,2-diamine;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate Chemical compound O.O.O.O.C=1C=CC=CC=1CNCCNCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 WIDKTXGNSOORHA-CJHXQPGBSA-N 0.000 description 1
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
- GMSCTAUKUATFHI-XIFFEERXSA-N n-[(1s)-2-oxo-2-(pentylamino)-1-phenylethyl]-2-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]quinoline-6-carboxamide Chemical compound N([C@H](C(=O)NCCCCC)C=1C=CC=CC=1)C(=O)C(C=C1C=C2)=CC=C1N=C2NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 GMSCTAUKUATFHI-XIFFEERXSA-N 0.000 description 1
- IDHGAQOVWWBGFK-UHFFFAOYSA-N n-benzyl-n-[2-[4-cyano-n-[(3-methylimidazol-4-yl)methyl]anilino]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)N(CCN(CC=2N(C=NC=2)C)C=2C=CC(=CC=2)C#N)CC=2C=CC=CC=2)=C1 IDHGAQOVWWBGFK-UHFFFAOYSA-N 0.000 description 1
- WVSPFSODZJZGMO-UHFFFAOYSA-N n-benzylsulfanylaniline Chemical compound C=1C=CC=CC=1CSNC1=CC=CC=C1 WVSPFSODZJZGMO-UHFFFAOYSA-N 0.000 description 1
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 1
- GYNAVKULVOETAD-UHFFFAOYSA-N n-phenoxyaniline Chemical compound C=1C=CC=CC=1NOC1=CC=CC=C1 GYNAVKULVOETAD-UHFFFAOYSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 229950006716 netobimin Drugs 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229940033757 niaspan Drugs 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- SGKGVABHDAQAJO-UHFFFAOYSA-N nitroxynil Chemical compound OC1=C(I)C=C(C#N)C=C1[N+]([O-])=O SGKGVABHDAQAJO-UHFFFAOYSA-N 0.000 description 1
- BGMYHTUCJVZIRP-GASJEMHNSA-N nojirimycin Chemical class OC[C@H]1NC(O)[C@H](O)[C@@H](O)[C@@H]1O BGMYHTUCJVZIRP-GASJEMHNSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N ortho-methoxybenzoic acid Natural products COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- JYWIYHUXVMAGLG-UHFFFAOYSA-N oxyclozanide Chemical compound OC1=C(Cl)C=C(Cl)C=C1NC(=O)C1=C(O)C(Cl)=CC(Cl)=C1Cl JYWIYHUXVMAGLG-UHFFFAOYSA-N 0.000 description 1
- 229950003126 oxyclozanide Drugs 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 229910052625 palygorskite Inorganic materials 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229960000490 permethrin Drugs 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- RMCNETIHECSPMZ-UHFFFAOYSA-N piperidine-3,4,5-triol Chemical class OC1CNCC(O)C1O RMCNETIHECSPMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229960005278 poloxalene Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920003199 poly(diethylsiloxane) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002469 receptor inverse agonist Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- HWECMADGHQKSLK-OLTWBHDESA-N rosenonolactone Chemical class C([C@H]1C(=O)C[C@@H]23)[C@@](C)(C=C)CC[C@@]1(C)[C@@]31CCC[C@]2(C)C(=O)O1 HWECMADGHQKSLK-OLTWBHDESA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960001548 salinomycin Drugs 0.000 description 1
- 235000019378 salinomycin Nutrition 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000849 selective androgen receptor modulator Substances 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 229960004509 serum gonadotrophin Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 108091008012 small dense LDL Proteins 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960002909 spirapril Drugs 0.000 description 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
- 108700035424 spirapril Proteins 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229960004673 sulfadoxine Drugs 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- VLYWMPOKSSWJAL-UHFFFAOYSA-N sulfamethoxypyridazine Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 VLYWMPOKSSWJAL-UHFFFAOYSA-N 0.000 description 1
- 229960004936 sulfamethoxypyridazine Drugs 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960004084 temocapril Drugs 0.000 description 1
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
- 229950001790 tendamistat Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000003777 thiepinyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 229960000223 tilmicosin Drugs 0.000 description 1
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 torcetrapib Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960000323 triclabendazole Drugs 0.000 description 1
- 229960002906 trimazosin Drugs 0.000 description 1
- YNZXWQJZEDLQEG-UHFFFAOYSA-N trimazosin Chemical compound N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 YNZXWQJZEDLQEG-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000777 urocortin Substances 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 208000012908 vascular hemostatic disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940072252 zestril Drugs 0.000 description 1
- 229940051223 zetia Drugs 0.000 description 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
- 229960002769 zofenopril Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Description
A-
SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS
The present invention relates to substituted heteroaryl- and phenylsulfamoyl- compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. The subject compounds are particularly useful as PPARa agonists and to treat atherosclerosis, hypercholesterolemia, hypertriglyceridemia, diabetes, obesity, osteoporosis and Syndrome
X (also known as metabolic syndrome) in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.
Atherosclerosis, a disease of the arteries, is recognized to be the leading cause of death in the United States and Western Europe. The pathological sequence leading to atherosclerosis and occlusive hear disease is well known. The earliest stage in this sequence is the formation of “fatty streaks" in the carotid, coronary and cerebral arteries and in the aorta.
These lesions are yellow in color due to the presence of lipid deposits found principally within smooth-muscle cells and In macrophages of the intima layer of the arteries and aorta. Further, it is postulated that most of the cholesterol found within the fatty streaks, in turn, gives rise to development of the “fibrous plague,” which consists of accumulated intimal smooth muscle cells laden with lipid and surrounded by exitra-cellular lipid, collagen, elastin and proteoglycans. These cells plus matrix form a fibrous cap that covers a deeper deposit of cell debris and more extracellular lipid. The lipid is primarily free and esterified cholesterol. The fibrous plaque forms siowly, and is likely in time to become calcified and necrotic, advancing to the "complicated lesion,” which accounts for the arterial occlusion and tendency toward mural thrombosis and arterial muscle spasm that characterize advanced atherosclerosis.
Epidemiological evidence has firmly established hyperlipidemia as a primary risk factor in causing cardiovascular disease (CVD) due to atherosclerosis. in recent years, leaders of the medical profession have placed renewed emphasis on lowering plasma cholesterol levels, and low density lipoprotein cholesterol in particular, as an essential step in prevention of CVD. The upper limits of “normal” are now known to be significantly lower than heretofore appreciated. As a result, large segments of Westem populations are now realized to be at particularly high risk. Additional independent risk factors include glucose intolerance, left ventricular hypertrophy, hypertension, and being of the male sex. Cardiovascular disease is especially prevalent among diabetic subjects, at least in part because of the existence of multiple independent risk factors in this population. Successful treatment of hyperlipidemia in the general population, and in diabetic subjects in particular, is therefore of exceptional medical importance.
In spite of the early discovery of insulin and its subsequent widespread use in the treatment of diabetes, and the later discovery of and use of suifonylureas, biguanides and thiazolidenediones, such as troglitazone, rosiglitazone or pioglitazone, as oral hypoglycemic agents, the treatment of diabetes could be improved. The use of insulin typically requires multiple daily doses. Determination of the proper dosage of insulin requires frequent estimations of the sugar in urine or biocd. The administration of an excess dose of insulin causes hypoglycemia, with effects ranging from mild apnormalities in blood glucose to coma, or even death. Treatment of non-insulin dependent diabetes mellitus (Type Il diabetes,
NIDDM) usually consists of a combination of diet, exercise, oral hypoglycemic agents, e.g., thiazolidenediones, and in more severe cases, insulin. However, the clinically available hypoglycemic agents can have side effects that limit their use. In the case of insulin dependent diabetes mellitus (Type I), insulin is usually the primary course of therapy.
Thus, although there are a variety of anti-atherosclerosis and diabetes therapies, there is a continuing need and a continuing search in this field of art for altemative therapies.
Moreover, negative energy balance (NEB) is a problem frequently encountered in ruminants particularly dairy cows. NEB may be experienced at any time during the cows life put it Is particularly prevalent during the transition period. The ruminant transition period is defined as the period spanning late gestation to early lactation. This is sometimes defined as from 3 weeks before to three weeks after parturition, but has been expanded to 30 days prepartum to 70 days postpartum (J N Spain and W A Scheer, Tri-State Dairy Nutrition
Conference, 2001, 13).
Energy balance is defined as energy intake minus energy output and an animal is descibed as being in negative energy balance if energy intake Is insufficient to meet the demands on maintenance and production (eg milk). A cow in NEB has to find the energy to meet the deficit from its body reserves. Thus cows in NEB tend to lose body condition and liveweight, with cows that are more energy deficient tending to lose condition and weight at a faster rate.
Its important that the mineral and energy balance and overall health of the cow is managed well in the transition period, since this interval is critically important to the subsequent health, production, and profitability in dairy cows.
Long chain fatty acids (or non esterified fatty acids, NEFAs) are also mobilised from body fat. NEFAs, already elevated from around 7 days prepartum, are a significant source of energy to the cow during the early postpartum period, and the greater the energy deficit the higher the concentration of NEFA in the blood. Some workers suggest that in early lactation (Bell and references therein-see above) mammary uptake of NEFAs accounts for some milk fat synthesis. The circulating NEFAs are taken up by the liver and are oxidised to carbon dioxide or ketone bodies, including 3-hydroxybutyrate, by mitochondria, or reconverted via esterification into triglycerides and stored. In non-ruminant mammals 1 is thought that entry of
NEFAs into the mitochondria is controlled by the enzyme carnitine paimitoyitransferase (CPT- 1) however, some studies have shown that in ruminants there is little change in activity of
CPT-1 during the transition period (G. N. Douglas, J. K. Drackley, T. R. Overton, H. G.
Bateman, J. Dairy Science, 1998, Supp 1, 81, 285). Furthermore, the capacity of the ruminant liver for synthesising very low density lipoproteins to export triglycerides from the liver is limited.
Significantly, if NEFA uptake by the bovine liver becomes excessive, accumulation of ketone bodies can lead to ketosis, and excessive storage of triglycerides may lead to fatty liver. Fatty liver can lead to prolonged recovery for other disorders, increased incidence of health problems, and development of “downer cows” that die.
Thus, fatty liver is a metabolic disease of ruminants, particularly high producing dairy cows, in the transition period that negatively impacts disease resistance (abomasal displacement, lameness), immune function (mastitits, metritis), reproductive performance (oestrus, calving interval, foetal viability, ovarian cysts, metritis, retained placenta), and milk production (peak milk yield, 305 day milk yield). Fatty liver has largely developed by the day after parturition and precedes an induced (secondary) ketosis. It usually results from increased esterification of NEFA absorbed from blood coupled with the low ability of ruminant liver to secrete triglycerides as very low-density lipoproteins.
By improving energy balance, or by treating the negative energy balance, the negative extent of the sequelae will be reduced. This is addressed by the compounds of the present invention.
The present invention is directed to compounds of Formula a ; \ (J)q—A?—B——Ar'—————N——S Q
I \_/
I
X
Formula or a prodrug of said compound or a pharmaceutically acceptable satt of said compound or prodrug, wherein
Q is carbon; each R' is independently hydrogen, halo, (C+-Cs)alky! optionally substituted with one or more halo or with (C,-C;)alkoxy, (C4-Cs)alkoxy optionally substituted with one to eleven halo, (C4-Cs)alkyithio optionally substituted with one or more halo, or R' in conjunction with the two adjacent carbon atoms forms a Cs-Cg fused fully saturated, partially unsaturated or fully unsaturated five or six membered carbocyclic ring wherein each carbon in the carbon chain may optionally be replaced with one heteroatom selected from oxygen and sulfur;
R? is hydrogen or (C4-Cs)alkyl optionally substituted with C,-Cj alkoxy;
X Is ~COOR’, -O-(CR%,)-COOR®, -S{CR%,)-COOR", -CH~(CR®,}-COOR*, 1H- tetrazol-5-yl-E- or thiazolidinedione-5-yl-G-; wherein wis 0, 1 or 2; E is (CHa) and ris 0, 1, 2 or 3, and G is (CH,)s or methylidene and sis 0 or 1; each R® is independently hydrogen, (C4-C)atky! optionally substituted with one to nine halo or with (C,-Ca)alkoxy optionally substituted with one or more halo, or R*and the carbon to which it is attached form a 3, 4, 5, or 6 membered carbocyciic ring;
R* is H, (C1-Cy)alkyl; benzyl or p-nitrobenzyl; each R®is independently hydrogen, (C+-Cs)alkyl optionally substituted with one to nine halo ar with {C4-Cs)alkoxy, (C+-C4)alkoxy optionally substituted with one to nine halo, (C4-Cs)alkyithio optionally substituted with one to nine halo or with (C4-Cs)alkoxy, or R® and the carbon to which it is attached form a 3, 4, 5, or 6 membered carbocyclic ring wherein any carbon of a 5- or 6-membered ring may be replaced by an oxygen atom;
Ar' is phenyt or phenyl fused to a member selected from thiazolyl, furanyl, oxazolyl, pyridine, pyrimidine, phenyl, or thienyl, wherein Ar' is optionally mono-, di- or tri-substituted independently with: halo, (Cs-Ca)alkyl optionally substituted with one to nine halo or (C,-
Cs)alkoxy optionally substituted with one to nine halo or (C+-Cs)alkyithio optionally substituted with one to nine halo;
Bis a bond, CO, (CY2)y, CYOH, CY=CY, -L~{CY2)s- , {CY2)n-L-, -L{CY2)-L-, NY-OC- -CONY-, -SO,NY--NY-SO,- wherein each L is independently O, S, SO, or SO,, each Y is independently hydrogen or (C4-Cs) alkyl, and nis 0, 1, 2 or 3;
Arf is a bond, phenyl, phenoxybenzyl, phenoxyphenyl, benzyloxyphenyl, benzyloxybenzyi, pyrimidinyl, pyridinyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl or phenyl fused to a ring selected from the group consisting of: phenyl, pyrimidinyl, thienyl, furanyl, pyrrolyl, thiazolyl, oxazolyl, pyrazolyi, and imidazolyi; sach J is independently hydrogen, hydroxy, halo, (C4-Cs)alky! optionally substituted with one to eleven halo, (C4-Cg)alkoxy optionally substituted with one to eleven halo, (C;- Cgalkyithio optionally substituted with one to eleven halo, (C:-C;)cycloalkyl, (Cs
C7)cycloalkoxy, (Cs-Cy)cycloalkylthio, or phenyl optionally substituted with one to four substituents from the group consisting of: halo, (C4-C;)alkyl optionally substituted with one to five halo, (C,-C;)alkoxy optionally substituted with one to five halo, (C4-Cs)alkyithio optionally substituted with one to five halo; p and q are each independently 0, 1, 2 or 3; and with the provisos:
a) if Ar" is phenyl, B is a bond, A” is a bond or phenyl, and X is —COOH then q is other than 0 and J is other than hydrogen, halo, (C,-Csg)alkyl or unsubstituted phenyl; b) if Ar’ is phenyl, B Is not a bond, Ar? Is phenyl and X is -COOR* then B is attached to Ar' para to NR? and c) ifB Is O, S, SO, NH, CO, CH, or SO, then R' is not H.
The present application also Is directed to methods for treating dyslipidemia, obesity, overweight condition, hypertriglyceridemia, hypertipidemia, hypoaiphalipoproteinsmia, metabolic syndrome, diabetes mellitus (Type | and/or Type Il), hyperinsulinemia, impaired glucose tolerance, insulin resistance, diabetic complications, atherosclerosis, hypertension, coronary heart disease, hypercholesteroiemia, inflammation, osteoporosis, thrombosis, peripheral vascular disease, cognitive dysfunction, or congestive heart failure in a mammai by administering to a mammal in need of such treatment a therapeutically effective amount of a compound of any of claims 1-18, or a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
The present application also is directed to pharmaceutical compositions which ’ comprises a therapeutically effective amount of a compound of formula |, or a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug and a pharmaceutically acceptable carrier, vehicle or diluent.
In addition, the present application is directed to pharmaceutical combination compositions comprising: a therapeutically effective amount of a composition comprising a first compound, said first compound being a compound of formula |, or a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug; a second compound, said second compound being a lipase inhibitor, an HMG-CoA reductase inhibitor, an HMG-CoA synthase inhibitor, an HMG-CoA reductase gene expression inhibitor, an HMG-CoA synthase gene expression inhibitor, an MTP/Apo B secretion inhibitor, a CETP inhibitor, a bile acid absorption inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a squalene synthetase inhibitor, a squalene epoxidase inhibitor, a squalene cyclase inhibitor, a combined squalene epoxidase/squalene cyclase inhibitor, a fibrate, niacin, a combination of niacin and lovastatin, an ion-exchange resin, an antioxidant, an ACAT Iinhibftor, a bile acid sequestrant, or a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug; and a pharmaceutically acceptable carrier, vehicle or diluent.
Moreover, the present invention is directed to methods for treating atherosclerosis in a mammal comprising administering to a mammal in need of treatment thereof; a first compound, said first compound being a compound of formula |, or a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug; and a second compound, said second compound being a lipase inhibitor, an HMG-CoA reductase inhibitor, an HMG-CoA synthase inhibitor, an HMG-CoA reductase gene expression inhibitor, an HMG-CoA synthase gene expression inhibitor, an MTP/Apo B secretion inhibitor, a CETP inhibitor, a bile acid absorption inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a squalene synthetase inhibitor, a squalene epoxidase inhibitor, a squalene cyclase inhibitor, a combined squalene epoxidase/squalene cyclase inhibitor, a fibrate, niacin, a combination of niacin and lovastatin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant wherein the amounts of first and second compounds result in a therapeutic effect.
Furthermore, the present application also is directed to kits for achieving a therapeutic effect in a mammal comprising packaged in association a first therapeutic agent ) comprising a therapeutically effective amount of a compound of the formula |, or a prodrug of said compound or a pharmaceuticaily acceptable salt of said compound or prodrug and a pharmaceutically acceptabie carrier, a second therapeutic agent comprising a therapeutically 156 effective amount of an HMG CoA reductase inhibitor, a CETP inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, slow-release niacin, a combination of niacin and lovastatin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant and a pharmaceutically acceptable carrier and directions for administration of said first and second agents to achieve the therapeutic effect. .
Another aspect of the present invention is the use of a compound of formula |, in the manufacture of a medicament for the palliative, prophylactic or curative treatment of negative energy balance in ruminants.
Another aspect of the invention Is the use of a compound of formula |, in the manufacture of a medicament for the palliative, prophylactic or curative treatment of negative energy balance or a ruminant disease associated with negative energy balance in ruminants, wherein the excessive accumulation of triglycerides in liver tissue is prevented or alleviated, and/or the excessive elevation of non-esterified fatty acid levels in serum is prevented or alleviated.
Another aspect of the invention is where the ruminant disease associated with negative energy balance in ruminants, as mentioned in the aspects of the invention herein, includes one or more diseases selected independently from fatty liver syndrome, dystocia, immune dysfunction, impaired immune function, toxification, primary and secondary ketosis, downer cow syndrome, indigestion, inappetence, retained placenta, displaced abomasum, mastitis, (endo-)-metritis, infertility, low fertility and lameness, preferably fatty liver syndrome, primary ketosis, downer cow syndrome, (endo-)-metritis and low fertility.
Another aspect of the invention is the use of a compound of formula |, in the improvement of fertility, including decreased return to service rates, normal oestrus cycling, improved conception rates, and improved foetal viability.
Another aspect of the invention is the use of a compound of formula |, in the manufacture of a medicament for the management of effective homeorhesis to accommodate parturition and lactogenesis.
Another aspect of the invention is the use of a compound of formula |, in the manufacture of a medicament for improving or maintaining the functioning of the ruminant liver and homeostatic signals during the transition period .
In one aspect of the invention, the compound of formula | is administered during the period from 30 days prepartum to 70 days postpartLam. in another aspect of the invention, the compound of formula | is administered prepartum and, optionally, also at parturition.
In yet another aspect of the invention, the compound of formula | is administered 16 postpartum. in yet another aspect of the invention, the compound of formula i Is administered at parturition.
More preferably, the compound of formula! is administered during the period from 3 weeks prepartum to 3 weeks postpartum.
In another aspect of the invention, the compound of formula | is administered up to three times during the first seven days postpartum.
Preferably, the compound of formula | is adrmninistered once during the first 24 hours postpartum.
In another aspect of the invention, the compound of formula | is administered prepartum and up to four times postpartum.
In another aspect of the invention, the compound of formula | is administered at parturition and then up to four times postpartum.
Another aspect of the invention is the use of the compound of formula | in the manufacture of a medicament for the palliative, prop hylactic or curative treatment of negative energy balance in ruminants and to increase ruminant milk quality and/or milk yield. In a preferred aspect of the invention, the milk quality increase is seen in a reduction in the levels of ketone bodies in ruminant milk.
In another aspect of the invention, peak millic yield is increased.
Preferably, the ruminant is a cow or sheep.
In another aspect of the invention, an overall increase in ruminant milk yield is obtained during the 305 days of the bovine lactation period.
in another aspect of the invention, an overall increase In ruminant milk yield is obtained during the first 60 days of the bovine lactation period.
Preferably, the overall increase in ruminant milk yield, or the increase in peak milk yield, or the increase in milk quality, is obtained from a dairy cow.
In another aspect of the invention, the increase in ruminant milk quality and/or milk yield is obtained after administration of a compound of formula | to a healthy ruminant. in another aspect of the invention, there Is provided a compound of formula |, for use in veterinary medicine.
The present application also Is directed to compounds having a Formula lI
R2 (J)g——Ar?—B——Ar'———NH
Formula I} or a pharmaceutically acceptable salt thereof, wherein
R? is hydrogen or (C4-Ca)alkyl;
Ar! is phenyl optionally mono-, di- or tri-substituted independently with: halo, (C4- . 15 Cjalkyl optionally substituted with one to five halo or (C4-Cs)alkoxy optionally substituted with one tc five halo or {C;-Cs)alkylithic optionally substituted with one to five halo;
Bis (CYz)n, O, S; -CH;S- or -CH,0 and n is1or2;
AP is phenyl or phenyl fused to a ring selected from the group consisting of: phenyl, pyrimidinyl, thienyt, furanyl, pyrrolyl, thiazolyl, oxazolyl, pyrazolyl, and imidazotyl; each J is independently hydrogen, hydroxy; halo; (C4-Ca)alkyl optionally substituted with one to eleven halo; (C+-Cg)alkoxy optionally substituted with one to eleven halo; (Cs-
Ca)alkylthio optionally substituted with one to eleven halo; (Cs-Cr)cycloalkyl; (Cx
Cy)cycloalkoxy; (Cs-Cr)cycloalkyithio; or phenyl optionally substituted with one or more: halo or (C+-Ca)alkyl optionally substituted with one to five halo or (C,-Cs)afkoxy optionally substituted with one to five halo or (C4-Cj)alkyithio optionally substituted with one to five halo; and qis0,1,20r3.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
Figure 1 shows the serum NEFA levels for transition cows administered with compound Z,: 2-Methyl-5-(4"-trifluoromethoxy-biphenyl-4-yisulfamoyl}-benzoic acid (EXAMPLE 193), compared to controls.
The present invention may be understood more readily by reference to the following detailed description of exemplary embodiments of the invention and the examples included therein.
Before the present compounds, compositions and methods are disclosed and described, it is to be understood that this invention is not limited to specific synthetic methods of making that may of course vary. Itis also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.
The present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the present invention. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, j.., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e, 1,1-methylene-bis-{2-hydroxy-3- naphthoate)) salts.
The invention also relates to base addition salts of the compounds of the present invention. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of the present invention that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.q., potassium and sodium) and alkaline earth metal cations (e.g. calcium and magnesium), ammonium or water-soluble amine addition salts such as N- methylglucamine-(meglumine}), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
The chemist of ordinary skill will recognize that certain compounds of this invention will contain one or more atoms that may be in a particular stereochemical or geometric configuration, giving rise to stereoisomers and configurational isomers. All such isomers and mixtures thereof are included in this invention. Hydrates and solvates of the compounds of this invention are aiso included.
Where the compounds of the present invention possess two or more stereogenic centers and the absolute or relative stereochemistry is given in the name, the designations R and S refer respectively to each stereogenic center in ascending numerical order (1, 2, 3, etc.) . according to the conventional IUPAC number schemes for each molecule. Where the compounds of the present invention possess one or more stereogenic centers and no stereochemistry is given in the name or structure, it is understood that the nam e or structure is intended to encompass all forms of the compound, including the racemic form.
The compounds of this invention may contain olefin-like double bonds. When such bonds are present, the compounds of the invention exist as cis and trans configurations and as mixtures thereof. The term “cis” refers to the orientation of two substituents with reference to each other and the plane of the ring (either both “up” or both “down”). Analogously, the term “trans” refers to the orientation of two substituents with reference to each other and the plane of the ring (the substituents being on opposite sides of the ring).
Alpha and Beta refer to the orientation of a substituent with reference to the plane of thering. Beta is above the plane of the ring and Alpha is below the plane of the ring.
This invention also includes isotopically-labeled compounds, which are identical to those described by Formulas | and Il, except for the fact that one or more atoms are replaced by one or more atoms having specific atomic mass or mass numbers. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine, and chlorine such as 2H, *H, **c, “c, "N, 0, 0, 8, and *ClI respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of the compounds or of the prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labeled compounds of the present invention, for €xample those into which radioactive isotopes such as *H and "C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated (i.e., °H), and carbon-14 (i.e., “C). isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., °H), can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life ©r reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically : labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings:
The term “treating”, "treat" or "treatment" as used herein includes preventative (e.g., prophylactic) and palliative treatment.
As used herein, “therapeutically effective amount of a compound” mearss an amount thats effective to exhibit therapeutic or biological activity at the site(s) of activity” in a mammalian subject, without undue adverse side effects (such as undue toxicity, irritation or allergic response), commensurate with a reasonable benefit/risk ratio when used in the manner of the present invention.
The term “cerebrovascular disease”, as used herein, is selected, but not limited to, the group consisting of ischemic attacks (e.g., transient), ischemic stroke (transient), acute stroke, cerebral apoplexy, hemorrhagic stroke, neurologic deficits post-stroke, first stroke, recurrent stroke, shortened recovery time after stroke and provision of thrombolytic therapy for stroke.
Preferable patient populations include patients with or without pre-existing stroke or coronary heart disease. "The term “coronary artery disease”, as used herein, Is selected, but not limited to, the group consisting of atherosclerotic plaque (e.g., prevention, regression, stablilization), vulnerable plaque (e.g., prevention, regression, stabilization), vulnerable plaque area (reduction), arterial calcification (e.g., calcific aortic stenosis), increased coronary artery calcium score, dysfunctional vascular reactivity, vasodilation disorders, coronary artery spasm, first myocardial infarction, myocardia re-infarction, ischemic cardiomyopathy, stent restenosis,
PTCA restenosis, arterial restenosis, coronary bypass graft restenosis, vascular bypass restenosis, decreased exercise treadmill time, angina pectoris/chest pain, unstable angina pectoris, exertional dyspnea, decreased exercise capacity, ischemia (reduce time to), silent ischemia (reduce time to), increased severity and frequency of ischemic symptoms, reperfusion after thrombolytic therapy for acute myocardial infarction.
The term “hypertension”, as used herein, is selected, but not limited to, the group consisting of lipid disorders with hypertension, systolic hypertension and diastolic hypertension.
The term “ventricular dysfunction”, as used herein, is selected, but not limited to, the group consisting of systolic dysfunction, diastolic dysfunction, heart failure, congestive heart fallure, dilated cardiomyopathy, idiopathic dilated cardiomyopathy, and non-dilated cardiomopathy. : }
The term “cardiac arrhythmia®, as used herein, is selected, but not limited to, the group consisting of atrial arrhythmias, supraventricular arrhythmias, ventricular arrhythmias and sudden death syndrome.
The term “pulmonary vascular disease”, as used herein, is selected, but not limited to, the group consisting of pulmonary hypertension, peripheral artery block, and pulmonary : embolism.
The term “peripheral vascular disease”, as used herein, is selected, but not limited to, the group consisting of peripheral vascular disease and claudication.
The term “vascular hemostatic disease”, as used herein, is selected, but not limited to, the group consisting of deep venous thrombosis, vaso-occlusive complications of sickle cell anemia, varicose veins, pulmonary embolism, transient ischemic attacks, embolic events,
including stroke, in patients with mechanical heart valves, embolic events, including stroke, in patients with right or left ventricular assist devices, embolic events, including stroke, in patients with intra-aortic balloon pump support, embolic events, including stroke, in patients with artificial hearts, embolic events, including stroke, in patients with cardiomyopathy, embolic events, including stroke, in patients with atrial fibriliation or atrial flutter.
The term “diabetes”, as used herein, refers to any of a number of diabetogenic states including type | diabetes, type |! diabetes, Syndrome X, Metabolic syndrome, lipid disorders associated with insulin resistance, impaired glucose tolerance, non-insulin dependent diabetes, microvascular diabetic complications, reduced nerve conduction velocity, reduced or loss of vision, diabetic retinopathy, increased risk of amputation, decreased kidney function, kidney failure, insulin resistance syndrome, pluri-metabolic syndrome, central adiposity (visceral)(upper body), diabetic dyslipidemia, decreased insulin sensitization, diabetic retinopathy/neuropathy, diabetic nephropathy/micro and macro angiopathy and micro/macro albuminuria, diabetic cardiomyopathy, diabetic gastroparesis, obesity, increased hemoglobin glycoslation (including HbA1C), improved glucose control, impaired renal function (dialysis, endstage) and hepatic function (mild, moderate, severe).
The terms “inflammatory disease, autoimmune disorders and other systemic diseases”, as used herein, are selected. but not limited to, the group consisting of multiple sclerosis, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, irritable bowel disease,
Crohn's disease, colitis, vasculitis, lupus erythematosis, sarcoidosis, amyloidosis, apoptosis, and disorders of the complement systems.
The term “cognitive dysfunction”, as used herein, Is selected, but not limited to, the group consisting of dementia secondary to atherosclerosis, transient cerebral ischemic attacks, neurodegeneration (including Parkinson's, Huntington's disease, amyloid deposition and amylotrophic lateral sclerosis), neuronal deficient, and delayed onset or procession of
Alzheimer’s disease.
The “transition period” means from 30 days prepartum to 70 days postpartum
The term “treating”, "treat", “treats” or “treatment” as used herein includes prophylactic, palliative and curative treatment. "Negative energy balance" as used herein means that energy via food does not meet the requirements of maintenance and production (milk).
The term “cow” as used herein includes heifer, primiparous and multiparous cow. “Healthy ruminant” means where the ruminant does not show signs of the following indications: fatty liver syndrome, dystocia, immune dysfunction, impaired immune function, toxification, primary and secondary ketosis, downer cow syndrome, indigestion, inappetence, retained placenta, displaced abomasum, mastitis, (endo-}-metritis, infertility, low fertility and/or lameness.
Milk “quality” as used herein refers to the levels in milk of protein, fat, lactose, somatic cells, and ketone bodies. An increase In milk quality is obtained on an increase in fat, protein or lactose content, or a decrease in somatic cell levels or ketone bodies levels.
An increase in milk yield can mean an increase in milk solids or milk fat or milk protein content, as well as, or instead of, an increase in the volume of milk produced. “Excessive accumulation of triglycerides” as used herein means greater than the physiological triglyceride content of 10%wi/w in liver tissue. “Excessive elevation of non-esterified fatty acid levels in serum” as used herein means non-esterified fatty acid levels of greater than 800pmollL in serum,
Unless otherwise specified, “prepartum” means 3 weeks before calving until the day of calving.
Unless otherwise specified, “postpartum” means from when the newborn is “expelled” from the uterus to 6 weeks after the newborn was expelled from the uterus. “At parturition” means the 24 hours after the newborn was expelled from the uterus. “Periparturient” means the period from the beginning of the prepartum period, to the end of the postpartum period. “Metabolic syndrome,” also known as "Syndrome X,” refers to a common clinical disorder that is defined as the presence of increased insulin concentrations in association with other disorders including viceral obesity, hyperlipidemia, dyslipidemia, hyperglycemia, hypertension, and potentially hyperuricemis and renal dysfunction.
By "pharmaceutically acceptable” is meant the carrier, diluent, excipients, and/or salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof. *Compounds” when used herein includes any pharmaceutically acceptable derivative or variation, including conformational isomers (e.q., cis and trans isomers) and all optical isomers (e.g., enantiomers and diastereomers), racemic, diastereomeric and other mixtures of such isomers, as well as solvates, hydrates, isomorphs, polymorphs, tautomers, esters, salt forms, and prodrugs. By “tautomers” is meant chemical compounds that may exist in two or more forms of different structure (isomers) in equilibrium, the forms differing, usually, in the position of a hydrogen atom. Various types of tautomerism can occur, including keto-enol, ring-chain and ring-ring tautomerism. The expression "prodrug" refers to compounds that are drug precursors which following administration, release the drug in vivo via some chemical or physiological process (e.g., a prodrug on being brought to the physiological pH or through enzyme action is converted to the desired drug form). Exemplary prodrugs upon cleavage release the corresponding free acid, and such hydrolyzable ester-forming residues of the compounds of the present invention include but are not limited to those having a carboxyl moiety wherein the free hydrogen is replaced by (C,-C,)alkyl, (C-C;)alkanoyloxymethyl, 1-
(alkanoyloxy)ethyl having from 4 to 8 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from § to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1- (alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1- (alkoxycarbonyloxy)ethyt having from & to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyi, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N ,N-(C-
Co)alkylamino(C2-Cs)alkyl (such as B-dimethylaminoethyl), carbamoyl-(C4-Ca)alkyl, N,N-di(C1-
Cz)alkylcarbamoyl-(Cs-Cz)alkyl and piperidino-, pyrrolidino- or morpholino(C2-Cs)alkyl.
The following paragraphs describe exemplary ring(s) for the generic ring descriptions contained herein.
Exemplary five to six membered aromatic rings optionally having one or two heteroatoms selected independently from oxygen, nitrogen and sulfur include phenyl, furyi, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridiazinyl, pyrimidinyl and pyrazinyl.
Exemplary partially saturated, fully saturated or fully unsaturated five to eight membered carbocyclic rings optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen include cyclopentyl, cyclohexyl, cycioheptyl, cyclooctyl and phenyi.
Further exemplary five membered carbocyclic rings include 2H-pyrrolyl, 3H-pyrrolyi, 2-pyrrolinyl, 3-pyrrolinyt, pyrrolidinyl, 1,3-dioxolanyi, oxazolyl, thiazolyl, imidazolyl, 2H- imidazolyl, 2-imidazolinyl, imidazolidinyl, pyrazolyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyt, isothiazolyl, 1,2-dithiolyl, 1,3-dithiolyl, 3H-1,2-oxathiolyl, 1,2,3-oxadiazolyl, 1,2 4-oxadiazoiyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,3,4-thiadiazolyt, 1,2,3,4- oxatriazolyl, 1,2,3,5-oxatriazolyl, 3H-1,2,3-dioxazolyl, 1,2,4-dioxazolyl, 1,3,2-dioxazolyl, 1,3,4- dioxazolyl, 5H-1,2,5-oxathiazolyl and 1,3-oxathiolyl.
Further exemplary six membered carbocyclic rings include 2H-pyranyl, 4H-pyranyi, pyridinyl, piperidinyl, 1,2-dioxinyl, 1,3-dioxinyi, 1,4-dioxanyl, morpholinyl, 1,4-dithianyi, thiomorpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 1,3,5-triazinyl, 1,2,4-triazinyi, 1,2,3-triazinyl, 1,3,5-trithianyl, 4H-1,2-oxazinyl, 2H-1,3-oxazinyl, 6H-1,3-oxazinyl, 6H-1,2- oxazinyl, 1,4-oxazinyl, 2H-1,2-oxazinyl, 4H-1,4-oxazinyl, 1,2 5-oxathiazinyl, 1,4-0xazinyl, o- isoxazinyl, p-isoxazinyl, 1,2,5-oxathiazinyl, 1,2,6-oxathiazinyl, 1,4,2-oxadiazinyl and 1,3,5,2- oxadiazinyl.
Further exemplary seven membered rings include azepinyl, oxepinyl, and thiepinyl.
Further exemplary eight membered carbocyclic rings include cyclooctyl, cyclooctenyl and cyclooctadienyl.
Exemplary bicyclic rings consisting of two fused partially saturated, fully saturated or fully unsaturated five or six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen include indolizinyl, indolyl, isoindalyl, 3H-indolyl, 1H-isoindolyl, indolinyi, cyclopenta(b)pyridinyl, pyrano(3,4- b)pyrrolyl, benzofuryl, isobenzofuryl, benzo(b)thienyl, benzo(c)thienyi, 1H-indazolvi, indoxazinyl, benzoxazolyl, benzimidazolyl, benzthiazolyl, purinyi, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazoliny, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, indenyl, isoindenyl, naphthyl, tetralinyl, decalinyl, 2H-1-benzopyranyl, pyrido(3,4-b)-pyridinyi, pyrido(3,2-b)-pyridinyl, pyrido(4,3-b)-pyridinyl, 2H-1,3-benzoxazinyl, 2H-1,4-benzoxazinyl, 1H- 2,3-benzoxazinyl, 4H-3,1-benzoxazinyl, 2H-1 ,2-benzoxazinyl and 4H-1,4-benzoxazinyl.
The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms In the moisty, l.e., the prefix Ci-C, indicates a moiety of the integer “i" to the integer “i” carbon atoms, inclusive.
Thus, for example, C1-C; alkyl refers to alkyl of one to three carbon atoms, inclusive, or methyl, ethyl, propyl and isopropyl, and all isomeric forms and straight and branched forms thereof.
By “aryl” is meant an optionally substituted six-membered aromatic ring, including polyaromatic rings. Examples of aryl include phenyl, naphthyl and biphenyl. “Heteroaryl” as used herein means an optionally substituted five- or six-membered aromatic ring, including polyaromatic rings where appropriate carbon atoms are substituted by nitrogen, sulfur or oxygen. Examples of heteroaryl include pyridine, pyrimidine, thiazole, oxazole, quinoline, quinazoline, benzothiazole and benzoxazole.
By “halo” or “halogen” is meant chloro, bromo, iodo, or fluoro.
By “alkyl” is meant straight chain saturated hydrocarbon or branched chain saturated hydrocarbon. Exemplary of such alkyl groups (assuming the designated length encompasses the particular example) are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, neopentyl, tertiary pentyl, 1-methyibutyl, 2-methyibutyl, 3-methyibutyl, hexyl, isohexyl, heptyl and octyl. This term also includes a saturated hydrocarbon (straight chain or branched) wherein a hydrogen atom is removed from each of the terminal carbons. “Alkenyt” referred to herein may be linear or branched, and they may also be cyclic (e.g. cyclobutenyi, cyciopentenyl, cyclohexenyl) or bicyclic or contain cyclic groups. They contain 1-3 carbon-carbon double bonds, which can be cis or trans,
By “alkoxy” is meant straight chain saturated alkyl or branched chain saturated alkyl bonded through an oxy. Exemplary of such alkoxy groups (assuming the designated length encompasses the particular example) are methoxy, ethoxy, propoxy, iSopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, neopentoxy, tertiary pentoxy, hexoxy, isohexoxy, heptoxy and octoxy .
It is to be understood that if a carbocyclic or heterocyclic molety may be bonded or otherwise attached to a designated substrate through differing ring atoms without denoting a specific point of attachment, then all possible points are intended, whether through a carbon atom or, for example, a trivalent nitrogen atom. For example, the term “pyridyl” means 2-, 3- or 4-pyridyl, the term “thienyl” means 2- or 3-thienyl, and so forth.
The term “HMG CoA reductase inhibitor” is selected, but not limited to, the group consisting of lovastatin, simvastatin, pravastatin, fluindostatin, velostatin, dihydrocompactin, compactin, fluvastatin, atorvastatin, glenvastatin, dalvastatin, carvastatin, crilvastatin, bervastatin, cerivastatin, rosuvastatin, pitavastatin, mevastatin, or rivastatin, or a pharmaceutically acceptable salt thereof.
The term “antihypertensive agent” is selected, but not limited to, a calcium channel blocker (including, but not limited to, verapamil, diltiazem, mibefradil, isradipine, lacidipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, avanidpine, amlodipine, amlodipine besylate, manidipine, cilinidipine, lercanidipine and felodipine), an ACE inhibitor (including, but not limited to, benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, trandolapri, ramipril, zestril, zofenopril, cilaapril, temocapril, spirapril, moexipril, delapril, imidapril, ramipril, terazosin, urapidin, indoramin, amolsulalol, and alfuzosin), an A-
Il antagonist (including, but not limited to, losartan, irbesartan, teimisartan and valsartan), a diuretic (including, but not limited to, amiloride, and bendrofiumethiazide), a beta-adrenergic receptor blocker (such as carvedilol) or an alpha-adrenergic receptor blocker (including, but not limited to, doxazosin, prazosin, and trimazosin), or a pharmaceutically acceptable sat of such compounds.
In one embodiment of the present invention, p is 1 or 2 and R' is bonded to Q.
In another embodiment of the present invention, Ar’ is: o N 1 s J / 2
HO HI +0 + [] N ’ ' '
N N oe ee eg)
Ss EN , OF s .
In another embodiment of the present invention, Ais
N N “a O,
Zs sx i N
Sm NE ak —~1T —{ TF ~~ T
Z Sh N x
Wg | ¢- LI ba] LF wf) ‘
AN S N Z i
AU
Se: Te: LIVE! a ——k Whe — j= i
ZZ a pos 0
ALN wt Et / ¢ van o} ol off aff 8 pt TNE)
V4 NED "TV lo] —N / = pr pk JOH NT
N nd 0% SSW or in another embodiment of the present invention,
Ar! is phenyl or phenyl fused to oxazolyl or thiazolyl; and
Ar? is phenyl or phenyl fused to a ring selected from the group consisting of: phenyl, pyridinyl, thieny, thiazolyl, oxazolyl, and imidazolyl.
In another embodiment of the present invention, halo is fluoro.
In another embodiment of the present invention, B is a bond or -L-(CY2)s- or «CY2)r
L-,and Lis OorS,andnis0,10r2. in another embodiment of the present invention,
X is -COORY;
B is a bond;
Ar! is phenyl or phenyl fused to oxazolyt or thiazolyl; and
Ar is phenyl or phenyl fused to a ring selected from the group consisting of: phenyl, pyridinyl, thienyt, thiazolyl, oxazolyl, and imidazolyi. in another embodiment of the present invention,
X is -COOR*;
B is -L-(CYa)s- Or (CYa)-L-, and Lis O or S,andnis 0,1 or 2;
Ar! is phenyl or phenyl fused to oxazoly! or thiazolyl; and
Ar is phenyl or phenyl fused to a ring selected from the group consisting of: phenyl, pyridinyl, thienyl, thiazolyl, oxazolyl, and imidazolyl.
in another embodiment of the present invention, } / i {Or +10 HK
Ar'ls , \! : pee : { or ; and
EN N N Sch
Or
Ais Fs , © A : , or 0] 5S N .
In another embodiment of the present invention, q is 1 or 2 and each J is independently halo, (Cs-Cs)alky! optionally substituted with one to three halo, or (C4-Cj)alkoxy optionally substituted with one to three halo.
In another embodiment of the present invention, pis 1 and R* is H or (Cy-Cs)alkyl.
In another embodiment of the present invention, Lis Sand nis 1. tn another embodiment of the present invention, the compound of formula | is selected from the group consisting of: 2-Methyl-5-[4-(5-methyl-benzooxazol-2-yl}-phenyisulfamoyi] benzoic acid; 5-[4~5-Chioro-benzooxazol-2-yl}-phenylsulfamoyl]-2-methyt-benzoic acid; 2-Methyl-5-{4-(4-trifluoromethyi-benzylsulfanyl)-phenyisulfamoyi}-benzoic acid; 5-[4-(4-tert-Butyl-benzylsulfanyl)-phenylsulfamoyi}-2-methyl-benzoic acid; 2-Ethyi-5-[4-(5-methyl-benzooxazol-2-yl)-phenyisulfamoyl]-benzoic acid; 5-[4-(4-Ethyl-benzylsulfanyl)-phenylsulfamoyl}-2-methyl-benzoic acid; 5-[4-(3,4-Diflucro-benzylsuifanyl)-phenylsulfamoyi]-2-methyl-benzoic acid; 5-[4-(3,4-Dimethyi-benzylsulfanyl)-phenyisulfamoyi}-2-methyi-benzoic acid; 5-[4-(5,7-Difluoro-benzothiazol-2-yimethyisulfanyl)-phenyisulfamoyi]-2-methyi-benzoic acid; 2,3-Dimethyi-5-(4"-trifluoromethoxy-biphenyl-4-ylsulfamoyl)-benzoic acid; 2-Ethyl-5-[4-(4-trifluoromethoxy-benzyisulfanyt)-phenyisulfamoyi]-benzoic acid; 2-Ethyl-5-{4-trifluoromethoxy-biphenyl-4-ylsulfamoyl)-benzoic acid; 2-Isopropyl-5-[2-(4-trifluoromethoxy-phenyl)}-benzooxazol-5-yisuifamoyl]-benzoic acid; and 2-Methyi-5-(4"-trifluocromethoxy-biphenyi-4-ylsuliamoyi)-benzoic acid; or a prodrug of sald compound or a pharmaceutically acceptable salt of said compound or prodrug
In another embodiment of the present invention, the compound of formula | is selected from the group consisting of: 2-Ethyl-5-[4-(6-methyl-benzothiazol-2-yl)-phenyisulfamoyl}-benzoic acid; 2-Methyl-5-(4"-rifluoromethyl-biphenyl-4-yisulfamoyl}-benzoic acid; 2-sopropyl-5-[propyi-(4'-triflucromethox y-biphenyi-4-yl)-sulfamoyl]-benzoic acid; 2-Methyl-5-{(4'-propoxy-biphenyl-4-yl}-propyl-suifamoyl}-benzoic acid; 2-Methyl-5-(4'-propoxy-biphenyl-4-ylsulfamoyl)-benzoic acid; 2-Ethyl-5-{4-(4-trifluoromethoxy-benzyls uifanyl}-phenyisulfamoyl}-benzoic acid; 5-(4'-tert-Butyl-biphenyi-4-yisutfamoyi}-2-methyl-benzoic acid; 5-[4-(4-Chloro-benzyisulfanyl}-phenylsulfamoyi}-2-methyl-benzoic acid; 2-Methyl-5-[4-(3-triflucromethoxy-benzylsulfanyl}-phenyisuifamoyl]-benzoic acid; 2-Methyl-5-[2-(4-trifluoromethyl-phenyl)-benzooxazol-5-yisulfamoyi}-benzoic acid; 2-Methyi-5-[4-(5-phenyl-benzooxazol-2-yl}-phenyisulfamoyl}-benzoic acid; and 2-Isopropyt-5-{4-{5-methyl-benzooxazol-2-yl}-phenyisuifamoyi]-benzoic acid; 16 ora prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
In one embodiment of the methods of the present invention, atherosclerosis is treated. in one embodiment of the methods of the present invention, peripheral vascular : disease is treated.
In one embodiment of the methods of the present invention, dyslipidemia is treated. in one embodiment of the methods of the present invention, diabetes is treated.
In one embodiment of the methods of the present invention, hypoalphalipoproteinemia is treated. in one embodiment of the methods of the present invention, hypercholesterolemia is treated.
In one embodiment of the methods of the present invention, hypertriglyceridemia is treated.
In one embodiment of the methods of the present invention, obesity is treated. in one embodiment of the methods of the present invention, osteoporosis is treated.
In one embodiment of the methods of the present invention, metabolic syndrome is treated. in another embodiment of the present invention, the pharmaceutical composition is for the treatment of atherosclerosis in a mammal which comprises an atherosclerosis treating amount of a compound of formula |, or a prodrug of said compound or a pharmaceutically 36 acceptable salt of said compound or prodrug and a pharmaceutically acceptable carrier, vehicle or diluent.
In one embodiment of the pharmaceutical combination compositions, methods and kits of the present invention, the second compound is an HMG-CoA reductase inhibitor or a
CETP inhibitor.
In one embodiment of the pharmaceutical combination compositions, methods and kits of the present invention, the second compound is rosuvastatin, rivastatin, pitavastatin, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin or cerivastatin or a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
In one embodiment of the pharmaceutical combination compositions, methods and kits of the present invention, the second compound is [2R 48] 4-[(3,5-bis-trifluoromethyi- benzyl)-methoxycarbonyl-amino}-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1- . carboxylic acid ethyl ester. in one embodiment of the pharmaceutical combination compositions, methods and kits of the present invention, the composition further comprises a cholesterol absorption inhibitor.
In one embodiment of the pharmaceutical combination compositions, methods and kits of the present invention, the cholesterol absorption inhibitor is ezetimibe.
In one embodiment of the pharmaceutical combination compositions, methods and kits of the present invention, the composition further comprises an antihypertensive agent.
In one embodiment of the pharmaceutical combination compositions, methods and kits of the present invention, said antihypertensive agent is a calcium channel blocker, an ACE inhibitor, an A-ll antagonist, a diuretic, a beta-adrenergic receptor blocker or an alpha- - adrenergic receptor blocker.
In one embodiment of the pharmaceutical combination compositions, methods and kits of the present invention, the antihypertensive agent is a calcium channel blocker, said calcium channel blocker being verapamil, diltiazem, mibefradil, isradipine, lacidipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, avanidpine, amlodipine, amlodipine besylate, manidipine, cilinidipine, lercanidipine or felodipine or a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
In another embodiment of the present invention, the compound of formula i is: 4-(5-Chlcro-benzooxazol-2-yl}-phenylamine; 4-(4-Trifluoromethyl-benzylsulfanyl}-phenylamine; 4-(4-tert-Butyl-benzyisulfanyl)-phenylamine; 4-(4-Ethyl-benzyisulfanyl}-phenylamine; 4-(3,4-Difluoro-benzylsulfanyt)-phenylamine; 4-(3,4-Dimethyl-benzylsulfanyl}-phenylamine; 4-(5,7-Difluorc-benzothiazol-2-yimethyisulfanyl)-phenylamine; 4'-Trifluoromethoxy-biphenyl-4-ylamine;
4-(4-Trifluoromethoxy-benzylsulfanyl}-phenylamine; or 4-Trifluoromethoxy-phenyl}-benzooxazol-5-ylamine; or a pharmaceutically acceptable salt thereof. in general, the compounds of this invention can be made by processes that include processes analogous to those known in the chemical arts, particularly in light of the description contained herein. Certain processes for the manufacture of the compounds of this invention are provided as further features of the invention and are illustrated by the following reaction schemes. Other processes may be described in the experimental section.
The Reaction Schemes herein described are intended to provide a general description of the methodology employed in the preparation of many of the Examples given.
However, it will be evident from the detailed descriptions given in the Experimental section that the modes of preparation employed extend further than the general procedures described herein. In particular, it is noted that the compounds prepared according to these
Schemes may be modified further to provide new Examples within the scope of this invention.
For example, an ester functionality may be reacted further using procedures well known to those skilled in the art to give another ester, an amide, an acid, a carbinol or a ketone.
As an initial note, in the preparation of compounds of the present invention, it is noted that some of the preparation methods useful for the preparation of the compounds described herein may require protection of remote functionality (e.g., primary amine, secondary amine, carboxy! in intermediates). The need for such protection will vary depending on the nature of the remote functionality and the conditions of the preparative methods and can be readily determined by one of ordinary skill in the art. The use of such protection/deprotection methods is also within the ordinary skill in the art. For a general description of protecting groups and their use, see T.W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New
York, 1991.
For example, in the reaction schemes below, certain compounds contain primary amines or carboxylic acid functionalities, which may interfere with reactions at other sites of the molecule if left unprotected. Accordingly, such functionalities may be protected by an appropriate protecting group, which may be removed in a subsequent step. Suitable protecting groups for amine and carboxylic acid protection include those protecting groups commonly used in peptide synthesis (such as N-t-butoxycarbonyl, benzyloxycarbonyl, and 8- fluorenylimethyienoxycarbonyl for amines and lower alkyl or benzyl esters for carboxylic acids) which are generally not chemically reactive under the reaction conditions described and can typically be removed without chemically altering other functionality in the compound.
Scheme 1 Ly o= o R* o AR RX. o $x Re 0 Halo-SOH 0 te (Jg—Ar “8s,
RY, Halo—S RY, R— 1a 1b ic
NaOH
R* = atkyl
OH lo) (ar Re) ®% of Hin © 1d
According to reaction Scheme 1, the compounds of formula 1d, which are compounds of formula | wherein X is <COOR®, R?is H, R (optionally present) is halo, alkyl, alkoxy or alkylthio and R', B, A%, J, p and q are as described above are prepared by procedures well known in the art. For example, treatment of the benzoic acid or ester 1a (which are commercially available or are known in the literature or may be prepared according to methods familiar to those skilled in the art) with chlorosulfonic acid (halo is chloro) at temperatures between about 90 and110° C, preferably 100° C, for a period of about 15 min to 3 hr, preferably 2.5 hr for the acid and 15 min for the ester, leads to the halogenated sulfonyl 1b.
The reaction of sulfonyl chloride 1b with appropriately substituted anilines 1e (preparation of anilines 1e described in Schemes 4, 5, 6, 7 and 8) to form the sulfanilides 1c may be performed under reaction conditions well known to those skilled in the art. For example, the reaction of sulfonyl chloide1b and an aniline 1e may be performed in an inert solvent such as tetrahydrofuran, dimethylformamide or a mixture of acetone and water, in the presence of a base such as pyridine, potassium carbonate or sodium carbonate, at temperatures between 20° C and 65° C, preferably at room temperature for a period of about 10 to 36 hr, preferably about 20 hr. If 1b is a chlorosulfonyl benzoic ester (R* = CH;), it may be preferable to perform the reaction in an organic solvent such as tetrahydrofuran in the presence of an amine base such pyridine and triethylamine.
The ester product 1c may be converted to the benzoic acid 1d by hydrolysis with an alkali metal hydroxide, preferably sodium hydroxide, in a mixture of an alcohol, preferably methanol, and water at a temperature of about 50 to 100° C preferably at reflux temperature, for a period of about 2 to 30 hr.
R4
Scheme 2 lo} qo RK /
Te SE Se
Hao—s— ) ed ao, NO oo =r RE_1
P
2a 2b 1b a=
Pd cat | Bio) 2c
RY
Jo) lo] a} iN ®R are 2d
According to reaction Scheme 2, the desired Formula ! compounds wherein X is —
COOR* R%isH, Bis abond, A? is phenyl, R (optionally present) is halo, alkyl, alkoxy or alkylthio, and R' J, p and q are as described above, are prepared by reacting a halogenated sulfonyl (wherein halo is chioro) 1b and 4-haloaniline 2a (wherein halo is bromo or iodo) in an inert solvent such as tetrahydrofuran or a solvent mixture such as acetone and water, in the presence of an amine base such as pyridine/triethylamine or an inorganic base such as potassium carbonate or sodium carbonate, at a temperature of about 20°C to 50° C, preferably room temperature, for a period of about 20 hr to form the halogenated suifaniiide 2b.
Reaction of the halogenated sulfanilide 2b in a solvent such as tetrahydrofuran, dioxane, dimethoxyethane or dioxane/water with an appropriately substituted benzene boronic 16 acid derivative 2c under palladium catalysis in the presence of a base such as potassium carbonate, cesium carbonate or sodium carbonate, at temperatures between 80° C and 110°
C, preferably at refiux, for 6-30 hr, preferably 20 hr, using procedures known to those skilled in the art, leads to the biphenylsulfanilide 2d. Further palladium catalysts, phosphine ligands, solvents, bases and reaction temperatures that can be used are exemplified in Chemical
Reviews 102, 1359 (2002). For example, reaction of bromosulfanilide as the halogenated sulfanilide 2b with an arytboronic acid 2c in the presence of a catalytic amount of dichloro[1,1'- bis(diphenylphosphino)ferrocene]palladium(!l) dichloromethane adduct and 1,1'- bis(diphenylphosphino)ferrocene, with potassium carbonate as base and aqueous dioxane as solvent, yields biphenylanilide 2d. As shown in Scheme 1, the ester group of compound 2d (X, -COOR*) may be converted to an acid group by basic hydrolysis.
Scheme 3 4 " gy " o= _ RYhalo o o fo]
WUg—Ar /\ ond, NRT, Wg—Ar? J Oe Rr AZ Osd TRY, of Hui SAS aA a So
R= FR ic ® 3c
According to reaction Scheme 3, the desired Formula | compounds wherein X Is —
COOR’, R? is alkyl, R (optionally present) is halo, alkyl, alkoxy or alkylthio, and R', R?, B, A”,
J, p and q are as described above, are prepared by treating a sulfanilide 1c with an appropriate halogenated alkyl (wherein halo is bromo or iodo) 3a or with an alkyl sulfonate in the presence of an alkali metal carbonate such as potassium, sodium or cesium carbonate in an inert solvent such as acetone or dimethyiformamide at temperatures between 60°C and 80° C, preferably acetone at reflux temperature to yield the n-alkyl sulfanilide ester 3b. } The n-alkyl sulfanilide ester 3b may be converted to acid 3c by basic hydrolysis such as the reaction conditions previously exemplified in Scheme 1.
Schemes 4, 5, 6, 7 and 8 describe the preparation of anilines 1e, used in the synthesis shown in Scheme 1. Altematively, the anilines 1e in Scheme 1 are commercially availabie or are known in the literature or may be prepared according to procedures well known in the art.
Scheme 4
DH PPA § me
EN wo oo Ny Sa
A Z IR
NH2 H oN 1e4 4a 4b
DH C= PD Wel
CN + ==\.(J a 01 + a — Jd X14 C5
NH, R Ul ad 4a 4c D
DEAD
PhsP / . Fe = 9} = IN x = { / —_— ive Co 1e4 de
The desired Formula 1e compounds wherein R? is hydrogen, R (optionally present) is halo, alkyl, alkoxy or alkylthio, B is a bond, Ar? is a phenyl ring fused to an imidazole, oxazole, or thiazole ring (D is N, O or S) and J and q are as described above, may be prepared by 4a and 4b (Scheme 4) or by similar synthetic routes familiar to those skilled in the art.
In Scheme 4a, a 2-aminophenal, 2-aminothiophenol or 2-aminoaniline derivative 4a is heated with an appropriately substituted 4-aminobenzoic acid 4b in polyphosphoric acid at about 170°C to 200° C for 4-10 hr, preferably 190° C for 6 hr, to yield the corresponding 4- benzoxazol-2-yl-phenylamine, 4-benzothiazol-2-yi-phenylamine, or 4-benzimidazol-2-yi- phenylamine derivatives 1e4.
Alternatively, as outlined in Scheme 4b, acyiation of a 2-aminophenol, 2- aminothiophenol or 2-aminoaniline derivative 4a with 4-nitrobenzoyl chloride or 4-nitrobenzoyl bromide 4c, in an inert solvent such as methylene chloride, in the presence of an amine base such as 4-dimethylaminopyridine, at a temperature of 20°C to 50° C for 10-30 hr, preferably at ’ room temperature for 20 hr, yields the corresponding benzamide 4d.
Under the acylation reaction conditions, the thiophenol derivative 4d (D = S) spontaneously cyclizes to the benzothiazole derivative 4e (D = S). The phenol derivative 4d (D = O) may be cyclized to the benzoxazole derivative 4e (D = O) by treatment with diethyt azodicarboxylate (DEAD) and triphenyiphosphine (PhsP), in a solvent such as tetrahydrofuran, dimethylformamide, methylene chloride or dioxane, preferably tetrahydrofuran at 15°C to 35°
C for 10-30 hr, preferably at room temperature overnight.
The nitro group in 4e may be reduced to form the aniline 1e4 by procedures familiar to those skilled in the art. For example, heating the nitro compound 4e with iron powder and calcium chloride in aqueous alcohol such as ethanol at about 60°C to100° C for 4 to 10 hr, preferably at reflux for 5 hr yields the aniline 1e4. Other reducing reagents swuch as iron and acetic acid, zinc and aqueous hydrochloric acid and catalytic hydrogenation are exemplified in
Richard Larock, Comprehensive Organic Transformations, VCH Publishers, New York, 1989 412.
Scheme 5
Mon q AN My 35 rs OY — OAR 5a th 5b ew J 1e5 J
The desired Formula 1e5 compounds wherein R? is hydrogen, Bis a bond, Af is an oxadiazole ring and J Is as described above, may be prepared by Scheme 5 or by similar synthetic routes familiar to those skilled in the art.
Acylation of commercially available 5-(4-nitrophenyi}-1H-tetrazole Sa with an acyl chloride 5b in pyridine at room temperature, followed by heating at 60° C for 1 hr and at 100°
C for 2 hr, yields 2-{4-nitrophenyl}-1,3 4-oxadiazole 5c.
Reduction of the nitro group to amine by methods known to those skitled in the art yields the aniline 1e5. For example, the reduction may be performed, as previously shown in
Scheme 4b, with iron powder and calcium chloride in aqueous ethanol.
Scheme 6 6a) OT), + padat = DN Cie LY A 6s 6b 6c 18
NaH Jha . 6d 6e 1e6-1 6a 6f 1662
The desired Formula 1e6 compounds wherein RZ is hydrogen, R (opti onally present) is halo, alkyl, alkoxy or alkylthio, B is —L-CHz- or —-CHz-L-, A is phenyl and J and q are as described above, may be prepared by the synthesis depicted in 6a, 6b and 6¢ of Scheme 6 or by similar synthetic routes familiar to those skilled in the art.
Benzyloxynitrobenzene or benzylsulfanylnitrobenzene derivatives (6c) may be prepared by the Mitsunobu reaction, for example, by the reaction of 4-nitrophenol or 4- nitrothiophenol 6b with an appropriate benzyl alcohol 6a, in the presence of diethyl azodicarboxylate (DEAD) and triphenylphosphine (PhsP), in a solvent such as tetrahydrofuran, dimethylformamide, methylene chloride or dioxane, at about 15°C to 35° C for about 10 to 30 hr, preferably in tetrahydrofuran at room temperature overnight (Scheme 6a). The reaction conditions, solvents, temperature and reaction time for the Mitsunobu reaction are reviewed in
Organic Reactions, Vol 42, 1992, 335, John Wiley, 2002. Reduction of the nitro group of 6c by methods known to those skilled in the art, including those exemplified in Scheme 4b, yields the corresponding aniline 1e6.
For example, in Scheme 6b, benzylsulfanylaniline 166-1 may be synthesized by treating 4-aminothiophenol 6d with an appropriately substituted benzyl chloride 6e in the presence of a base such as sodium hydride, cesium carbonate or sodium tert-butoxide, in a solvent such as tetrahydrofuran, dimethytformamide or dimethoxyethane, preferably tetrahydrofuran, at a temperature of about 20°C to 70°C for about 8 to 30 hr, preferably at room temperature overnight. 4-Benzyloxyaniline 1e6-2 may be prepared by the Mitsunobu reaction (Scheme 6c), wherein the reaction of 4-aminophenol 6f with an appropriate benzyl alcohol 6a, in a solvent such as tetrahydrofuran, is mediated by diethyl azodicarboxylate (DEAD) and triphenylphasphine (Ph,P), at room temperature overnight as exemplified for 6c.
Scheme 7
Halo—¢ H ( Lia LO) ow
URI SY a Wa 2a 2c 187
The desired Formula 1e compounds wherein R?is hydrogen, R (optionally present) is halo, alkyl, alkoxy or alkylthio, B is a bond, Ar? is phenyl and J and q are as described above, may be prepared by the synthesis depicted in Scheme 7 or by similar synthetic routes familiar to those skilled in the art.
Biphenylamine derivatives 1e7 may be synthesized by a Suzuki coupling of 4- haioaniline 2a wherein halo is bromo or iodo and an appropriately substituted benzene boronic acid derivative 2c, using procedures known to those skilled in the art as exemplified in
Scheme 2c. Benzene boronic acid derivatives 2c are commercially available or may be readily prepared by literature methods known to those skilled in the art as exemplified in
Scheme 2c. For example, reaction of 4-bromoaniline with an arylboronic acid 2c in the presence of a catalytic amount of dichioro[1,1'-bis(diphenylphosphino)ferrocene]palladium(il) dichloromethane adduct and 1,1"-bis(diphenylphosphino)ferrocens, with potassium carbonate as base and aqueous dioxane as solvent, at reflux temperature overnight yields biphenylamine derivative 1e7.
Scheme 8
Q, ) /\ He = { \ JF NaH a a3 wn FEE NY TT wd) EY:
Ba ab Org 8c e8
The desired Formula 1e compounds wherein R? is hydrogen, R (Optionally present) is "5 halo, alkyl, alkoxy or alkylthio, B is L, Ar? is phenyt and J and q are as described above, may be prepared by the synthesis depicted in Scheme B or by similar synthetic routes familiar to those skilled in the art.
Phenoxyaniline and phenylsulfanyianiline derivatives 1e8 (Scheme 8) may be prepared by reaction of 4-halonitrobenzene 8b, wherein halo is chloro, bromo or iodo, with an appropriate phenol or thiophenol 8a in the presence of a base such sodiurn hydride, sodium tert-butoxide or cesium carbonate in an inert solvent such as dimethylform amide, tetrahydrofuran or dimethoxyethane, at about 60° C to 90°C for about 10 to 30 hr, preferably at 80° C overnight yields the nitro derivative 8c. Aniline 18 may be produced by reducing the nitro derivative 8c, using procedures known to those skilled in the art, such as those 156 previously exemplified in Scheme 4b.
Scheme 9
Os H 1)MesSICN Z._CN HP & NHC A 1) NH,CSNH, 0/5 "re Fsoor BP enna ®Y% 9a 9 8c ad
R
He OAR Yr OsMoo 07S fe R 0 s
Pe — om B10
CI0;S “ZR = ERY, 9d 9e
Compounds of Formula | wherein X is thiazolidinedione-5-y-G-, G is (CH), sis 0,
R?is H, R (optionally present) is halo, alkyl, alkoxy or alkylthio and RY, B, Ar?, J, p and q are as described above, may be prepared by the synthetic sequence outlined in Scheme 9, as taught by J. Med. Chem. ,29, 773 (1986) and Chem. Pharm. Bull., 30, 3601 (1982). An appropriately substituted benzaldehyde 9a is treated with trimethylsilyl cyanide and a catalytic amount of zinc iodide in anhydrous methylene chloride or chloroform at about 20° C to 30° C for about 15 to 30 hr, preferably in methylene chioride at room temperature overnight to yield the cyanohydrin 9b (Z=CH).
The cyanohydrin 8b (Z=OH) is converted to the chlorocyanide 9b (Z = Cl) with thionyl chloride in chloroform or methylene chloride at about 30° C to 65° C for about 30 to 60 min, preferably in chloroform at reflux temperature for 45 min. Reaction of chlorocyanide 9b (Z=
Ci) with thiourea in an alcoholic solvent such as ethanol at about 60° C to 80° C for about 4 to hr, preferably in ethanol at reflux temperature for 5 hr followed, by hydrolysis of the 10 intermediate iminothiazolidinone with aqueous acid at about 85° C to 120° C for about 4 to 10 hr, preferably 6N aqueous hydrochloric acid at refiux temperature for 5 hr leads to the thiazolidinedione Sc.
Alternatively, appropriate benzaldehyde 9a is treated with sodium cyanide in a mixture of water, acetic acid and ethylene glycol monomethyl ether at room temperature for 1.5 hr followed by the addition of thiourea and concentrated hydrochloric acid and heating at about 100° C for 18 hr to yield thiazolidinedione 9c (Chem. Pharm. Bull, 45, 1984 (1997).
Heating thiazolidinedione 9c in neat chiorosulfonic acid at about 90° C to 110° C for about 15 to 30 min, preferably at 100° C for 15 min yields sulfonyl chloride 9d. Reaction of sulfonyl chloride 9d with appropriately substituted anilines 1e using procedures known to those skilled in the art, such as the reaction described in Scheme 1, leads to the desired thiazolidinedione derivatives Se.
Scheme 10
Og H Lion On © NL & S= <a CISOgH Ps
RY — ® 1S FS oa 7 CIO 8“ ~~(R"), : 10b 10¢c :
R
1e H
R ug = z° LIBH4 o fro
Hs del ead A 2 < ° 10d © P — "i Rr 10e
Compounds of Formula | wherein X is thiazolidinedione-5-yl-G-, G is methytidine or (CHz)sandsis 1, RZis H, R (optionally present) is halo, alkyl, alkoxy or alkylthio and R' B,
Ar? J, p and q are as described above, may be synthesized by the reaction sequence outlined in Scheme 10, as taught by Chem. Pharm. Bull., 45, 1984 (1997). Condensation of an appropriately substituted benzaldehyde 9a and thiazolidinedione mediated by piperidine in acetic acid or ethanol or ammonium acetate in acetic acid at about 110° C to 120° C for about 8 to 30 hr, preferably piperidine in acetic acid at reflux for about 20 hr, or by piperidine and benzoic acid in toluene at reflux for about 3 to10 hr leads to benzylidene thiazolidinedione 10b.
Heating thiazolidinedione 10b in neat chlorosulfonic acid at about 90° C to 110° C for about 15 to 25 min, preferably about 100° C for 15 min yields sulfonyl chloride 10c.
Reaction of sulfonyi chloride 10c with appropriately substituted anilines 1e using procedures known to those skilled in the art, such as the process described in Scheme 1, leads to benzylidene thiazolidinedione derivatives 10d.
Reduction of the olefinic bond of 10d using methods familiar to those skilled in the art, such as lithium borohydride in pyridineftetrahydrofuran at about 65°C to 90°C for about 2 to 6 hr or sodium borohydride/lithium chloride in pyridine/tetrahydrofuran at about 65 °C to 90°C for about 3 to 6 hr, or catalytic hydrogenation with 10% Pd-C in 1,4-dioxane or methanol at about 50 to 60 psi for about 36 to 60 hr, preferably lithium borohydride in pyridine/tetrahydrofuran at reflux for 3 hr, yields the desired thiazolidinedione derivative 10e.
Scheme 11
R’ 0 po OAc OAc
R Na,S0 1 1 8 OH Pb(OAc)y yore 2503 . R' PCls > R
HO3S ClO,8 11a 11b 11¢c 11d / ) 1) (A? 2 H R! 2) NaOH 1e (NgA
A= RN
R O “ 11e
Br CO, Et
NA Ré 2) NaOH 9) %° eg 1
R el 8 CT
KA
0" “o 11f
Compounds of Formula |, wherein X is “O(CR%}COOR®, R? is CHs, R'is alkyl, R? is
H, R {optionally present) is halo, alkyl, alkoxy or alkylthio and, B, A, J and q are as described above, may be prepared by the synthetic route outlined in Scheme 11 as taught by Monat.
Chem. 99, 2048 (1968). The reaction of substituted phenot 11a with lead tetraacetate in acetic acid at about 20° C to 30° C for about 3 to 6 hr, preferably at room temperature for 3 hr yields quinol acetate 11b. . Upon treatment with sodium sulfite in water at about 20° C to 30° C for about 3 to 6 hr, preferably room temperature for 3 hr, quinol acetate 11b is converted to sulfonic acid 11c.
Sulfonyl chioride 11d is prepared by heating sulfonic acid 11c¢ with phosphorus pentachloride at about 110° C to 130° C for about 25 to 55 min, preferably about 120° C for about 30 min.
Reaction of sulfonyl chloride 11d with appropriately substituted anilines 1e using 16 procedures known to those skilled in the art, such as the process described in Scheme 1, followed by alkaline hydrolysis of the acetate yields sulfonamide 11e.
Alkylation of sulfonamide 11e with ethyl 2-bromoisobutyrate and potassium carbonate in dimethylformamide or ethanol at about 80° C to 100° C for about 12 to 24 hr, preferably dimethytformamide at about 95° C for about 18 hr, followed by basic hydrolysis of the product, leads to the desired acid 111.
Scheme 12 (EtO)2(0)P~_CO.EL
Ow H T CO,Et COLE = CISOzH Zz yy ——— —
RY NS
9a ClO,S P 12b 12c 2 8)
COR 1e
HC” — Ar? H f
Oh Mad Hn LR = N
R O° 12d 1) Mg/MeOH 2)NaOH CO,R* ~~
H.C
J)—AL H (he Fa SWE RM = & AY
R O ‘0 128
Compounds of Formula | wherein X is -CH(CR®,)-COOR* and R® is CH;CH,, w is 1,
R? is H, R (optionally present) is halo, alkyl, alkoxy or alkylthio and R', B, Ar%, J, p and q are as described above, may be synthesized by the reaction sequence outlined in Scheme 12.
Reaction of an appropriately substituted benzaldehyde 9a with the carbanion formed from triethyl-2-phosphonobutyrate and potassium t-butoxide or sodium hydride in tetrahydrofuran or dimethoxyethane at about 20° C to 30° C for about 2 to 5 hr, preferably at room temperature for 3 hr, yields olefinic ester 12b.
Ester 12b is converted to sulfonyl chloride 12¢ by heating in chlorosulfonic acid at about 55° C to 70° C for about 15-25 min, preferably at about 60° C for about 15 min.
Reaction of sulfonyl chloride 12¢ with appropriately substituted anilines 1e using methods know to those skilled in the art, such as the process described in Scheme 1, yields sulfonamide12d.
Reduction of the olefinic bond of 12¢ using procedures known to those skilled in the art, such as magnesium in methanol or ethanol at about 60° C to 85° C until the magnesium is consumed, or catalytic hydrogenation with 10% Pd-C in 1,4-dioxane or methanol at about 50 to 60 psi for about 36 to 60 fr, preferably magnesium in methanol at about 65° C, followed by alkaline hydrolysis of the product, yields the desired acid 12e.
Scheme 13 “OO + (orcom—= O40 a Oe ICL, .
P15 (Vg Ula 13b ta 13¢ © Ph a9
The compounds of Formula 1 wherein Ar' is other than phenyl may be prepared by the reaction sequence outlined in Scheme 1 by replacing aniline 1e with anilines fused to a member selected from thiazolyl, furanyl, oxazoly!, pyridine, pyrimidine, phenyl or thienyl which are prepared from intermediates that are commercially available or known in the literature by methods known to those skilled in the art.
For example, Scheme 13 depicts a process wherein Ar' is benzooxazole or benzothiazole, B is a bond, Ar” is phenyl, and J and q are as defined above. in the first step of
Scheme 13, a 2-aminophenol or 2-aminothiophenol (wherein D is O or S) 13a is reacted with an appropriate benzoic acid in polyphasphoric acid at about 190° C for about 6 hr as exemplified in Scheme 4a yields the benzoxazole or benzothiazole 13b. Nitration of 13b with concentrated nitric acid and sulfuric acid at about 75° C for about 30 min and at about 100° C for about 1 hr leads to the nitro derivative 13c, which is reduced to the desired aminobenzoxazole or aminobenzothiazole 13d using procedures shown in Scheme 4b.
Scheme 14 oo (J)q-Ar>-B(OH), oo > S
CIN Pdcat (AZ N 14a 14b
Compounds wherein Ar' is quinoline, B is a bond, Ar? is phenyl, and J and q are as defined above may be prepared, for example, from chloroquinoline 14a, which is known in the literature [J. Amer. Chem. Soc., 60, 2104 (1938)], by reaction with an appropriate aryl- or alkylboronic acid using methods exemplified in Scheme 2.
Scheme 15 oO
Os H N+ Fe N? x NH; & ceeds oye — KIO ay Pi q NH ()gA-B" N (J)q-Ar>-B 15d 0 15a 16b 15¢c
Compounds wherein Ar'is quinazoline, and B, A, J, and q are as defined above may be prepared, for example, by the method described in Synlett, p.1993 (1999). Reaction ofan appropriate amidine 15b with nitrobenzaidehyde 15a in acetonitrile in the presence of potassium carbonate and molecular sieves at refiux temperature for about 5 to 10 hr yields the nitroquinazoline15c. Reduction of 15¢c to the desired amine 15d may be carried out by the methods described in Scheme 4b.
Scheme 16
HQ & _ MeSOCI i Na-L-Ar%-(J)q & Fe, NH, 16a 16b WAL “gee Ural 164
Compounds wherein Ar' is benzothiophene, B is -L-CH,-, Lis O or S, and Ar, J, and q are as defined above may be prepared, for example, from hydroxymethylbenzothiophene 16a, which is known in the literature (J. Heterocycl. Chem., 20, 129 (1983)). Reaction of 16a with methanesulphonyl chloride and pyridine in methylene chioride, as taught by J. Med. Chem., 35, 457 (1992), at room temperature overnight leads to chloromethylbenzothiophene 16b. Treatment of 16b with an appropriate alcohol or mercaptan in the presence of a base such as sodium hydride or sodium tert-butoxide in an inert solvent such as tetrahydrofuran, dimethoxyethane or dimethyiformamide at about 20° C to 60° C for about 6 to 30 hr, preferably at room temperature ovemight, yields the nitro derivative 16¢c. Reduction of 16¢ to the desired amine 16d may be performed by the methods described in Scheme 4b.
Scheme 17 x" (J)gAr2-CO-CHBr hia 1) NaBH, ie CF rye yon coc YN an A oN Pret fz 0 DESH ear © or e ire
O 17a 17c
Compounds wherein Ar' is benzofuran, B Is CH», and Ar, J, and q are as defined above may be prepared as taught by J. Med. Chem., 39, 3897 (1996), for example, by the reaction of S-nitrosalicylaidehyde 17a with an appropriate bromomethyl arylketone and a base such as diisopropylethylamine, potassium fluoride or potassium carbonate in a solvent such as dimethylformamide, ethanol or acstone, at a temperature of about 75 to 95° C, for about 3 to 24 hr, preferably dilsopropylethylamine in dimethylformide at 92°C for 4 hr. The ketone 17¢ is reduced to the corresponding alcohol with sodium borohydride in methanol, which is converted to the nitro compound 17d with triethylsilane in trifluoroacetic acid. Reduction of 17d to the desired amine may be carried out by the methods described in Scheme 4b.
The compounds of this invention may also be used in conjunction with other pharmaceutical agents (e.g., LDL-cholesterol lowering agents, triglyceride lowering agents) for the treatment of the diseasel/conditions described herein. For example, they may be used in combination with a HMG-CoA reductase inhibitor, a cholesterol synthesis inhibitor, a cholesterol absorption inhibitor, a CETP inhibitor, a MTP/Apo B secretion inhibitor, another
PPAR modulator and other cholesterol lowering agents such as a fibrate, niacin, an ion- exchange resin, an antioxidant, an ACAT inhibitor, and a bile acid sequestrant. Other pharmaceutical agents would also include the following: a bile acid reuptake inhibitor, an ileal bile acid transporter inhibitor, an ACC inhibitor, an antihypertensive (such as NORVASC®), a selective estrogen receptor modulator, a selective androgen receptor modulator, an antibiotic, an antidiabetic (such as metformin, a PPARY activator, a sulfonylurea, insulin, an aldose reductase inhibitor (ARI) and a sorbitol dehydrogenase inhibitor (SDI)), and aspirin (acetytsalicylic acid). A slow-release form of niacin is available and is known as Niaspan.
Niacin may also be combined with other therapeutic agents such as statins, i.e. lovastatin, which is an HMG-CoA reductase inhibitor and described further below. This combination therapy is known as ADVICOR® (Kos Pharmaceuticals Inc.) In combination therapy treatment, both the compounds of this invention and the other drug therapies are administered to mammals (e.g., humans, male or female) by conventional methods.
The term HMG-CoA reductase inhibitor refers to compounds which inhibit the bioconversion of hydroxym ethylglutaryl-coenzyme A to mevalonic acid catalyzed by the enzyme HMG-CoA reductase. Such inhibition is readily determined by those skilled in the art according to standard assays (e.g., Meth. Enzymol. 1981; 71:455-509 and references cited therein). A variety of these compounds are described and referenced below however other
HMG-CoA reductase inhibitors will be known to those skilled in the art.
Atorvastatin calcium (i.e., atorvastatin hemicalcium), disclosed in U.S. Patent No. 5,273,995, which is incorporated herein by reference, is currently sold as Lipitor® and has the formula a
OC ha 2
Atorvastatin calcium is a selective, competitive inhibitor of HMG-CoA. As such, atorvastatin calcium is a potent lipid lowering compound. The free carboxylic acid form of atorvastatin may exist predominantly as the lactone of the formula 0] gue
Me L.,
OH oO / N = azdee
OTT and is disclosed in U.S. Patent No. 4,681,893, which Is incorporated herein by reference.
Statins also inciude such compounds as rosuvastatin disclosed in U.S. RE37,314 E, pitivastatin disclosed in EP 304063 B1 and US 5,011,930, simvastatin, disclosed in U.S. 4,444,784, which is incorporated herein by reference; pravastatin, disclosed in U.S. 4,346,227 which is incorporated herein by reference; cerivastatin, disclosed in U.S. 5,502,199, which is incorporated herein by reference; mevastatin, disclosed in U.S. 3,983,140, which is incorporated herein by reference; velostatin, disclosed in U.S. 4,448,784 and U.S. 4,450,171, both of which are incorporated herein by reference; fluvastatin, disclosed in us. 4,739,073, "15 which is incorporated herein by reference; compactin, disclosed in U.S. 4,804,770, which is incorporated herein by reference; lovastatin, disclosed in U.S. 4,231,938, which is incorporated herein by reference; dalvastatin, disclosed in European Patent Application
Publication No. 738510 A2; fluindostatin, disclosed in European Patent Application Publication
No. 363934 A1; and dihydrocompactin, disclosed in U.S. 4,450,171, which is incorporated herein by reference.
Any compound that decreases HMG-CoA reductase gene expression may be used in the combination aspect of this invention. These agents may be HMG-CoA reductase transcription inhibitors that block the transcription of DNA or translation inhibitors that prevent or decrease translation of MRNA coding for HMG-CoA reductase into protein. Such compounds may either affect transcription or translation directly, or may be biotransformed to compounds that have the aforementioned activities by one or more enzymes in the cholesterol biosynthetic cascade or may lead to the accumulation of an isoprene metabolite that has the aforementioned activities. Such compounds may cause this effect by decreasing levels of SREBP (sterol receptor binding protein) by inhibiting the activity of site-1 protease (S1P) or agonizing the oxzgenal receptor or SCAP. Such regulation is readily determined by those skilled in the art according to standard assays (Meth. Enzymol. 1985; 110:9-19).
Severai compounds are described and referenced below, however other inhibitors of HMG-
CoA reductase gene expression will be known to those skilled in the art. U.S. Pat. No. 5,041,432 (the disclosure of which is incorporated by reference) discloses certain 15- substituted lanosterol derivatives. Other oxygenated sterols that suppress synthesis of HMG-
CoA reductase are discussed by E.I. Mercer (Prog.Lip. Res. 1993;32:357-416).
Any compound having activity as a CETP inhibitor can serve as the second compound in the combination therapy aspect of the present invention. The term CETP inhibitor refers to compounds that inhibit the cholesteryl ester transfer protein (CETP) mediated transport of various cholesteryl esters and triglycerides from HDL to LDL and VLDL.
Such CETP inhibition activity is readily determined by those skilled in the art according to standard assays (e.g., U.S. Pat. No. 6,140,343). A variety of
CETP inhibitors will be known to those skilled in the art, for example, those disclosed in commonly assigned U.S. Patent Number 6,140,343 and commonly assigned U.S. Patent
Number 6,197,786. CETP inhibitors disclosed in these patents include compounds, such as [2R 48] 4-[(3,5-bis-trifluoromethyl-benzyl}methoxycarbonyl-amino}-2-ethyi-6-trifluoromethyi- : 3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, which is also known as torcetrapib.
U.S. Patent Number 5,512,548 discloses certain polypeptide derivatives having activity as
CETP inhibitors, while certain CETP-inhibitory rosenonolactone derivatives and phosphate- containing analogs of cholesteryl ester are disclosed in J. Antibiot., 49(8): 815-816 (1996), and
Bioorg. Med. Chem. Lett.; 6:1951-1954 (1996), res pectively.
Any other PPAR modulator may be used in the combination aspect of this invention. in particular, modulators of PPARB and/or PPARY may be useful incombination with compounds of the present invention.
Any MTP/Apo B (microsomal triglyceride transfer protein and or apolipoprotein B) secretion inhibitor may be used in the combination aspect of this invention. The term
MTP/Apo B secretion inhibitor refers to compounds which inhibit the secretion of triglycerides,
cholesteryl ester, and phospholipids. Such inhibition is readily determined by those skilled in the art according to standard assays (e.g., Wetterau, J. R. 1992; Science 258:999). A variety of these compounds are described and referenced below however other MTP/Apo B secretion inhibitors will be known to those skilled in the art, including imputapride (Bayer) and additional compounds such as those disclosed in WO 96/40640 and WO 98/23583, (two exemplary publications).
For example, the following MTP/Apo B secretion inhibitors are particularly useful: 4-trifluoromethyl-biphenyl-2-carboxylic acid [2-(1 H-{1,2,4,)triazol-3-yimethyl)-1,2,3,4- tetrahydro-isoquinolin-6-yi]-amide; 4'-trifluoromethyl-biphenyl-2-carboxylic acid [2-(2-acetylamino-ethyl}-1,2,3,4- tetrahydro-isoquinolin-6-yil-amide; (2-{6-[(4 -trifluoromethyl-biphenyl-2-carbonyl}-amino]-3,4-dihydro-1H-isoquinolin-2- yi}-ethyl)}-carbamic acid methyi ester; 4'-trifluoromethyl-biphenyi-2-carboxylic acid [2-(1 H-imidazol-2-yimethyi)-1,2,3,4- tetrahydro-isoquinolin-6-yll-amide; 4'-trifluoromethyl-biphenyt-2-carboxylic acid [2«(2, 2-diphenyl-ethyl)-1,2,3,4- tetrahydro-isoguinolin-6-yi}-amide; and 4'-trifluoromethyl-biphenyl-2-carboxylic acid [2-(2-ethoxy-ethyl}-1,2,3,4-tetrahydro- isoquinolin-6-yl}-amide. (S)-N-{2-[benzyl(methyl)amino}-2-oxo-1-phenylethyl}-1-methyi-5-[4'- (trifluoromethyl){1,1'-biphenyi}-2-carboxamido}- 1 H-indole-2-carboxamide; (S)-2-[(4'-Trifluoromethyl-biphenyl-2-carbonyl}-amino}-quinoline-6-carboxylic acid (pentylcarbamoyl-phenyl-methyl)-amide; 1 H-indole-2-carboxamide, 1-methyl-N-{(1 S)-2-[m ethyl(phenylmethyl)amino]-2-oxo-1- phenylethyl]-5-[[[4'-(trifluoromethyl)[1,1’-biphenyl]-2-yflcarbonyilamino}; and
N-[(1S)-2-(benzylmethylamino)-2-oxo- 1-phenylethyfl-1-methyl-5-[[{4'- (trifluoromethyl)biphenyl-2-yljcarbonyflamino}- 1 H-indole-2-carboxamide.
Any cholesterol absorption inhibitor can be used as an additional in the combination aspect of the present invention. The term cholesterol absorption inhibition refers to the ability of a compound to prevent cholesterol contained within the lumen of the intestine from entering into the intestinal cells and/or passing from within the intestinal cells into the lymph systam and/or into the blood stream. Such cholesterol absorption inhibition activity is readily determined by those skilled in the art according to standard assays (e.g., J. Lipid Res. (1993) 34: 377-395). Cholesterol absorption inhibitors are known to those skilled in the art and are described, for example, in PCT WO 94/00480. An example of a cholesterol absorption inhibitor is ZETIA ™ (ezetimibe) (Schering-Plough/Merck).
Diabetes can be treated by administering to a patient having diabetes (especially
Type 11), insulin resistance, impaired glucose tolerance, metabolic syndrome, or the like, or any of the diabetic complications such as neuropathy, nephropathy, retinopathy or cataracts, a therapeutically effective amount of a compound of the present invention in combination with other agents (e.g., insulin) that can be used to treat diabetes. This includes the classes of anti-diabetic agents (and specific agents) described herein.
Any glycogen phosphorylase inhibitor can be used as the second agent in combination with a compound of the present invention. The term glycogen phosphorylase inhibitor refers to compounds that inhibit the bioconversion of glycogen to glucose-1- phosphate which is catalyzed by the enzyme glycogen phosphorylase. Such glycogen phosphorylase inhibition activity is readily determined by those skilled in the art according to standard assays (e.g., J. Med. Chem. 41 (1998) 2934-2938). A variety of glycogen phosphorylase inhibitors are known to those skilled in the art including those described in
WO 96/39384 and WO 96/39385.
Any aldose reductase inhibitor can be used in combination with a compound of the present invention. The term aldose reductase inhibitor refers to compounds that inhibit the bioconversion of glucose to sorbitol, which is catalyzed by the enzyme aldose reductase.
Aldose reductase inhibition is readily determined by those skilled in the art according to standard assays (e.g., J. Malone, Diabetes, 29:861-864 (1980). "Red Cell Sorbitol, an indicator of Diabetic Control®). A variety of aldose reductase inhibitors are known to those skilled in the art, such as those described in U.S. Patent No. 6,579,879, which includes 6-(5- chloro-3-methyi-benzofuran-2-sulfonyl)}-2H-pyridazin-3-one.
Any sorbitol dehydrogenase inhibitor can be used in combination with a compound of the present invention. The term sorbitol dehydrogenase inhibitor refers to compounds that inhibit the bioconversion of sorbitol to fructose which is catalyzed by the enzyme sorbitol dehydrogenase. Such sorbitol dehydrogenase inhibitor activity is readily determined by those skilled in the art according to standard assays (e.g., Analyt. Biochem (2000) 280: 329- 331). A variety of sorbitol dehydrogenase inhibitors are known, for example, U.S. Patent
Nos. 5,728,704 and 5,866,578 disclose compounds and a method for treating or preventing diabetic complications by inhibiting the enzyme sorbitol dehydrogenase.
Any glucosidase inhibitor can be used in combination with a compound of the present invention. A glucosidase inhibitor inhibits the enzymatic hydrolysis of compiex carbohydrates by glycoside hydrolases, for example amylase or maltase, into bioavaitable simple sugars, for example, glucose. The rapid metabolic action of glucosidases, particularly following the intake of high levels of carbohydrates, results in a state of alimentary hyperglycemia which, in adipose or diabetic subjects, leads to enhanced secretion of insulin, increased fat synthesis and a reduction in fat degradation. Following such hyperglycemias,
hypoglycemia frequently occurs, due to the augmented levels of insulin present.
Additionally, it is known chyme remaining in the stomach promotes the production of gastric juice, which initiates or favors the development of gastritis or duodenal uicers. Accordingly, glucosidase inhibitors are known to have utility in accelerating the passage of carbohydrates through the stomach and inhibiting the absorption of glucose from the intestine.
Furthermore, the conversion of carbohydrates into lipids of the fatty tissue and the subsequent incorporation of alimentary fat into fatty tissue deposits is accordingly red uced or delayed, with the concomitant benefit of reducing or preventing the deleterious abnormalities resulting therefrom. Such glucosidase inhibition activity is readily determined by those skilled in the art according to standard assays (e.g., Biochemistry (1 069) 8: 4214).
A generally preferred glucosidase inhibitor includes an amylase inhibitor. An amylase Inhibitor is a glucosidase inhibitor that inhibits the enzymatic degradation of starch or glycogen into maltose. Such amylase inhibition activity is readily determined by those skilled in the art according to standard assays (e.g., Methods Enzymol. (1955) 1: 149). The inhibition of such enzymatic degradation is beneficial in reducing amounts of bioavailable sugars, including glucose and maltose, and the concomitant deleterious conditions resulting therefrom.
A variety of glucosidase inhibitors are known to one of ordinary skill in the art and examples are provided below. Preferred glucosidase Inhibitors are those inhibitors that are selected from the group consisting of acarbose, adiposine, voglibose, miglitol, emiglitate, camiglibose, tendamistate, trestatin, pradimicin-Q and salbostatin. The glucosidase : inhibitor, acarbose, and the various amino sugar derivatives related thereto are disclosed in
U.S. Patent Nos. 4,062,950 and 4,174,439 respectively. The glucosidase inhibitor, adiposine, is disclosed in U.S. Patent No. 4,254,256. The glucosidase inhibitor, voglibose, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyi)ethyljamino]-2-C-(hydroxymethyl)-D-epi- : inositol, and the various N-substituted pseudo-aminosugars related thereto, are disclosed in
U.S. Patent No. 4,701,559. The glucosidase inhibitor, miglitol, (2R,3R,4R,55)-1-(2- hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol, and the various 3,4,5- trihydroxypiperidines related thereto, are disclosed in U.S. Patent No. 4,639,436. The glucosidase inhibitor, emiglitate, ethyl p-[2-[(2R,3R 4R,5S)-3,4,5-trihydroxy-2- (hydroxymethyl)piperidino}ethoxy}-benzoate, the various derivatives related thereto and : pharmaceutically acceptable acid addition salts thereof, are disclosed in U.S. Patent No. 5,192,772. The glucosidase inhibitor, MDL-25637, 2,6-dideoxy-7-O-B-D-glucopyrano-syi- 2,6-imino-D-glycero-L-gluco-heptitol, the various homodisaccharides related thereto and the pharmaceutically acceptable acid addition salts thereof, are disclosed in U.S. Patent No. 4,634,765. The glucosidase inhibitor, camiglibose, methyl 6-deoxy-6-[(2R,3R,4R,5S5)-3,4,5- trinydroxy-2-(hydroxymethyl)piperidino}-a-D-glucopyranoside sesquihydrate, the deoxy-
nojirimycin derivatives related thereto, the various pharmaceutically acceptable salts thereof and synthetic methods for the preparation thereof, are disclosed in U.S. Patent Nos. 5,157,116 and 5,504,078. The glycosidase inhibitor, salbostatin and the various pseudosaccharides related thereto, are disclosed in U.S. Patent No. 5,091,524.
A varlety of amylase inhibitors are known to one of ordinary skill in the art. The amylase inhibitor, tendamistat and the various cyclic peptides related thereto, are disclosed in U.S. Patent No. 4,451,455. The amylase inhibitor Al-3688 and the various cyclic polypeptides related thereto are disclosed in U.S. Patent No. 4,623,714. The amylase inhibitor, trestatin, consisting of a mixture of trestatin A, trestatin B and trestatin C and the various trehalose-containing aminosugars related thereto are disclosed in U.S. Patent No. 4,273,765.
Additional anti-diabetic compounds, which can be used as the second agent in combination with a compound of the present invention, includes, for example, the following: biguanides (e.g., metformin), insulin secretagogues (e.g., sulfonylureas and glinides), glitazones, non-glitazone PPARYy agonists, PPARB agonists, inhibitors of DPP-IV, inhibitors of } PDES, inhibitors of GSK-3, glucagon antagonists, inhibitors of f-1,6-
BPase(Metabasis/Sankyo), GLP-1/analogs (AC 2993, also known as exendin-4), insulin and insulin mimetics (Merck natural products). Other examples would include PKC- inhibitors and AGE breakers.
The compounds of the present invention can be used in combination with other anti- obesity agents. Any anti-obesity agent can be used as the second agent in such combinations and examples are provided herein. Such anti-obesity activity is readily determined by those skilled in the art according to standard assays known in the art.
Suitable anti-obesity agents include phenylpropanolamine, ephedrine, pseudoephedrine, phentermine, Ba adrenergic receptor agonists, apolipoprotein-B secretion/microsomal triglyceride transfer protein (apo-BMTP) inhibitors, MCR-4 agonists, cholecystokinin-A (CCK-A) agonists, monoamine reuptake inhibitors (e.g., sibutramine), sympathomimetic agents, serotoninergic agents, cannabinoid-1 (CB-1) receptor antagonists (e.g., rimonabant (SR-141,716A)), dopamine agonists (e.g., bromocriptine), melanocyte- stimulating hormone receptor analogs, SHT2c agonists, melanin concentrating hormone antagonists, leptin (the OB protein), leptin analogs, leptin receptor agonists, galanin antagonists, lipase inhibitors (e.g., tetrahydrolipstatin, i.e. orlistat), bombesin agonists, anorectic agents (e.g., a bombesin agonist), Neuropeptide-Y antagonists, thyroxine, thyromimetic agents, dehydroepiandrosterones or analogs thereof, glucocorticoid receptor agonists or antagonists, orexin receptor antagonists, urocortin binding protein antagonists, glucagon-like peptide-1 receptor agonists, ciliary neurotrophic factors (e.g., Axokine™),
~42- human agouti-related proteins (AGRP), ghrelin receptor antago nists, histamine 3 receptor antagonists or inverse agonists, neuromedin U receptor agonists, and the like.
Rimonabant (SR141716A also known under the trade mame Acomplia™ available from Sanofi-Synthelabo) can be prepared as described in U.S_ Patent No. 5,624,941. Other suitable CB-1 antagonists include those described in U.S. Patent Nos. 5,747,524, 6,432,984 and 6,518,264; U.S. Patent Publication Nos. US2004/0092520, US2004/0157839,
US2004/0214855, and US2004/0214838; U.S. Patent Application Serial No. 10/971599 filed on October 22, 2004; and PCT Patent Publication Nos. YWO 02/076949, WO 03/075660, WO04/048317, WO04/013120, and WO 04/01267° 1.
Preferred apolipoprotein-B secretion/microsomat trigly ceride transfer protein (apo-
B/MTP) inhibitors for use as anti-obesity agents are gut-selecti ve MTP inhibitors, such as dirlotapide described in U.S. Patent No. 6,720,351; 4-(4-(4-(4—((2-((4-methyl-4H-1,2,4- triazol-3-ylthio)methyl)-2-(4-chlorophenyl}-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1- yl)phenyi)}-2-sec-butyl-2H-1,2 4-triazol-3(4H)-one (R103757) described in U.S. Patent Nos. 5,521,186 and 5,929,075; and implitapide (BAY 13-9952) described in U.S. Patent No. 6,265,431. As used herein, the term “gut-selective” means thaat the MTP inhibitor has a higher exposure to the gastro-intestinal tissues versus systemic exposure.
Any thyromimetic can be used as the second agent in combination with a compound of the present invention. Such thyromimetic activity” is readily determined by those skilled in the art according to standard assays (e.g., Athexrosclerosis (1996) 126: 53- 63). A variety of thyromimetic agents are known to those skilled in the art, for example those disclosed in U.S. Patent Nos. 4,766,121; 4,826,876; 4,91 0,305; 5,061,798; 5,284,971; 5,401,772; 5,654,468; and 5,569,674. Other antiobesity agentss include sibutramine which can be prepared as described in U.S. Patent No. 4,929,629. and bromocriptine which can be prepared as described in U.S. Patent Nos. 3,752,814 and 3,752,888.
The compounds of the present invention can also be used in combination with other antihypertensive agents. Any anti-hypertensive agent can be used as the second agent in such combinations and examples are provided herein. Such antihypertensive activity is readily determined by those skilled in the art according to standard assays (e.g., blood pressure measurements).
Amiodipine and reiated dihydropyridine compounds are disclosed in U.S. Patent No. 4,572,909, which is incorporated herein by reference, as potent anti-ischemic and antihypertensive agents. U.S. Patent No.4,879,303, which is incorporated herein by reference, discloses amiodipine benzenesulfonate salt (also termed amlodipine besylate).
Amlodipine and amlodipine besylate are potent and ong lasting calcium channel blockers. As such, amlodipine, amlodipine besyiate, amlodipine maleate and other pharmaceutically acceptable acid addition salts of amlodipine have utility as antihy pertensive agents and as antiischemic agents. Amlodipine besylate is currently sold as Norvasc®. Amlodipine has the formula
CH; N CH,OCH,CH,NH,
CHO J CO,CH,CH, 0 cl
The starting materials and reagents for the above-described compounds of the present invention and combination agents, are also readily available or can be easily synthesized by those skilled in the art using conventional methods of organic synthesis. For example, many of the compounds used herein, are related to, or are derived from compounds in which there is a large scientific interest and commercial need, and accordingly many such compounds are commercially available or are reported in the literature or are easily prepared from other commonly available substances by methods which are reported in the literature.
Some of the compounds of the present invention or intermediates in their synthesis have asymmetric carbon atoms and therefore are enantiomers or diastereomers.
Diasteromeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known per se., for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by, for example, chiral HPLC methods or converting the enantiomeric mixture into a diasteromeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the comesponding pure enantiomers. Also, an enantiomeric mixture of the compounds or an intermediate in their synthesis which contain an acidic or basic moiety may be separated into their compounding pure enantiomers by forming a diastereomeric salt with an optically pure ’ chiral base or acid (e.g., 1-phenyil-ethyl amine or tartaric acid) and separating the diasteromers by fractional crystallization followed by neutralization to break the salt, thus providing the corresponding pure enantiomers. All such isomers, including diastereomers, enantiomers and mixtures thereof are considered as part of the present invention. Also, some of the compounds of the present invention are atropisomers (e.g. substituted biaryls) and are considered as part of the present invention.
More specifically, the compounds of the present invention can be obtained by fractional crystallization of the basic intermediate with an optically pure chiral acid to fom a
-A4- diastereomeric salt. Neutralization techniques are used to remove the salt and provide the enantiomerically pure compounds. Alternatively, the compounds of the present invention may be obtained in enantiomerically enriched form by resolving the racernate of the final compound or an intermediate in its synthesis (preferably the final compound) ermploying chromatography (preferably high pressure liquid chromatography [HPLC]) on an asyrmmetric resin (preferably
Chiralcel™ AD or OD (obtained from Chiral Technologies, Exton, Pennsylvania)) with a mobile phase consisting of a hydrocarbon (preferably heptane or hexane) containing between 0 and 50% isopropanol (preferably between 2 and 20 %) and between 0 and 5% of an alkyl amine (preferably 0.1% of diethylamina). Concentration of the produ ct containing fractions affords the desired materials.
Some of the compounds of the present invention are acidic and they form a salt with a pharmaceutically acceptable cation. Some of the compounds of the present invention are basic and they form a salt with a pharmacsutically acceptable anion. All such salts are within the scope of the present invention and they can be prepared by conventional methods such as combining the acidic and basic entities, usually in a stoichiometric ratio, in either an aqueous, non-aqueous or partially aqueous medium, as appropriate . The salts are recovered either by filtration, by precipitation with a non-solvent followed by filtration, by evaporation of the solvent, or, in the case of aqueous solutions, by lyophilization, as appropriate. The compounds can be obtained in crystalline form by dissolution in an appropriate solvent(s) such as ethanol, hexanes or water/ethanol mixtures.
The compounds of the present invention, their prodrugs and the salts of such compounds and prodrugs are all adapted to therapeutic use as agents that activate peroxisome proliferator activator receptor (PPAR) activity in mammals, particularly humans.
Thus, it is believed the compounds of the present invention, by activating the PPAR receptor, stimulate transcription of key genes involved in fatty acid oxidation and also those involved in high density lipoprotein (HDL) assembly (for example apolipoprotein Al gene transcription), accordingly reducing whole body fat and increasing HDL cholesterol By virtue of their activity, these agents also reduce plasma levels of triglycerides, VLDL cholesterol, LDL cholesterol and their associated components in mammals, particularly humans, as well as increasing HDL cholesterol and apolipoprotein Al. Hence, these compounds are useful for the treatment and correction of the various dyslipidemias observed to be associated with the development and incidence of atherosclerosis and cardiovascular disease, including hypoalphalipoproteinemia and hypertriglyceridemia.
The present compounds are also useful for modulation of plasma and or serum or tissue lipids or lipoproteins, such as HDL subtypes (e.g., increase, including pre-beta HDL,
HDL-1,-2 and 3 particles) as measured by precipitation or by apo-protein content, size, . density. NMR profile, FPLC and charge and particle number and its constituents; and LDL subtypes (Including LDL subtypes e.g., decreasing small dense LDL, oxidized LDL, VLDL, apo(a) and Lp(a)) as measured by precipitation, or by apo-protein content, size density, NMR profile, FPLC and charge; IDL and remnants (decrease); phospholipids (e.g., increase HDL phospholipids); apo-lipoproteins (increase A-l, A-li, A-1V, decrease total and LDL B-100, decrease B-48, modulate C-li, C-lll, E, J); paraoxonase (increase, anti-oxidant effects, anti- inflammatory effects); decrease post-prandial (hyper)lipemia; decrease triglycerides, clecrease non-HDL; elevate HDL in subjects with low HDL and optimize and increase ratios of HDL to
LDL (e.g., greater than 0.25).
Given the positive correlation between triglycerides, LDL cholesterol, and ther assoclated apolipoproteins in blood with the development of cardiovascular, cerebral vascular and peripheral vascular diseases, the compounds of the present invention, their prodr-ugs and the salts of such compounds and prodrugs, by virtue of their pharmacologic action, are useful for the prevention, arrestment and/or regression of atherosclerosis and its associated disease states. These include cardiovascular disorders (e.g., cerebrovascular disease, corona ry artery disease, ventricular dysfunction, cardiac arrhythmia, pulmonary vascular disease, vas cular ; hemostatic disease, cardiac ischemia and myocardial infarction), complications due to } cardiovascular disease, and cognitive dysfunction (including, but not limited to, dementia secondary to atherosclerosis, transient cerebral ischemic attacks, neurodegeneration, neuronal deficient, and delayed onset or procession of Alzheimer's diseass).
Thus, given the ability of the compounds of the present invention, their prodru gs and the salts of such compounds and prodrugs to reduce plasma triglycerides and total piaasma cholesterol, and increase plasma HDL cholesterol, they are of use in the treatment of diabetes, including impaired glucose tolerance, diabetic complications, insulin resistarsce and metabolic syndrome, as described previously. In addition, the compounds are useful for the treatment of polycystic ovary syndrome. Also, the compounds are useful in the treatment of obesity given the ability of the compounds of this invention, their prodrugs and the salts of such compounds and prodrugs to increase hepatic fatty acid oxidation.
The utility of the compounds of the present invention, their prodrugs and the s alts of such compounds and prodrugs as medica! agents in the treatment of the above described disease/conditions in mammals (e.g. humans, male or female) is demonstrated by the activity of the compounds of the present invention in one or more of the conventional assays and /n vivo assays described below. The in vivo assays (with appropriate modifications withira the skill in the art) can be used to determine the activity of other lipid or triglyceride controling agents as well as the compounds of the present invention. Thus, the protocols described below can also be used to demonstrate the utility of the combinations of the agents (i.e., the compounds of the present invention) described herein. In addition, such assays provide a means whereby the activities of the compounds of the present invention, their prodrugs and the salts of such compounds and prodrugs (or the other agents described herein) can be compared to each other and with the activities of other known compounds. The results of these comparisons are useful for determining dosage levels in mammals, including humans, for the treatment of such diseases. The following protocols can of course be varied by those skilled in the art.
PPAR FRET Assay
Measurement of coactivator recruitment by a nuclear receptor-ligand association is a method for evaluating the ability of a ligand to produce a functional response through a nuclear receptor. The PPAR FRET (Fluorescence Resonance Energy Transfer) assay measures the ligand-dependent interaction between nuclear receptor and coactivator. GST/
PPAR (o,p,and v) ligand binding domain (LBD) is labeled with a europium-tagged anti-GST : antibody, while an SRC-1 (Sterol Receptor Coactivator-1) synthetic peptide containing an amino terminus long chain biotin molecule is labeled with streptavidin-linked allophycocyanin (APC). Binding of ligand to the PPAR LBD causes a conformational change that allows SRC- 1 to bind. Upon SRC-1 binding, the donor FRET molecule (europium) comes in close proximity to the acceptor molecule (APC), resulting in fluorescence energy transfer between donor (337 nm excitation and 620 nm emission) and acceptor (620 nm excitation and 665 nm emission). Increases in the ratio of 665nm emission to 620 nm emission is a measure of the abllity of the ligand-PPAR LBD to recruit SRC-1 synthetic peptide and therefore a measure of the ability of a ligand to produce a functional response through the PPAR receptor.
[1] GST/ PPAR LBD Expression. The human PPARa LBD (amino acids 235-507) is fused to the carboxy terminus of glutathione S-transferase (GST) in pGEX-6P-1 (Pfizer, Inc.).
The GST/PPARe LBD fusion protein is expressed in BL21[DE3]pLysS cells using a 50 uM
IPTG induction at room temperature for 16 hr (cells induced at an Ag of ~0.6). Fusion protein is purified on glutathione sepharose 4B beads, eluted in 10 mM reduced glutathione, and dialyzed against 1x PBS at 4°C. Fusion protein is quantitated by Bradford assay (M.M.
Bradford, Analst. Biochem. 72:248-254; 1976), and stored at -20°C in 1x PBS containing 40% glycerol and 5 mM dithiothreitol.
[2] FRET Assay. The FRET assay reaction mix consists of 1x FRET buffer (60 mM
Tris-Cl pH 8.0, 50 mM KC}, 0.1 mg/ml BSA, 1 mM EDTA, and 2 mM dithiothreitol) containing 20 nM GST/ PPARa LBD, 40 nM of SRC-1 peptide (amino acids 676-700, 5'-long chain biotin-CPSSHSSLTERHKILHRLLQEGSPS-NH,, purchased from American Peptide Co.,
Sunnyvale, CA), 2 nM of europium-conjugated anti-GST antibody (Wallac, Gaithersburg, MD), 40 nM of streptavidin-conjugated APC (Wallac), and control and test compounds. The final volume is brought to 100 ul with water and transferred to a black 96-well plate (Microfuor B,
Dynex (Chantilly, VA)). The reaction mixes are incubated for 1 hr at 4°C and fluorescence is read in Victor 2 plate reader (Wallac). Data is presented as a ratio of the emission at 665 nm to the emission at 615 nm.
Assessment of lipid-modulating activity in mice
[1] Triglyceride lowering. The hypolipidemic treating activity of the compounds of the present invention can be demonstrated by methods based on standard procedures. For example, the in vivo activity of these compounds in decreasing plasma triglyceride leve Is may be determined in hybrid BECBAF1/J mice.
Male BECVAF4/J mice (8-11 week old) are obtained from The Jackson Laboratory and housed 4-5/cage and maintained in a 12hr light/12hr dark cycle. Animals have ad 7b. access to Purina rodent chow and water. The animals are dosed daily (9 AM) by oral gavage with vehicle (water or 0.5% methyl cellulose 0.05% Tween 80) or with vehicle containing test compound at the desired concentration. Plasma triglycerides levels are determined 24 hours after the administration of the last dose (day 3) from blood collected retro-orbitally with heparinized hematocrit tubes. Triglyceride determinations are performed using a commercially available Triglyceride E kit from Wako (Osaka, Japan).
[2] HDL cholesterol elevation. The activity of the compounds of the present invention for raising the plasma level of high density lipoprotein (HDL) in a mammal can be demonstrated in transgenic mice expressing the human apoAl and CETP transgenes (HUAICETPTg). The transgenic mice for use in this study are described previously in W alsh etal, J. Lipid Res. 1993, 34: 617-623, Agellon et al., J. Biol. Chem. 1991, 266: 10796- 10801. Mice expressing the human apoAl and CETP transgenes are obtained by mating transgenic mice expressing the human apoAl transgene (HuAITg) with CETP mice (HUCETPTg).
Male HUAICETPTg mice (8-11 week old) are grouped according to their human apo
Al levels and have free access to Purina rodent chow and water. Animals are dosed dai ly by oral gavage with vehicle (water or 0.5% methylcellulose 0.05% Tween 80) or with vehicle containing test compound at the desired dose for 5 days. HDL-cholesterol and human a poAl are determined initially (day 0) and 90 minutes post dose (day 5) using methods based ©n standard procedures. Mouse HDL is separated from apoB-containing lipoproteins by dextran sulfate precipitation as described elsewhere (Francone et al., J. Lipid. Res. 1996, 37:1268-1277). Cholesterol is measured enzymatically using a commercially available cholesterol/HP Reagent kit (Boehringer MannHeim, Indianapolis, IND) and spectrophotometrically quantitated on a microplate reader. Human apoAl is measured by a sandwich enzyme-linked immunosorbent assay as previously described (Francone et al., J.
Lipid. Res. 1996, 37:1268-1277). :
Measurement of glucose lowering in the ob/ob mouse
The hypoglycemic activity of the compounds of the present invention can be determined by the amount of test compound that reduces glucose levels relative to a vehicle without test compound in male ob/ob mice. The test also allows the determination of an approximate minimal effective dose (MED) value for the in vivo reduction of plasma glucose concentration in such mice for such test compounds.
Five to eight week old male C57BL/6J-obfob mice (obtained from Jackson Laboratory,
Bar Harbor, ME) are housed five per cage under standard animal care practices. After a one- week acclimation period, the animals are weighed and 25 microliters of blood are collected from the retro-orbital sinus prior to any treatment. The blood sample is immediately diluted 1:5 with saline containing 0.025% sodium heparin, and held on ice for metabolite analysis.
Animals are assigned to treatment groups so that each group has a similar mean for plasma glucose concentration. After group assignment, animals are dosed orally each day for four days with the vehicle consisting of either: (1) 0.25% wiv methyl cellulose in water without pH . adjustment; or (2) 0.1% Pluronic® P105 Block Copolymer Surfactant (BASF Corporation,
Parsippany, NJ) in 0.1 9, saline without pH adjustment. On day 5, the animals are weighed again and then dosed orally with a test compound or the vehicle alone. All compounds are administered in vehicle consisting of either: (1) 0.25% wiv methyl cellulose in water, (2) 10% )
DMSO0/0.1% Pluronic® in 0.1% saline without pH adjustment; or 3) neat PEG 400 without pH adjustment. The animals are then bled from the retro-orbital sinus three hours \ater for determination of blood metabolite levels. The freshly collected samples are centrifuged for two minutes at 10,000 x g at room temperature. The supematant is analyzed for glucose, for example, by the Abbott VP™ (Abbott Laboratories, Diagnostics Division, Irving, TX) and VP
Super System® Autoanaiyzer (Abbott Laboratories, Irving, TX), or by the Abbott Spectrum ccxX™ (Abbott Laboratories, irving, TX) using the A-Gent™Glucose-UV Test reagent system (Abbott Laboratories, Irving, TX) (a modification of the method of Richterich and Dauwalder,
Schweizerische Medizinische Wochenschnift, 101: 860 (1971)) (hexokinase method) using a 100 mg/d! standard. Plasma glucose is then calculated by the equation: Plasma glucose (mg/dl)=Sample value x 8.14 where 8.14 is the dilution factor, adjusted for plasma hematocrit (assuming the hematocrit is 44%).
The animals dosed with vehicle maintain substantially unchanged hypergiycemic glucose levels (e.g., greater than or equal to 250 mg/dl), animals treated with compounds having hypoglycemic activity at suitable doses have significantly depressed glucose levels.
Hypoglycemic activity of the test compounds is determined by statistical analysis {unpaired t- test) of the mean plasma glucose concentration between the test compound group and vehicle-treated group on day 5. The above assay carried out with a range of doses of a test compound allows the determination of an approximate minimal effective dose (MED) value for the in vivo reduction of plasma glucose concentration.
Measurement of insulin, trig iyceride, and cholesterol levels in the ob/ob mouse
The compounds of the present invention are readily adapted to clinical use as hyperinsulinemia reversing agents, triglyceride lowering agents and hypocholesterolemic agents. Such activity can be determined by the amount of test compound that reduces insulin, triglycerides or cholesterol levels relative to a control vehicle without test compound in male ob/ob mice.
Since the concentration of cholesterol in blood is closely related to the development of cardiovascular, cerebral vascular or peripheral vascular disorders, the compounds of the present invention, by virtue of their hypocholesterolemic action, prevent, arrest and/or regress atherosclerosis.
Since the concentration of insulin in blood is related to the promotion of vascular cell growth and increased renal sodium retention, (in addition to the other actions, e.g., promation of glucose utilization) and these functions are known causes of hypertension, the compounds of the present invention, by virtue of their hypoinsulinemic action, prevent, arrest and/or regress hypertension.
Since the concentration of triglycerides in blood contributes to the overall levels of blood lipids, the compounds of the present invention, by virtue of their triglyceride lowering andlor free fatty acid lowering activity prevent, amrest and/or regress hyperlipidemia.
Free fatty acids contribute to the overall level of blood lipids and independently have been negatively correlated with insulin sensitivity in a variety of physiologic and pathologic states.
Five to eight week oid male C57BL/6J-ob/ob mice (obtained from Jackson Laboratory,
Bar Harbor, ME) are housed five per cage under standard animal care practices and fed standard rodent diet ad libitum. After a one-week acclimation period, the animals are weighed and 25 microliters of blood are collected from the retro-orbital sinus prior to any treatment. The biood sample is immediately diluted 1:5 with saline containing 0.025% sodium heparin, and held on ice for plasma glucose analysis. Animals are assigned to treatment groups so that each group has a similar mean for plasma glucose concentration. The compound to be tested is administered by oral gavage as an about 0.02% to 2.0% solution (weight/volume (w/v)) in either (1) 10% DMSO0/0.1% Pluronic® P105 Block Copolymer Surfactant (BASF Corporation,
Parsippany, NJ) in 0.1% saline without pH adjustment or (2) 0.25% w/v methylcellulose in water without pH adjustment. Alternatively, the compound to be tested can be administered by oral gavage dissolved in or in suspension in neat PEG 400. Single daily dosing (s.i.d.) or twice daily dosing (b.i.d.) is maintained for 1 to, for example, 15 days. Control mice receive the 10% DMSO/0.1% Fluronic® P105 in 0.1% saline without pH adjustment or the 0.25% wiv methylcellulose in water without pH adjustment, or the neat PEG 400 without pH adjustment.
Three hours after the last dose is administered, the animals are sacrificed and blood is collected into 0.5 ml serum separator tubes containing 3.6 mg of a 1:1 weight/weight sodium fluoride: potassium oxalate mixture. The freshly collected samples are centrifuged for two minutes at 10,000 x g at room temperature, and the serum supematant is transferred and diluted 1:1 volume/volume with a 1TIU/m| aprotinin solution in 0.1% saline without pH adjustment.
The diluted serum sampies are then stored at -80°C until analysis. The thawed, diluted serum samples are analyzed for insulin, triglycerides, free fatty acids and cholesterol levels. Serum insulin concentration is determined using Equate® RIA INSULIN kits (double antibody method; as specified by the manufacturer) available from Binax, South Portland, ME.
The interassay coefficient of variation is < 10%. Serum triglycerides are determined using the
Abbott VP™ and VP Super System® Autoanalyzer (Abbott Laboratories, Irving, TX), or the
Abbott Spectrum CCX” (Abbott Laboratories, Irving, TX) using the A-Gent™ Triglycerides Test reagent system (Abbott Laboratories, Diagnostics Division, Irving, TX) (lipase-coupled enzyme method; a modification of the method of Sampson, et al., Clinical Chemistry 21: 1983 (1975)).
Serum total cholesterol levels are determined using the Abbott VvP™ and VP Super System®
Autoanalyzer (Abbott Laboratories, Irving, TX), and A-Gent™ Cholesterol Test reagent system (cholesterol esterase-coupled enzyme method; a modification of the method of Allain, et al.
Clinical Chemistry 20: 470 (1974)) using 100 and 300 mg/dl standards. Serum free fatty acid concentration is determined utilizing a kit from WAKO (Osaka, Japan), as adapted for use with the Abbott VP™ and VP Super System® Autoanalyzer (Abbott Laboratories, Irving, TX), or the
Abbott Spectrum CCX™ (Abbott Laboratories, Irving, TX). Serum insulin, triglycerides, free fatty acids and total cholesterol levels are then calculated by the equations: Serum insulin (pU/mIl) = Sample value x 2; Serum triglycerides (mg/dl) = Sample value x 2; Serum total : cholesterol (mg/dl) = Sample value x 2; Serum free fatty acid (uEq/l) = Sample value x 2; where 2 is the dilution factor.
The animals dosed with vehicle maintain substantially unchanged, elevated serum insulin (e.g., 275 pU/ml), serum triglycerides (e.g., 235 mg/dl), serum free fatty acid (1500 mEq/ml) and serum total cholesterol (e.g., 190 mg/dl) levels. The serum insulin, triglycerides, free fatty acid and total cholesterol lowering activity of the test compounds are determined by statistical analysis (unpaired t-test) of the mean serum insulin, triglycerides, or total cholesterol concentration between the test compound group and the vehicle-treated control group.
Measurement of energy expenditure in rats
As would be appreciated by those skilled in the relevant art, during increased energy expenditure, animals generally consume more oxygen. In addition, metabolic fuels such as, for example, glucose and fatty acids, are oxidized to CO; and H,O with the concomitant evolution of heat, commonly referred to in the art as thermogenesis. Thus, the measurement of oxygen consumption In animals, including humans and companion animals, is an indirect measure of thermogenesis. Indirect calorimetry is commonly used in animals, e.g., humans, by those skilled in the relevant art to measure such energy expenditures.
Those skilled in the art understand that increased energy expenditure and the concomitant buming of metabolic fuels resulting in the production of heat may be efficacious with respect to the treatment of, e.g., obesity.
The ability of the compounds of the present invention to generate a thermogenic response can be demonstrated according to the following protocol: This in vivo screen is designed to evaluate the efficacy of compounds that are PPAR agonists, using as an efficacy endpoint measurement of whole body oxygen consumption. The protocol involves: (a) dosing fatty Zucker rats for about 6 days, and (b) measuring oxygen consumption. Male fatty Zucker rats having a body weight range of from about 400 g to about 500 g are housed for from about 3 to about 7 days in individual cages under standard laboratory conditions prior to the initiation of the study. A compound of the present invention and a vehicle is administered by oral gavage as a single daily dose given between about 3 p.m. to about 6 p.m. for about 6 days. A compound of the present invention is dissolved in vehicle containing about 0.25 % of methyl cellulose. The dosing volume is about 1 mi.
About 1 day after the last dose of the compound is administered, oxygen consumption is measured using an open circuit, indirect calorimeter (Oxymax, Columbus Instruments,
Columbus, OH 43204). The Oxymax gas sensors are calibrated with N, gas and a gas mixture (about 0.5 % of CO,, about 20.5 % of O,, about 78 % of N,) before each experiment.
The subject rats are removed from their home cages and their body weights recorded. The rats are placed into the sealed chambers (43 x 43 x 10 cm) of the Oxymax, the chambers are placed in the activity monitors, and the air flow rate through the chambers is then set at from about 1.6 L/min to about 1.7 L/min. The Oxymax software then calculates the oxygen consumption (mL/kg/h) by the rats based on the flow rate of air through the chambers and the difference in oxygen content at the inlet and output ports. The activity monitors have 15 infrared light beams spaced about one inch apart on each axis, and ambulatory activity is recorded when two consecutive beams are broken, and the results are recorded as counts.
Oxygen consumption and ambulatory activity are measured about every 10 min for from about 5 h to about 6.5 h. Resting oxygen consumption is calculated on individual rats by averaging the values excluding the first § values and the values obtained during time periods where ambulatory activity exceeds about 100 counts.
In Vivo Atherosclerosis Assay
Anti-atherosclerotic effects of the compounds of the present invention can be determined by the amount of compound required to reduce the lipid deposition in rabbit aorta. Male New Zealand White rabbits are fed a diet containing 0.2% cholesterol and 10% coconut oil for 4 days (meal-fed once per day). Rabbits are bled from the marginal ear vein and total plasma cholesterol values are determined from these samples. The rabbits are ihen assigned to treatment groups so that each group has a similar mean +SD for total plasma cholesterol concentration, HDL cholesterol concentration and triglyceride concentration. After group assignment, rabbits are dosed daily with compound given as a dietary admix or on a small piece of gelatin based confection. Control rabbits receive only the dosing vehicle, be it the food or the gelatin confection. The cholesterol/coconut oil diet is continued along with the compound administration throughout the study. Plasma cholesterol, HDL-cholesterol, LDL cholesterol and triglyceride values can be determined at any point during the study by obtaining blood from the marginal ear vein. After 3-5 months, the rabbits are sacrificed and the aortae are removed from the thoracic arch to the branch of the iliac arteries. The aortae are cleaned of adventitia, opened longitudinally and then stained with Sudan IV as described by Holman et. al. (Lab. Invest. 1958, 7, 42-47). The percent of the surface area stained is quantitated by densitometry using an Optimas Image
Analyzing System (Image Processing Solutions; North Reading MA). Reduced lipid deposition is indicated by a reduction in the percent surface area stained in the compound- receiving group in comparison with the control rabbits.
The utility of the formula | compounds useful in the present invention, their prodrugs and the salts of such compounds and prodrugs as agents in the treatment of the above described disease/conditions in ruminants is additionally demonstrated by the activity of the compounds of the present invention in the assays described below.
Neaative energy balance
To determine negative energy balance, serum concentrations of NEFAs or ketone bodies, or levels of triglycerides in liver tissues, are measured. Higher than ‘normal’ levels of NEFA's and/or triglycerides and/or ketone bodies are indicators of negative energy balance. Levels considered ‘higher than normal’ or ‘excessive’ are:
NEFA’s >800umol/L in serum.
Triglycerides >10% w/w in liver tissue. :
Ketone bodies >1.2 Omol/L in serum.
Determination of changes in blood non-esterified fatty acid (NEFA) concentrations and liver triglycerides levels:
Compounds are administered once or several times in the transition period at dose levels predicted to be effective by comparing results of in-vitro receptor affinity tests in laboratory species and pharmacokinetic evaluations in cattle. NEFA levels are determined via standard laboratory methods, for example, using the commercial WAKO NEFA kit (Wako
Chemical Co., USA, Dallas, TX, 994-75409), and liver trigiyceride content is determined using the method as described in the literature (J. K. Drackley, J. J. Veenhuizen, M. J.
Richard and J. W. Young, J Dairy Sci, 1991, 74, 4254)).
All animals may be obtained from a commercial dairy farm approximately thirty days prior to anticipated calving date. The cows are moved into separate building, approximately
10-14 days prior to their anticipated calving dates and switched to the TMR-Close-Up dry diet.
Enrolment of animals in the study begins approximately 7 days prior to their anticipated calving dates. The animals may be moved to the “on-test’ pen, weighed and are locked each
AM into feed stanchions. At that time, appropriate doses are administered and appropriate blood samples obtained (see table below for sample data for a PPAR alpha agonist, compound Z, 2-Methyl-5-(4"trifluoromethoxy-biphenyl-4-visutfamovi}-benzoic acid (EXAMPLE 193).
Animals enrolled in T01 were treated with vehicle control every other day (eod) beginning at the estimated Day —~7 prior to calving, and once again at calving. Animals enrolled in T02 were treated with compound Z, 2-Methy!-5-(4'-triflucromethoxy-biphenyi-4-yisulfamoyl)- benzoic acid (EXAMPLE 193) every other day beginning at the estimated Day —7 prior to calving, and once again at calving.
Treatment Dosage | Animals per | Pre Partum Dosing | Treatment at
Treatment (every other day = Calving eod - beginning targeted day -7)
TO1 1 X X
Vehicle =
TO2 0.5mg/k X X pc il I
As soon as possible post-calving (~ 30 minutes) the cow is transferred to the freestall bam for the next scheduled milking (6:00 hrs and 19:00 hrs). Treatments on postpartum animals are administered every other day through day 8. Pre and post-calving NEFA samples are analyzed using the WAKO NEFA-C test kit (#994-75409). Post-calving liver biopsies are performed on all cows on days 5, 10 and 14 post-calving. Tissues are transported on ice and stored frozen at -70°F. At the conclusion of the study, samples are analysed of liver triglyceride levels using the method described by Drackley, J.K. et al. (1991, J Dairy Sci (74):4254-4264).
All animals treated with test article (T02) exhibited significantly lower (p<0.10) serum
NEFA levels as compared to control on days 1-8, with the exceptions of T02 on day 5(p=0.17). All treatment regimens significantly lowered fiver triglyceride levels com pared to placebo at all time points measured (Days 5, 10 and 14 postcalving).
Ketone bodies
Levels of ketone bodies in serum can be measured by standard methods well known to the person skilled in the art, for example, by using the commercially available kits for this purpose, including Sigma BHBA kit of order number 310-A..
Milk content:
Machines to assay for milk protein, fat, or lactose content are commercially available (MilkoScanTM 50, MilkoScanTM 4000, MilkoScanTM FT 6000 available from Foss Group).
Machines to assay for somatic cell content are also commercially available {Fossomatic TM
FC, Fossomatic TM Minor available from Foss Group).
Compounds used in this invention may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof).
For example, compounds of this invention can also be mixed with one or more biologically active compounds or agents selected from sedatives, analgesics, antiinlammatories, analeptics, antibacterials, antidiarrhoeals, anti-endotoxin, antifungals, respiratory stimulants, corticosteroids, diuretics, parasiticides, electrolyte preparations and nutritional supplements, growth promoters, hormones, and metabolic disease treatments, giving an even broader spectrum of veterinary or agricultural utility.
Examples of suitable active compounds or agents are found below:
Amylase inhibitors: Acarbose,
Glucosidase Inhibitors: Acarbose;
Sedatives: xylazine;
Analgesics and antiinflammatories: Lignocaine, Procaine, flunixin, oxytetracycline, ketoprofen, meloxicam and carprofen;
Analeptics :Etamiphylline, Doxapram, Diprenorphine, Hyoscine, Ketoprofen,
Meloxicam, Pethidine, Xylazine and Butorphanol;
Antibacterials: Chlortetracycline, Tylosin, Amoxycillin, Ampicillin, Aproamycin,
Cefquinome, Cephalexin, Clavulanic acid, Florfenicol, Danofloxacin, Enrofloxacin,
Marbofloxacin, Framycetin, Procaine penicillin, procaine benzyipenicillin, Benzathine penicillin, sulfadoxine, Trimethoprim, sulphadimidine, baquiloprim,streptomyein, dihydrostreptomycin, sulphamethoxypyridazine, sulphamethoxypuridazine, oxytetracycline, flunixin, tilmicosin, cloxacillin, ethyromycin, neomycin, nafcillin, Aureomycin, lineomycin, cefoperazone, cephalonium, oxytetracycline, formosulphathiazole, sulphadiazine and zinc;
Antidiarrhoeals: Hyoscine, Dipyrone, charcoal, attapulgite, kaolin, Isphaghula husk;
Anti-endotoxins :Flunixin, ketoprofen;
Antifungals : Enilconazole, Natamycin;
Respiratory stimulants: florfenicol;
Corticosteroids: dexamethasone, betamethasone;
Diuretics: frusemide,
Parasiticides — amitraz, dettamethrin, moxidectin, doramectin, alpha cypermethrin, fenvalerate, eprinomectin, permethrin, ivermectin, abamectin, ricobendazole, levamisole, febantel, triclabendazole, fenbendazole, albendazole, netobimin, oxfenazole, oxyclozanide, nitroxynil, morantel;
Electrolyte preparations and nutritional supplements: dextrose, lactose, propylene glycol, whey, glucose, glycine, calcium, cobalt, copper, iodine, iron, magnesium, manganese, phosphorous, selenium, zinc, Biotin, vitamin By, Vitamin E, and other vitamins;
Growth Promoters: monensin, flavophospholipol, bambermycin, salinomycin, tylosin;
Hormones: chorionic gonadotrophin, serum gonadotrophin, atropine, melatonin, oxytocin, dinoprost, cloprostenol, etiproston, fuprostiol, buserslin, oestradiol, progesterone, and bovine somatotropin; and
Metabolic Disease Treatments: calcium gluconate, calcium borogluconate, propylene glycol, magnesium sulphate.
Compounds of this invention can also be mixed with one or more biologically active compounds or agents selected from antiprotozoals such as imidocarb, bloat remedies such as dimethicone and poloxalene, and probiotics such as Lactobacilli and streptococcus.
Administration of the compounds of the present invention can be via any method which delivers a compound of this invention systemically and/or locally. These methods include oral routes, parenteral, intraduode nal routes, etc. Generally, the compounds of this invention are administered orally, but parenteral administration (e.g., intravenous, intramuscular, subcutaneous or intramedullary) may be utilized, for example, where oral administration is inappropriate or where the patient is unable to ingest the drug.
In general an amount of a campound of the present invention is used that is sufficient to achieve the therapeutic effect desired (e.g., lipid lowering).
In general an effective dosage for the compounds of the present invention, their prodrugs and the salts of such compounds and prodrugs is in the range of about 0.001 to about 100 mg/kg/day, preferably about 0.005 to about 5 mg/kg/day.
A dosage of the combination pharmaceutical agents to be used in conjuction with the
PPAR agonists is used that is effective for the indication being treated. Such dosages can be determined by standard assays such as those referenced above and provided herein. The combination agents may be administered simuttaneously or sequentially in any order.
For example, typically an effective dosage for HMG-CoA reductase Inhibitors is in the range of about 0.01 to about 100 mg/kg/day.
The compounds of the present invention are generally administered in the form of a pharmaceutical composition comprising at least one of the compounds of this invention together with a pharmaceutically acceptable vehicle, diluent or carrier. Thus, the compounds of the present invention can be administered individually or together in any conventional oral, parenteral, rectal or transdermal dosage form.
For oral administration a pharmaceutical composition can take the form of solutions, suspensions, tablets, pills, capsules, powders, and the like. Tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch and preferably potato or tapioca starch and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, jubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection aiso include lactose or milk sugar as well as high molecular weight polyethylene glycols. A preferred formulation is a solution or suspension in an oll, for example olive ofl, Miglyol™ or Capmul™, in a soft gelatin capsule. Antioxidants may be added to prevent long term degradation as appropriate. When aqueous suspensions and/or elixirs are desired for oral administration, the compounds of the present invention can be combined with various sweetening agents, flavoring agents, coloring agents, em ulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
For purposes of parenteral administration, solutions in sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions of the corresponding water-soluble salts. Such aqueous solutions may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well known to those skilled in the art.
For purposes of transdermal (e.g., topical) administration, dilute sterile, aqueous or partially aqueous solutions (usually in about 0.1% to 5% concentration), otherwise similar to the above parenteral solutions, are prepared.
Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient are known, or will be apparent in light of this disclosure, to those skilled in this art. For examples of methods of preparing pharmaceutical compositions, see Remington's
Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 19th Edition (1995).
Pharmaceutical compositions according to the present invention may contain 0.1%- 95% of the compound(s) of the present invention, preferably 1%-70%. In any event, the composition or formulation to be administered will contain a quantity of a compound(s) according to the present invention in an amount effective to treat the disease/condition of the subject being treated, e.g., atherosclerosis.
Since the present invention has an aspect that relates to the treatment of the disease/conditions described herein with a combination of active ingredients, which may be administered separately, the invention aiso relates to combining separate pharmaceutical compositions in kit form. The kit comprises two separate pharmaceutical compositions: a compound of the present invention, a prodrug thereof or a salt of such compound or prodrugs and a second compound as described above. The kit for example comprises means for containing the separate compositions such as a container, a divided bottle or a divided foil packet. Typically the kit comprises directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process, recesses are formed in the plastic foil. The recesses have the size and shape of the tablets or capsules to be packed. Next, the tablets or capsules are placed in the recesses and the sheet of relatively stiff material is sealed against the plastic foll at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are sealed in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
It may be desirable to provide a memory aid on the kit, @.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the tablets or capsules so specified should be ingested. Another example of such a memory aid is a calendar printed on the card, e.g., as follows "First Week, Monday, Tuesday, ...etc.... Second Week, Monday, Tuesday,..." etc. Other variations of memory aids will be readily apparent. A “daily dose" can be a single tablet or capsule or several pills or capsules tobe taken on a given day. Also, a dally dose of a compound of the present invention can consist of one tablet or capsule while a dally dose of the second compound can consist of several tablets or capsules and vice versa. The memory ald should reflect this.
In another specific embodiment of the invention, a dispenser designed to dispense the daily doses che at a time in the order of their intended use is provided. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter which indicates the number of daily doses that has been dispensed. Another example of such a memory-aid Is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.
The compounds of the present invention either alone or in combination with each other or other compounds generally will be administered in a convenient formuiation. The following formulation examples only are illustrative and are not intended to limit the scope of the present invention. in the formulations which follow, "active ingredient” means a compound of the present invention. Fommuiation 1: Gelatin Capsules
Hard gelatin capsules are prepared using the following:
Trgredient Quantity (mglcapsule) “Active ingredient 025100
Starch, NF 0-650
Starch flowable powder 0-50
Silicone fluid 350 centistokes 0-15 ee ——————
A tablet formulation is prepared using the ingredients below.
Formulation 2: Tablets
Segredient Quantity (mglablety “Active ingredient 025100
Cellulose, microcrystalline 200-650
Silicon dioxide, fumed 10-650
Stearate acid 5-18 ——————
The components are blended and compressed to form tablets.
Alternatively, tablets each containing 0.25-100 mg of active ingredients are made up as follows:
Formulation 3: Tablets ingredient Quantity (mghabiet) ’
Active ingredient 025-100
Starch 45
Cellulose, microcrystalline 35
Polyvinyipyrrolidone (as 10% solution in water) 4
Sodium carboxymethyl! cellulose 45
Magnesium stearate 0.5
Talc 1
The active ingredients, starch, and cellulose are passed through a No. 45 mesh u.s. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50° - 60°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 u.s. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets.
Suspensions each containing 0.25-100 mg of active ingredient per 5 ml dose are made as follows:
Formulation 4: Suspensions
Ingredient Quantity (mg/5 ml)
Active ingredient 0.25-100 mg
Sodium carboxymethyl cellulose 50 mg
Syrup 1.25mg
Benzoic acid solution 0.10 mL
Flavor q.v.
Color q.v.
Purified Water to 5mL
The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.
An aerosol solution is prepared containing the following ingredients:
Formulation 5: Aerosol
Trgedemt Quanity (%byweigh) “Active mgredent 0
Ethanol 25.75
Propellant 22 (Chlorodifluoromethane) 70.00
The active ingredient is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to 30°C, and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remaining propellant. The valve units are then fitted to the container.
Suppositories are prepared as follows:
Formulation 6: Suppositories
Theoedent Quantity (mgisuppostory) “Adve mgrediert 250
Saturated fatty acid glycerides 2,000
The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimal necessary heat. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool. "An intravenous formulation is prepared as follows:
Formulation 7: Intravenous Solution
Tngedent Quay “Active ingredient dissolved in ethanol 1% 20mg
Intralipid. ™ emulsion 1,000 mL
The solution of the above ingredients is intravenously administered to a patient at a rate of about 1 mL per minute.
Soft gelatin capsules are prepared using the following:
Formulation 8: Soft Gelatin Capsule with Oil Formulation
Thgediemt Quantity (mglcapsule) “Active mgredent 10600
Olive Oil or Miglyol™ Oil 500-1000
The active ingredient above may also be a combination of therapeutic agents.
GENERAL EXPERIMENTAL PROCEDURES
The following examples are put forth so as to provide those of ordinary skill in the art with a disclosure and description of how the compounds, compositions, and methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended ta limit the scope of what the inventors regard as their invention. Unless indicated otherwise, percent is percent by weight given the component and the total weight of the composition, temperature is in °C or Is at ambient temperature, and pressure is at or near atmospheric. Commercial reagents were utilized without futther purification. Room or ambient temperature refers to 20-25 °C. All non-aqueous rea ctions were run under a nitrogen atmosphere fcr convenience and to maximize yields. Conceratration in vacuo means that a rotary evaporator was used. The names for the compounds of the invention were created by the Autonom 2.0 PC-batch version from Beilstein informations systeme GmbH (ISBN 3-89536- 976-4). “DMSO” means dimethyl sulfoxide.
NMR spectra were recorded on a Varian Unity 400 (Varian Co., Palo Alto, CA} NMR spectrometer at ambient temperature. Chemical shifts are expressed in parts per million (5) relative to an external standard (tetramethyisilane). The peak shapes are denoted as follows: s, singlet; d, doublet, t, triplet, q, quartet, m, multiplet with the prefix br indicating a broadened signal. The coupling constant (J) data given have a maximums error of £0.41Hz due to the digitization of the spectra that are acquired. Mass spectra were obtained by (1) atmospheric pressure chemical ionization (APCI) in alternating positive ancl negative ion mode using a
Fisons Platform II Spectrometer or a Micromass MZD Spectro meter (Micromass, Manchester,
UK) or (2) electrospray ionization in alternating positive and nexgative ion mode using a
Micromass MZD Spectrometer (Micromass, Manchester, UK} with a Gilson LC-MS interface (Gilson Instruments, Middleton, W!) or (3) 2a QP-8000 mass sp ectrometer {Shimadzu
Corporation, Kyoto, Japan) operating in positive or negative single ion monitoring mode, utilizing electrospray ionization or atmospheric pressure chemical ionization. Where the intensity of chlorine- or bromine-containing ions are described, the expected intensity ratio was observed (approximately 3:1 for *Cl/*’Cl-containing ions and 1:1 for ™Br/*'Br-containing ions) and the position of only the lower mass ion is given.
Column chromatography was performed with either Baker Silica Gel (40 um) (J.T.
Baker, Phillipsburg, N.J.) or Silica Gel 60 (40-63 um)(EM Sciences, Gibbstown, N.J.). Flash chromatography was performed using a Flash 12 or Flash 40 column (Biotage, Dyar Corp.,
Charlottesville, VA). Preparative HPLC purification was perforrmed on a Shimadzu 10A preparative HPLC system (Shimadzu Corporation, Kyoto, Japan) using a model SIL-10A autosampler and model 8A HPLC pumps. Preparative HPLC-NS was performed on an identical system, modified with a QP-8000 mass spectrometer operating in positive or negative single ion monitoring mode, utilizing electrospray ionization or atmospheric pressure chemical ionization. Elution was carried out using water/acetonitrile gradients containing either 0.1% formic acid or ammonium hydroxide as a modifier. In acidic mode, typical columns used include Waters Symmetry C8, Sum, 19x50mm or 30x50mm, Waters XTerra
C18, 5um, 50x50 (Waters Corp, Milford, MA) or Phenomenex Synergi Max-RP 4pm,
50x50mm (Phenomenex Inc., Torrance, CA). in basic mode, the Phenomenex Synergi Max-
RP 4pm, 21.2x50mm or 30x50mm columns {Phenomenex Inc., Torrance, CA) were used.
Optical rotations were determined using a Jasco P-1020 Polarimeter Jasco tnc., Easton, MD) Dimethylformamide, tetrahydrofuran, toluene and dichloromethane were the anhydrous grade supplied by Aldrich Chemical Company (Milwaukee, WI). Unless otherwise specified, reagents were used as obtained from commercial sources. The terms “concentrated” and “evaporated” refer to removal of solvent at 4-200 mm of mercury pressure on a rotary evaporator with a bath temperature of Jess than 45°C. The abbreviation “min” stand for “minutes” and *h” or *hr" stand for “hours.” The abbreviation “gm” or “g” stand for grams. The : abbreviation “pl” or “pL” stand for microliters.
EXAMPLE 1: 5-(4-Benzyloxy-phenylsulfamovi}-2-methyl-benzoic acid fo)
Ny
OAC
To a solution of 5-chlorosulfonyl-2-methylbenzoic acid (200 mg, 0.85 mmol) and p- benzyloxyaniline (187 mg, 0.94 mmol) in 6 mi acetone and 3 ml dimethylformamide was added a solution of sodium bicarbonate (215 mg, 0.56 mmol) in 2 mi water. The resulting mixture was stirred overnight at room temperature. The acetone was then removed under reduced pressure and the residual mixture was partitioned between 25 ml 1N aqueous hydrochloric acid solution and 25 ml ethyl acetate. The aqueous phase was separated and extracted with 2 x 25 mi ethyl acetate. The combined ethyl acetate extracts were dried (anhydrous sodium sulfate) and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 15 gm) eluting with 9:1 chloroform/methanol to yield a white solid (154 mg). The solid was triturated with dichloromethane to yield the title compound (93 mg, 28 % yield) as a white solid. MS: 395.6 (M-1); "H NMR (400 MHz, CD;0D): 8 2.57(s, 3H), 4.96 (s, 2H), 6.81 (m, 2H), 6.83 (m, 2H), 7.30 (m, 6H), 7.60 (m, 1H), 8.20 {(m, 1H).
The title compounds of EXAMPLES 2-26 were prepared using procedures analogous to that of EXAMPLE 1 from appropriate starting materials.
EXAMPLE 2: 2-Methyl-5-[4-(6-methyl-benzothiazol-2-vi}-phenyisulfamoy] benzoic acid
0
OH
H,C Ss Q
N Oo . 8% yield. MS: 439.4 (M+1); '"H NMR (400 MHz, CDs0D): 52.44 (s, 3H), 2 .53 (s, 3H), 7.23 (m, 2H), 7.29 (m, 1H), 7.34 (m, 1H), 7.72 (m, 1H), 7.75 (m, 1H), 7,80 (m, 1H), 7.88 (m, 2H), 8.19 (m, 1H).
EXAMPLE 3: 2-Methyl-5-[4-(5-methyl-benzooxazol-2-yl)-phenyisulfamoyl] benzoic acid 0
OH
! jg. — Joo
H.C N S 4% yield. MS: 423.4 (M+1); "H NMR (400 MHz, CD;0D): 52.42 (s, 3H), 2.51 (s, 3H), 7.17 (m, 1H), 7.26 (m, 2H), 7.35(m, 1H), 7.44 (m, 2H), 7.56 (m, 1H), 8.0 (m, 2H), 815 (m, 1H). .
EXAMPLE 4: 5-(4-Benzooxazol-2-yl-phenylsutfamoy}-2-methyk-benzoic acid
Oo
OH
0 ?
N o} 10 % yield. MS: 407.1 (M-1); 'H NMR (400 MHz, CD,OD): 52.48 (s, 3H), 7.38 (m, 3H), 7.65 (m, 1H), 7.7 (m, 1H), 7.92 (m, 3H), 8.22 (m, 1H).
EXAMPLE 5: 2-Methvi-5-{4-(5-phenyl-benzooxazol-2-yi)-phenvisulfamoyf] -benzoic acid
Q
OH
T-0O- che
Soa ieiiinds 7% yield. MS: 483.2 (M-1); 'H NMR (400 MHz, CD,0D): 52.48 (s, 3H), 7.35 (m,2H), 7.44 (m, 2H), 7.64 (m, 3H), 7.71 (d, 1H), 7.82 (m, 1H), 7.92 (m, 4H), 8.23 (m, 2H).
EXAMPLE 6: 5-[4-(5-Chloro-benzooxazol-2-vi}-phenylsulfamoyfl-2-methyl —benzoic acid
Oo
OH o) ? y/ N= CH, cl N Ho 10 % yield. MS: 441.1 (M-1); TH NMR (400 MHz, CD,OD): $2.47 (s, 3H), 7.37 (m, 2H), 7.63 {d, 1H), 7.7 (b, 1H), 7.81 (m, 1H), 7.92 (m, 3H), 8.21 (m, 2H).
EXAMPLE 7: 5-(4-Benzothiazol-2-yl-phenyisulfamovyl}-2-methyl-benzoic acid 0
OH s Q p N-S CH,
HU .
N 0] 7% yield. MS: 425.1 (M+1), 'H NMR (400 MHz, CD;0D); 5246 (s, 3H), 7.26 (m, 3H), 7.37 {t, 1H), 7.47 (t, 1H), 7.62 (d, 1H), 7.91 (m 4H), 7.98 (b, 1H).
EXAMPLE 8:2-Methvi-5-[4-{4-trifluoromethyl-benzylsulfanyl)-phenwisutfamoyl}-benzoic acid
QO
FF OH aS
Oo 33% yield. MS: 480.2 (M-1); 'H NMR (400 MHz, CD;OD): 52.49 (s, 3H), 4.04 (s, 2H), 6.96 (d, 2H), 7.1 (d, 2H), 7.23 (d, 1H), 7.29 (m, 2H), 7.47 (m, 3H), 7.94(b, 1 H). 16 EXAMPLE 9: 2-Methvl-5-[4-(4-trifluoromethyl-benzyloxy}-phenylsulfamoyll-benzoic acid (0)
FF OH
FO yp Coo o . 28% yield. MS: 464.1 (M-1); H NMR (400 MHz, CD;OD): 82.56 (s , 3H), 5.07 (s, 2H), 6.83 (m, 2H), 6.95 (m, 2H), 7.30 (d, 1H), 7.57 (m, 3H), 7.63 (d, 2H), 8.13 (s, 1H).
EXAMPLE 10: 2-Methyl-5-(4-styryl-phenylsulfamoyt)-benzoic acid a
SN] g o OH
CH, 33% yield. MS: 392.2 (M-1), "H NMR (400 MHz, CD,0D): 32.54 (s, 3H), 7.05 (m, 4H), 7.18 {t, 1H), 7.26-7.4 (m, 5H), 7.46 (m, 2H), 7.67 (m, 1H), 8.18 (s, 1H).
EXAMPLE 11: 2-Methyl-5-[4-(3-trifluoromethyl-benzyisulfanyl )-phenyisulfamo vi]-benzoic acid 0. OH
A
AR
AT
0] “or 21% yield. MS: 480.1 (M-1); 'H NMR (400 MHz, CD;OD): 52.59 (s, 3H), 4.06 (s, 2H), 6.98 (m, 2H), 7.13 (m, 2H), 7.34 (m, 3H), 7.44 (m, 2H), 7.68 (m, 2H), 8.26 (d, 1H).
EXAMPLE 12: 5-[4-{4-teri-Butyl-benzyisulfanyl)-phenvisulfamovl]-2-methyl-benzoic acid 0] pe
Q
NH OL
I] (0)
S
H.C
HsC
CH, 31% yield. MS: 468.2 (M-1); 'H NMR (400 MHz, CD,OD): 31.24 (s, 9H), 2.57 (s, 3H), 3.95 (s, 2H), 6.95 (m, 2H), 7.05 (d, 1H), 7.11 (m, 1H), 7.21 (d, 1H), 734 (d, 1H), 7.66 (Mm, 1H), 8.22 {d, 1H).
EXAMPLE 13: 5-(4-Benzothiazol-2-yl-phenyisulfamowl}-2-ethyl-benzoic acid 0)
OH
S N Q
) { > —
N H i CH, 6% yield. MS: 439.1 (M+1); 'H NMR (400 MHz, CD,0D): $1.18 (t, 3H), 2.96 (gq, 2H), 7.27 (d, 2H), 7.39 (t, 2H), 7.49 (t, 1H), 7.79 (d, 1H), 7.94 (m, 4H), 8.15 (d, 1H).
EXAMPLE 14: 2-Ethy}-5-[4-(5-methvi-benzooxazol-2-yl)-phenylsulfamoyli-benzoic acid 0]
OH jas p — 1
H,C N le) CH; 9% yield. MS: 437.1 (M+1); 'H NMR (400 MHz, CD,OD): 51.18 (t, 3H), 2.45 (s, 3H), 2.954q, 2H), 7.19 (m, 1H), 7.29 (m, 2H), 7.38 (d, 1H), 7.47 (d, 2H), 7.78 (m, 1H), 8.04 (d, 2H), 8.2 (d, 1H).
EXAMPLE 15: 2-Ethyl-5-[4-(4-trifluoromethvi-benzylsulfanyl)-phenvisulfamoyll-benzoic acid (0)
F OH
TO) 2 i iB cH, 32% yield. MS: 495.2 (M-1); 'H NMR (400 MHz, CD,0OD): §1.17 (t, 3H), 2.93 (q, 2H), 4.04 (s, 2H), 6.97 (m, 2H), 7.11 (m, 2H), 7.3 (m, 3H), 7.46 (d, 2H), 7.59 (m, 1H), 8.0 (d, 1H).
EXAMPLE 16: 5-[4-(4-Isopropyl-benzyisulfanyt)-phenylsutfamoyll-2-methyi-benzoic acid [®) OH & ” (@)
Jef 1 oO
S
«JO
CH,
B67- 10% vield. MS: 454.2 (M-1); HNMR (400 MHz, CD30D): $1.17 (d, 6H), 2.8 (m, 1H), 3.94 (s,
ZH), 6.95 (d, 2H), 7.04 (5, 4H), 7.1 (m, 2H), 7.31 (d, 1H), 7.61 (d, 1H), 8.16 (s, 1H).
EXAMPLE 17: 2-Methyl-5-[4-(4-triflucromethoxy-benzylsulfan henylisulfamoyll-benzoic acd
Os__OH
CH, y lo) . KX!
S
Lr o
Lo )
Ao 29 % yield. MS:496.1 (M-1); "H NMR (400 MHz, CD,0D): 52.59 (s, 3H), 4.01 (s, 2H), 6.98 (m, 2H), 7.06 (d, 2H), 7.14 (m, 2H), 7.20 (d, 2H), 7.36 (d, 1H), 7.67 (d, 1H), 8.22 (s, 1H).
EXAMPLE 18: 5-f4~(4-Chioro-benzyisulfanyl)-phenylsuifamovil-2-methyl-benzoic acid [e} OH
CH,
H (e] 3 ra oe
Cl 7% yield. MS: 448.1 (M+1), 'H NMR (400 MHz, CD,0OD): 52.53 (s, 3H), 3.95 (s, 2H), 6.95 (d, 2H), 7.09 (t, 4H), 7.14 {d. 2H), 7.28 (d, 1H), 7.55 (m, 1H), 8.07(d, 1H). 16 EXAMPLE 19: 2-Methyi-5-[4-(3-phenoxy-benzylsulfanyl}-phenvisulfamoyi]-benzoic acid
Os OH ’
CH, 4 [e] 1 25% yield. MS: 504.2 (M+1); 'H NMR (400 MHz, CD50D): 52.54 (s, 3H), 3.94 (s, 2H), 6.77 (m, 4H), 6.88 (d, 1H), 6.95 (d, 2H), 7.09 (m, 4H), 7.28 (m, 3H), 7.63 (m, 1H), 8.24 (d, 1H).
EXAMPLE 20: 2-Methyi-5-(4-{2-[2(4-triflucromethyi-phenyl)-thiazol-4-vil-ethoxy}- phenyisuifamovi}benzoic acid
Sy :
F N o OH 1 ren 72 % yield. MS: 563.1 (M+1); 'H NMR (400 MHz, CD,0D): 52.54 (s, 3H), 3.22 (t, 2H), 4.27 (1, 2H), 6.77 (m, 2H), 6.93 (m, 2H), 7.29 (d, 1H), 7.34 (s, 1H), 7.55 (m, 1H), 7.74 (d, 2H), 8.09 (d, 3H).
EXAMPLE 21: 2-Methyl-5-(4-{2-[2-{4-trifluoromethoxy-phenyl)-thiazol-4-yli-ethoxy}- phenylsulfamoyl}-benzoic acid
F S
Fo
F A 0 A
Oren © 31% yield. MS: 579.1 (M+1); H NMR (400 MHz, CD,0OD): 52.48 (s, 3H), 3.20 (i, 2H), 4.25 (t, 2H), 6.75 (d, 2H), 6.94 (d, 2H),7.22 (m, 1H), 7.29 (s, 1H), 7.35 (m, 2H), 7.44 (m, 1H), 7.89 (s, 1H), 8.00 (d, 2H).
EXAMPLE 22: 2,3-Dimethyl-5-[4-(5-methyl-benzooxazol-2-yl}-phenyisulfamoyil-benzoic acid 0)
OH
0 q
OC
H 0
H.C N (o]
CH, 7% yield. MS: 437.3 (M+1),; 'H NMR (400 MHz, CD;0D): 52.38 (s, 3H), 2.39 {s, 3H), 2.48 (s, 3H), 7.23 (d, 1H), 7.53 (m, 2H), 7.74 (s, 2H), 7.94 (d, 2H), 8.21 (d, 2H).
EXAMPLE 23: 2.6-Dimethyl-3-[4-(6-methyl-benzothiazol-2-yi)-phenylsulfamovil-benzoic acid
JOOS WLY
HC S ps CH, 0]
H.C 0)
HO
16% yield. MS: 453.1 (M+1); "H NMR (400 MHz, CD5OD): 82.33 (s, 3H), 2.46 (s, 3H), 2.63 (s, 3H), 7.2-7.3 (c, 3H), 7.32 (¢, 1H), 7.73 (s, 1H}, 7.8 (d, 1H), 7.88 (m, 2H), 8.0 (d, 1H).
EXAMPLE 24: 2.6-Dimethyl-3-[4-{3-trifluoromethoxy-benzyisulfanyl}-phenylsulfamoyll-benzoic acid
CH, i LI 2%
F . 6% yield. MS: 510.1 (M-1); H NMR (400 MHz, CD,0D): 52.34 (s, 3H), 2.57 (s, 3K), 4.02 (s, 2H), 6.95 (m, 2H), 7.07 (d, 1H) 7.12 (m, 4H), 7.22 (m, 2H), 7.85 (d, 1H).
EXAMPLE 25: 2.6-Dimethyl-3-[4-(4-trifluoromethoxy-benzylsutfanyl}phenvisulfamovll-benzoic acid 0
F H,C OH
On od
F Ss N-S CH,
Hl [o] 32 % yield. MS: 510.3 (M-1); 'H NMR (400 MHz, CD;0D): $2.35 (s, 3H), 2.62 (s, 3H), 4.01 (s, 2H), 6.97 (m, 2H), 7.12 (m, 5H), 7.24 (d, 2H), 7.77 (d, 1H).
EXAMPLE 26: 2,6-Dimethyl-3-(4'-trifluoromethoxy-biphenyl-4-ylsulfamoyi}-benzoic acid
CH, 0] ig CIs
JTLT
LC
Ao
F
13 % yield. TH NMR (400 MHz, CDsOD): 82.33 (s, 3H), 2.62 (s, 3H), 7.17 (m, 2H), 7.22 (d, 1H), 7.28 (d, 2H), 7.47 (m, 2H), 7.60 (m, 2H), 7.93 (d, 1H).
EXAMPLE 27; 5-[4-{4-tert-Butyl-phenoxy}-phenyisulfamoyl]-2-methyl-benzoic acid
0)
OH
CH; 0
CH, Oo
A solution of 4-(4-tert-butyl-phenoxy}-phenylamine (0.1 g, 0.41 mmol). 5-chlorosulfonyt-2- methylbenzoic acid (0.097 g, 0.41 mmol) and pyridine (0.1 ml, 1.24 mmol) in 2 ml anhydrous tetrahydrofuran was heated at 60° C for 2 hr. The reaction mixture was cooled to room temperature and diluted with 30 mi ethyl acetate. The ethyl acetate solution was washed sequentially with 25 ml 1N aqueous hydrochloric acid solution and 25 mi brine, dried (anhydrous sodium sulfate) and concentrated to dryness under reduced pressure. The crude product was purified by preparative thick layer chromatography (silica gel), eluting with 9:1 chiloroform/methanoi to yield the title compound. 82% yield. MS: 438.3 (M-1); 'H NMR (400 MHz, CD,0D): §1.30 (s, 9H), 2.58 (s, 3H), 6.82 (m, 4H), 7.02 (d, 2H), 7.36 (d, 3H), 7.63 (d, 1H), 8.1 (b, 1H).
The title compounds of EXAMPLES 28-40 were prepared using procedures analogous to that 16 of EXAMPLE 27 from appropriate starting materials.
EXAMPLE 28: 5-[4-(4-Ethyl-benzyisuifanyi}-phenylsutfamoyll-2-methyi-benzoic acid
O~_ OH
Pea ol 0
[0] .
S
78% yield. MS: 442.1 (M+1); 'H NMR (400 MHz, CD,0D): $1.15 (t, 3H), 2.54 {(q, 2H), 2.57 {s, 3H), 3.94 (s, 2H), 6.94 (m, 3H), 7.01 (m , 3H), 7.10 (d, 2H). 7.33 (d, 1H), 7.64 (m, 1H), 8.20 (d, 1H).
EXAMPLE 29: 2-Methyl-5-[3-methyl-4-(4-trifluoromethyi-benzyloxy)- phenyisulfamoyi]-benzoic acid
0]
F a H,C OH " 0 t C
F N i H, 6% yield. MS: 478.2 (M-1}; TH NMR (400 MHz, CD;0D): §2.17 (s, 3H), 2.60 (s, 3H), 5.11 (s, 2H), 6.80 (m, 2H), 6.88 (s, 1H), 7.36 (d, 1H), 7.63 (m, 5H), 8.20 (d, 1H).
EXAMPLE 30: 2-Methyl-5-[2-methyi-4-{4-trifluoromethyl-benzyloxy)-phenvisulfamoyll-benzoic acid (0)
F CH, OH
Fy—¢ a Q _—
F 0 N-% \ / CH, 0] 65% yield. 'H NMR (400 MHz, CD3;0D): 52.00 (s, 3H), 2.62 (s, 3H), 5.10 (s, 2H), 6.71 (m, 1H), 6.79 (d, 1), 6.87 {d, 1H), 7.36 (d, 1H), 7.59 (m, 3H), 7.66 (d, 2H).
EXAMPLE 31: 5-{4-{2-[5-(3,5-Dimethyi-pheny)-[1,3,4loxadiazol-2-ylsulfanyl}-ethvi}- phenvisulfamoyi}-2-methyl-benzoi¢ acid
OH
CH aN: INS we O~""% o CH, 49% yield. MS: 524.4 (M+1); HNMR (400 MHz, CDCl,): 82.36 (s, 3H), 2.59 (s, 3H), 3.03 {t, 2H), 3.41 (t, 2H), 7.05 (d, 2H), 7.13 (d, 3H), 7.27, (b, 1H), 7.61 (s, 2H), 7.75 (b, 1H), 8.14 (b, 1H).
EXAMPLE 32; 5-(4-{2-[5-(3,5-Dichloro-phenvl)-[1,3 4loxadiazol-2-ylsulfanvi]-ethyl}- phenylisulfamovyi}-2-methyl-benzoic acid ’
OH al © o N-N te Y3gA ~~) a 0]
Cl 90% yield. MS: 566.3 (M+1); TH NMR (400 MHz, CDCL): 52.55 (s, 3H), 2.97 (t, 2H), 3.38 (t, 2H), 7.03 (m, 5H), 7.18 (d, 1H), 7.63 (d, 1H), 7.63 (m, 1H), 7.77 (m, 1H), 8.02 (d, 1H).
EXAMPLE 33: 5-[4-(3-Diflugromethoxy-benzyisulfanyl}-phenyisulfamoyil-2-methyi-benzoi acid
OH F o—L
[0] 0 F
H,C Es (o] 40 % yield. MS:478.2 (M-1); 'H NMR (400 MHz, CD,0D): 52.58 (s, 3H), 4.01 (s, 2H), 6.98 (c, 5H), 7.14 (m, 2H), 7.20 {t, 1H), 7.33 (d, 1H), 7.63 (m, 1H), 7.87 (s, 1H), 8.19 (d, 1H).
EXAMPLE 34: 2-Methyi-5-[4-(2-trifluoromethoxy-benzyisulfanyl)-phenylsulfamovil-benzoic acid
OH
© ? ao Yu) 0 lo)
F
1
F
27% yield. MS: 498.3 (M+1); 'H NMR (400 MHz, CDCl,): 52.60 (s, 3H), 3.98 (s, 2H), 7.01 (d, 2H), 7.10 {c, 5H), 7.23 (c, 2H), 7.68 (m, 1H), 8.41 (d, 1H).
EXAMPLE 35: 2-Methyl-5-[4-(4-triflucromethyl-phenylsulfamovi}-phenylsulfamoyvil-benzoic acid
Q aula’ Spun
F lo} NR CH,
Oo 6% yield. MS: 512.9 (M-1); 'H NMR (400 MHz, CD;OD): $2.55 (s, 3H), 7.20 (m, 3H), 7.30 (d, 1H), 7.48 (d, 2H), 7.66 (m, 3H), 7.90 (s, 1H), 8.20 (d, 1H).
EXAMPLE 36; 5-{4-[5-(4-Ethyl-phenvyl)-[1.3 4]oxadiazol-2-y{}-phenylsulfamoyi}-2-methyl- benzoic acid 0
N— ~O3-0c
H,C 0 N-% CH,
34% yield. 'H NMR (400 MHz, CD,0D): 51.28 {t, 3H), 2.60 (s, 3H), 2.74 (q, 2H), 7.34 (m, 2H), 7.43 (m, 3H), 7.87 (m, 2H), 8.03 (m, 3H), 8.38 (d, 1H).
EXAMPLE 37: 5-[4-(5-tert-Butyi-[1,3,4]oxadiaz I-2-vi)-phenylsulfamoyil-2-meth l-benzoic acid
O
OH
H, N—N 0 fo I
HC N—S CH, fe) H I
CH, 0] 51% yield. MS: 416.7 (M+1); "H NMR (400 MHz, CD;OD): 81.46 (s, gH), 2.60 (s, 3H), 7.30 (m, 2H), 7.42 (d, 1H), 7.84 (m, 1H), 7.89 (m, 2H), 8.35 (d, 1H).
EXAMPLE 38: 2-Methyl-5-{4-[5-(4-trifluoromethoxy-phenyl M1.3.4loxadiazolk2-V1]- phenytsulfamoyl}-benzoic acid (o}
F
N—
OBO
F 0 N-% CH, o] 6% yield. MS: 518.0 (M+1); 'H NMR (400 MHz, CD;0D): §2.47 (s, 3H), 7.2-7.34 (m, 4H), 7.50 (d, 1H), 7.67 (m, 1H), 7.92-8.04 (m, 4H), 8.22 (d, 1H). "15 EXAMPLE 39: 2-Methyl-5-[4-(5-trifluoromethyl-pyridin-2-yicarbamoyi)-phenyisuttamovil- penzoic acid methyl ester
F XY © 0 “0, tl
R
H H O
60% vield. MS: 492.0 (M-1)
EXAMPLE 40: 5.{4-(5-Cyclohexyl-[1,3.4loxadiazol-2-vi)-phenyisulfamoyfl-2-methyi-benzoic acid methvi ester
Qo. 7 0
MYC HQ
\ N—§ 0] 32% yield. MS: 454.1 (M-1)
The title compounds of EXAMPLES 41-82 were prepared using procedures analogous to that of EXAMPLE 1 from appropriate starting materials.
Chemical Structure Chemical Name Data
H © 0}
NJ & 5-(4-Benzyloxy- v7 OH 29% 41 o (®) phenylsulfamoyl)-2- yield. MS:
Sf cl chloro-benzoic acid 416.2 (M- 1)
H Oo
N< 2 36%
S 2-Chloro-5-(4-oxazol-5- 42 o OH \-phenylsulfamoyl)- yield. MS: -phenylsulfamo ¢ : P o acid 379.29 enzoic aci \ | Cc! (M1)
N
2-Chloro-5-(4- iohexy! 44% cyclohexyl- 43 H o ’ isulfamoyl)- yield. MS: enylsulfamo
Nig’ : y y 392.0 (M- enzoic aci d OH 1
Cl
H.C
Co 2-Chloro-5-{4-(6-methyl- | 4% yieid. a4 N= benzothiazol-2-y1)- MS:
H o phenylisulfamoyl]- 459.2 . N< 2”
Foo benzoic acid (M+1)
Cl
H,C a 2-Chloro-5-(4-hexylo 46% 0- exyloxy- us RQ nenysut y ¥" | yield. Ms: enyisulfamo
H 0 Pp y 410.3 (M- ~g benzoic acid &’ OH 1)
Cl
[ Ex. | Chemical Structure Chemical Name
A
2-Chloro-5-(4-styryl- 29% 45 phenylsuffamoyl}- yield. MS: 2] y oO 0] benzoic acid 411.9 (M-
J
$F Cr R
Cl
Ql 2-Chloro-5-(4- ! 41%
N phenylcarbamoy!- . 47 H henylsulfamoy) yield. MS: enylsulfamoyl)-
Ho phenysutamoy 431.2 ~g benzoic acid / OH (M+1) 0]
Cl
F eA F 2-Chloro-5-[4-(3- >) I uorome razol-1-
NN Johenyi oo . yield. MS: enylsulfamoyl}-
TL, o yTPnenyisaTamoy w62
Nog’ benzoic acid (M+1) 0 OH ) Cl
N=y ~u 2-Chloro-5-(4- 17% 1,2,3]thiadiazol-4- ield. MS: 49 H 0 6 [ Jthiadi yi- yiel 8 OH phenylsulfamoyl)- 394.3 (M- © benzoic acid 1)
Cl
AL 2-Chioro-5-(4- 36% phenylamino- yield. MS: 50 H o
N.g phenylsulfamoyl)- 403.1 o OH benzoic acid (M+1)
Cl
EX. | Chemical Structure [Cremieal Name Dalz _| Name [Data ) | Ci : : i a. 2-Chloro-5-{4-(4-chloro- | 41% phenoxy}- yield. MS: | N92 phenylsulfamoyl}- 436.0 (M- > OH benzoic acid 1)
Cl
H.C hn. 51% eo} 2-Chloro-5-(4-pentyloxy- | yield. 52 phenylsutfamaoyt)- MS:
H o 0
NL benzoic acid 396.0 (M- i» OH ! [eo] 1)
Cl 0 7% yield. 5-(4-Benzoyl- er 53 a. & phenylsulfamoyl)-2- “161 2 oH | chloro-benzoic acid 0) (M+1)
Cl
NP
Or 3S. 2-Chioro-5-(4- 5% yield. (o] TL o phenylsulfamoyt- MS:
Ng! op | Premvisuamoyi)- 465.0 o benzoic acid (M-1)
Cl
CH,
ON
SS 2-Chloro-5-[2~(5-methyl- | 5% yield. 55 o) 2-phenyl-oxazol-4- MS: \ 0 yimethyl)-benzofuran-5- | 524.3
Art ylsulfamoyl]-benzoic acid | (M+1)
J OH of}
i — chi 5 38% \ / y > noe yield. / ) enyls ulfanyl- % S Nog? i . }- MS: mo
J oH | Pe y 418.0 benzoic acid
Ci (M-1)
GH, 0} g 2-Chioro-5-4{4-{2-(4- 13% 57 methoxy-phenyl)-vinyl} | yield. $ A o phenyls ulfamoyf}- MS:442.1
I oS benzoic acid M-1)
Ao cl
Ql 2-Chioro-5-[3-(2- 54% 0 phenoxy-ethoxy)- yield. MS: 58 Q phenylsulfamoyl}- 446.1 o 0 OH | penzoic acid (M-1)
H Oo
Q
O 4% yield - 0 2-Chloro-5-[4~(5-p-tolyk-
Sd ' [1,3.4loxadiazok-2-yl)- (0) 0 470.2 phenylsulfamoyi}- (M+1)
HC benzoic acid 0] 2-Chloro-5-{4-(4,5- 31% yield
I OH
6 Ci _ o dichioro-imidazol-1-yl} | MS: as Cl | phenylsutfamoyil- 448.0
N=~/ H i oO benzoic acid (m+1)
FEx. | Chemical Structure Chemical Name ; 0 (] 2-Chioro-5-{4-[2-(4- 45% yield a 7 8) hydroxy-phenyl}-vinyl}- | MS: 61 © = H i phenylsulfamoyf}- 428.1
HO benzoic acid (M-1)
Q_ | 2-Chloro-5-[4-(4- 15% yield
FF 4 trifluoromethyi- | Ms: ks J a od) Bl Q J) benzyloxy)- 484.1
N 8 phenylsulfamoyl}- (M-1) benzoic acid
QO 2-Chiloro-5-[444-
E a 35% yield
F q 4 trifluoromethyi- MS: 63 7 a Ss Ys § ) benzylsulfanyl)- coo.
Io} phenylsulfamoyl]- a. (M-1) benzoic acid ! Q on | ZCerosu22.2- 39% yield
F 0] . trifluoro-acetylamino)- MS: on | 9
F N N—S Cl phenyisulfamoyl}- 421.0
H H 5 benzoic acid {M-1)
Q 50% yield 0 4 2-Chloro-5-(4-heptyloxy- ME: 65 | HiCa~~ o~ i Q ) phenylsulfamoyl)- 423 5 0 benzoic acid ) (M-1)
Q 0, lo} 47%
Q 5-(4-Butoxy- yield. 66 neo Hn Cl| phenytsulfamoyl)-2- MS: 0 chloro-benzoic acid 382.4 (M-1)
Ex. | Chemical Structure Chemical Name [Data
H,C—O i
Q o 2-Chloro-5-{4-(4- 43% yield 67 0 methoxy-phenylamino} | MS: v— H cl | phenylsulfamoyl}- 433.0
H H LL benzoic acid (M+1)}
Q 9; 2-Chloro-5-(4- 14% vield 68 E Io) © trifluoromethyisulfanyl- MS:
F—— syns cl phenylsulfamoyl)- 410.0
F Ho benzoic acid (M-1)
R %e d 5% yiel o OR 5.(4-Benzooxazol-2-y- ve y 0) i : 69 — - Hs c| | phenylsutfamoyi)-2 429.1
N HM chioro-benzoic acid 0 (M+1) 0 fo) i 2% yield
H o 5-[4-(1H-Benzoimidazol- MS:
N it y N : 70 4 )- N—S cl 2-yi)}-phenyisulfamoyf}-2 428.1
N H XU chloro-benzoic acid o (M+1) 0
OH 2-Chloro-5-[4-(5-methyl- | 13% yield 71 0] i | benzooxazol-2-yl}- MS:
K N i phenylsutfamoyil- 443.1
HC benzoic acid (M+1) 0, o OH | 2_Chloro-5-[4-(5-phenyl- | 14% yield 0] 72 $ Ory Cl | benzooxazol2-yl} MS:
C N phenylsulfamoyl}- 505.0 benzoic acid (M+1)
0]
OH | 5% yield 0 5-{4-Benzothiazol-2-yi- MS:
S Yo : 73 — ws ci phenyisulfamoyl)-2 445.1
N —/ HX chioro-benzoic acid 0 (M-1) 0) fe) 2.Chloro-5-[4-(5-chloro- | 7% vield fo) Q benzooxazol-2-yi)- MS: 74 - ci x — N ? phenylsulfamoyl]- 463.0 a N © benzoic acid (M-1)
R 58% yield (0) ob yie: 5-(4-Be od yi 0 phenytsulfamoyl)-2- 398.3
HI hydroxy-benzoic acid 0 (M-1)
Q 58% yield a 2 | eteBenayony MS: 76 0 N- 4 0 phenyisutfamoyl)-2- “1 16 un CH, | methoxy-benzoic acid (M-1)
O,
OH| 2-Ethoxy-5-(4"- 88% yield
F : , . 2 |e | ° ATA: 0 tifluoromethoxy MS: ; 3 > biphenyl-4-yisutfamoyl}- | 480.3
H.C | benzoic acid (M-1)
Q 60 % 0 . 3{4-Benzyloxy- yield 78 o {Hn phenylsulfamoyi)- MS: —/ H g benzoic acid 381.6 (M-1)
CL LC BN Lo
I R J 3-4-(4-Trifluoromethyl- | 49% yield + ol ~ benzyisulfanyl)- MS:
F s— N-& phenyisulfamoyl]- 466.3 © benzoic acid {M-1) 0) q 3-[4-(5-Methyl- 12% yield 80 o Q bes benzooxazol-2-yl)- MS: x a N=& phenyisulfiamoyl]- 409.0
HC N © benzoic acid (M+1) < d 3-[4-(6-Methyl- 17% yield 81 H,C s Q Ios benzothiazol-2-yl}- MS:
XI — Si phenylsulfamoyll- 425.1 ! N © benzoic acid (M+1)
OH ho a UTC ail 82 8 H “AJ benzylsulfanyl)- Yield. phenyisulfamoyi}- MS:498.3 =a benzoic acid M+1)
EXAMPLE 83: 2-Methyl-5-[4-{4-trifluoromethvl-benzvisulfanvi}-phenyisulfamovil-benzoic acid methyl ester . o F Hy
F 0]
I 9
F Yr In o
A solution of sodium bicarbonate (667 mg, 7.94 mmol) in 4.5 ml water was added to a solution of 4-(4-trifiuoromethyi-benzylsulfanyl}-phenylamine (750 mg, 2.65 mmol) and 5- chlorosulfonyl-2-methyl-benzoic acid methyl ester (855 mg, 3.44 mmo!) in 14 ml acetone and the resulting mixture was stirred at room temperature ovemight. The reaction mixture was then diluted with 60 ml chloroform and washed sequentially with 1N aqueous hydrochloric acid solution (2 x 50 ml), water (50 ml) and brine (40 mi). The chloroform solution was dried {anhydrous sodium sulfate) and concentrated under reduced pressure to a brownish oil {1.58 g). The crude product was purified by flash column chromatography (silica ge I, 40 g), eluting with 8:2 hexane/ethyl acetate to yield a yellowish oil (1.3 g). Trituration of the ©il in 5 mi of a mixture of 98:2 hexane/diethyl ether and filtration of the resulting solid yielded the title compound as a white solid (1.13 g, 86% yield). MS: 480.2 (M-1)
The title compounds of EXAMPLES 84-153 were prepared using procedures analogous to that of EXAMPLE 83 from appropriate starting materials and are shown in the table that follows.
Ex. | Chemical Structure Chemical Name
CH
I 3
Oy0
CH, 5-{4-(Biphenyi-4- 18% ag yimethyisulfanyl)- yield. 84 NH oO phenyisulfamoylf}- 2- MS:
Or methy-benzoic acid | 502.2 ® S methyl ester (M-1) oJ 4-[2-(4-Chloro- 544-2 8% phenyl)-thiazol-5- . yield. pS yimethylsulfanyl} MS: "NS . 0 henyisulfamoyi}-2-
NH phenyt vi . 545.1 methyl-benzoic acid (M1) \ J methyl ester
Chemical Structure Chemical Name Data i CHy | :
Os 0 i 2-Methyl-5-[4- i CH, 10 % {quinolin-2- )
Os yimethylsulfanyl)- yield. 86 70 nenyisulfamoyl] MS: enylsulfamoyl]-
A Pp oo y 479.2
N benzoic acid methyl
Co Ns NF (M+1) ester i = : o, 2-Methyl-5-{4-(5- lo] yi-5-f4-( 559% phenyl- old teid.
Qe CHy| [1,2,4Joxadiazol-3- Le ~N IN : 87 A 0 methyisuifan
A) vimethylsutanyl-
N phenyisulfamoyl]- (M1) od benzoic acid methyl ester
CH, 0 / 0] 5-{4-(4-Fluoro- 67% 0 CH, benzytsulfanyl)- yield. 88 Sg phenyisulfamoyi}-2- MS:
N © methyl-benzoic acid 446.2
Ls methyl ester (M+1) 1 CH, 0x0 2-Methyi-5-{4- (naphthalen-2 49% naphthalen-2-
CH, P yield. o yimethylisulfanyl)- MS: 89 Ss enylsulfamo ’
To ph y vi 478.2 benzoic acid methyl (M+1) ester
Ex. | Chemical Structure Chemical Name
Zi CH, 1 ; HO
ANS NN O| 2-Methy}-5-[4-(3- 76%
JO 3 o | tifluorormethoxy- yield.
ES] | - . 90 CH, benzyisulfanyl) MS: phenyisuiifamoyl(l- 511.9 eR 6 benzoic acid methyl | (M+1) i hd aster
F
70%
Nor 2-Methyr-s- or yield. 0] {1,141 "fterphenyi-4- "| OOO ET =
H i 3} yisulfam oyl)}-benzoic 458.3 acid methyl ester (M+1)
CH
: CH, 5-[(4-Hydroxy- 60% i Io) biphenyl—4-yl}-propyl- yield. 92 "5 © sulfamoyi}-2-methyl- 0] ? benzoic acid methyl MS: > CH, | ester 440.2
HO (M+1)
Q_ [CH, |5H41H- 41%
Oo Benzoim idazol-2-yl)- | yield. 93 N, N ? cH, phenyisu famoyl]-2- MS:
N H i methyl-benzoic acid 420.0
H methyl ester (M-1)
CH
0] 80%
NS 0 2-Methyl-5-(4*-
S yield. 04 3 propoxy-biphenyl-4- MS:
OC) %. ylsulfamowyl)-benzoic 438.3 acid methyt ester )
HC ~o 4 (M-1)
I'Ex. | Chemical Structure Chemical Name [Data ! : 0 64% o-cl 2-Methyl-5-(2-phenyl-
N yield. ! 0 benzooxazol-6- 95 7 I MS: 0 N-S CH; | yisulfamoyl)-benzoic
H Hh 423.3 0 acid methyl ester (M+1) 0 49%
O-C| 2-Methyl-5-(2-phenyl- | i
N . yield. 0 benzothiazol-6- 96 7 I MS:
S N—S CH; | ylsutfamoyl)-benzoic
HU 439.3 0) acid methyl ester (M+1) 0 0, od 5-(5-tert-Buty- 50 % 0 Q benzooxazol-2-yl}- yield. & ng LL = NE CH, phenylsulfamoyl]-2- MS:
H.C cH, methyl-benzoic acid 479.5 methyl ester (M+1) 83% yield.
Q 5-[4-(3,4-Difluoro- MS: 0 0-C benzyisulfanyl)- 462.2 98 pao ue CH, | phenyisutfamoyi}-2- (M-1)
F HO methyl-benzoic acid : methyl ester
FOF 5-[4-(3,5-Bis- - | Q 4 65% 0 O-Q trifluoromethyi- eid yield. [ ifan ” ar i I Le nyisulfamoyl}-2-
F 0 pre roe aad | 2922
FF methyl-benzoic aci (M-1) methyl ester
Ex. | Chemical Structure Chemical Name cr 2-MethyF5-{4-(2- 74% £ Q oC friflucromethyl- yield. 100 | Q __ benzylsuifanyl)- MS: s— Ns \ / CH, | phenylisulfamoyi]- 494.2 fo benzoic acid methyl | (M-1) ! ester
Q 5-[4-(3,4-Dimethyl- 92% bl © 9 © benzylsulfanyl)- yield. ] 101 LI Ch CH, | phenylsulfamoyf}-2- MS:
HC Ho methy-benzoic acid | 454.3 methyl ester (M-1) 4-(2,4-Bis-
F F o 54 ( 88%
F trifluoromethyi- .
F 0=¢ benzyisulfanyl)- ied, 102 | ¢ ? MS:
E s—~_)N3 CH, | phenylsulfamoyi}-2- 561.8 o methyl-benzoic acid (M-1) methyl ester cl 0) 5-{4-(2-Chloro-4- 93% o O=C fuoro-benzyisulfanyly | yield. 1 - . 103 | F s NS CH, phenyisulfamoyl}-2 MS:
Ho methyl-benzoic acid 477.9 methyl ester (M-1)
Cl 4-(5,6-Difluoro-
NS $g | SHHes 65% i benzothiazol-2- .
N ‘ J O| yimethyisuftanyl) yield . methylsulfanyl)- 104 Ss YY oatamonz. | MS : | phenylsulfamoyl)-2-
F S | 5221 me enzoic ac wb (M+1)
F methyl ester
Ex. | Chemical Structure Chemical Name i Tr > 5-[4~(5-Fluoro-
H 65% a: — A b% benzothiazol-2- . y ! ield. ps { yimethyisuffanyl)- y 105 o MS: phenyisuifamoyl]-2-
C oh 503.0 0 methyl-benzoic acid “oH M1) 3} methyl ester
H,C 0) 5-[4-(3,5-Dimethyl- 93% ° O0~C| benzyloxy)- yield. 106 o—_H- CH, | Phenyisulfamoyl}2- | MS:
H,C H & methyl-benzoicacid | 438.0 methyl ester (M-1) o 5-{4-(4-Butoxy- 61% ~~ 0—-( benzyloxy)- yield. 107 H,C ° 3 Ng cH] phenylsulfamoyl}-2- MS:
H
0 methyl-benzoic acid 482.1 methyl ester (M-1) 93% cl Q 5-{4-(2-Chioro-4- 0-C yield. fluoro-benzyloxy)- 108 | F 9 phenyisulfamoyl]-2- MS: o—_H- CH, UT 14620 fo) methyl-benzoic acid MA) methyl ester
F F 0) 5-[4-(2,3-Diflucro- 67% o O~C| benzyloxy)- yield. 109 o—{_Hp-5 CH phenylsuifamoyi}-2- MS:
H 5 3 methyl-benzoic acid 445.9 methyl ester (M-1)
F 0) 5-[4-(3,5-Difluoro- 91% o 0-C benzyloxy)- yield. 110 o~ Hs CH, | Phenyisulfamoyil-2- | Ms:
F H 3 : methyl-benzoic acid 446.1 methyl ester (M-1)
Chemical Structure Chemical Name [Data ’ i = [e) 5-[4-(3,4-Difluoro- 77% a o O0=C benzyloxy)- yield.
F 1 9. . 11 o— Hp CH, phenylsulfamoyf}-2 MS:
HS methyl-benzoic acid | 446.2 methyl ester {M-1)
Cc
HO 4 5-{4-(5,7-Difluoro-
NO w 59% i benzothiazol-2- o O| vimethvisuit ir yield. methylisulfan 112 Ns gre Ms: phenyisulfamoyl}-2-
F Ss 521.0 methyl-benzoic acid (M+1)
F methyl ester xN 2-isopropyl- 6- methyl-benzothiazol-
He” NF TS ps d 241, yield. 113 © MS:
O | phenyisulfamoyi}- fo) . . 481.1 . benzoic acid methyl
CH, (M+1) ester a 2-Methyl-5-[4-(5- =| [5] = c N “rey 27% > trifluoromethyl-
H yield. s s NP benzothiazol-2- iS
S C : 114 / Imethylsulfanyl o . . - 553.0 enylsulfamoyl]- q Preny=ie (M#1)
Q benzoic acid methyl
CH, ester
N H
— )H Jo q 2-Ethyl-5-[4-6-methyt- | 70%.yi
HC S J benzothiazol-2-yl}- eld. 116 0 phenylsulfamoyl}- MS: 0 benzoic acid methyl 467.1 \
CH; | ester (M+1)
[ Ex. | Chemical Structure Chemical Name [Data
CH, ! i c " 4 23 Dimethyl 51446
NJ «4 methyl-benzothiazolk i ) 116 Nao o ? MS: c phenyisuifamoyl}- ; 467.1
Ss benzoic acid methyl (M+1) ester
H,C
CH, of i HO 2,3-Dimethyl-5-[4-(3- 60%
NJ 4 trifluoromethyi- . t benzylsulfanyl)- viel, 117 s 0 ? henylsulfamoyT] MS: enylsuifamoyi}-
Cc P . 510.1 benzoic acid methyl (M+1)
F ester
F F
C _d 5i4-(4-Ethy- 60%
HiC 4 ) o benzylsulfanyt)- yield. 118 s— ni CH,| phenylisulfamoyi}-2,3- | MS: 0 ch, | dimethyi-benzolc acid | 470.1 methyl ester (M+1)
Q
O-q 0 5-{2-(4-tert-Butyl- 77% 4 CH; | phenyl)-benzooxazot | yield. 119 <\ 0 5-yisutfamoyi}-2- MS:
H.C methyl-benzoic acid 479.1
H,C CH, methyl ester {M+1)
Ex. | [Chemical Structure | Structure | Chemical Name | Name Data "H,C 0 5-[4-(3,5-Dimethy- | 97% 7 \ 0G benzylisulfanyl)- yield. ! , 0 120 | — S nibas CH, | Phenylsulfamoyl}-2- Ms:
HC =/ HJ methykbenzoic acid | 454.2. methyl ester (MS-1) od 5-[4-(4-Butoxy- 78% o ]
HG A 0 benzyisulfanyl) yield. 121 & 5 Hus of Phenylsulfamoyl}-2- | MS:
Ho methyl-benzoic acid 498.2 methyl ester (M-1)
F F Q 5-[4~(2,3-Difluoro- 79% a ° O~C| penzylsulfanyly vie
I - co 122 s— Hn CH, | Prenvisultamoyt-2- | MS:
H o methyl-benzoic acid | 463.8 methyl ester (M+1)
F Q 5-[4-(3,5-Difiuoro- 81% o 0-C benzyisulfanyl}- yield.
Ii 2- . 123 s— Hn CH, | Phenvisuliamoyt-2- | MS:
F H 5 methyk-benzoic acid | 462.2 . methyl ester (M-1) 2-Methyl-5-[4-(4- i ° yk-5-{4+( 98% trifluoromethyisulfanyl-
E o-¢ yield. 124 sO, 4 ) 2 cH benzyisulfanyl)- MS:
F - 3| phenyisulfamoyf]- i
N 6 Phenyisulfamoyl 528.3 benzoic acid methyl (M+1) ester
01-
Chemical Structure Chemical Name
CH, i i C
HQ 4 2,3-Dimethyt-5-(4-(3-
NOL A ' ye 48% i triflucromethoxy- oO % benzylsulfanyl)} yield. 125 S CH phenylsufamoy] MS: enyisulfamoyl}- pheny y 526.0 benzoic acid methyl eh 6 (M+1)
Y ester
F
& i | C 0 . 74% y 0 2,3-Dimethyl-5-(4- . ~s = yield. 1 trifluoromethoxy- 126 © ? MS: biphenyl-4-
C | 4800 yisutfamoyl)-benzoic
F : (M+1)
F +O acid methyl ester
F o 5-[2-(4-tert-Butyl- 67%
Hy o o 0—4 phenyl}-benzooxazol- | yield. 127 od — TL 5-ylsulfamoyl]-2-ethyl- | MS:
CH, H lo] CH benzoic acid methyl 493.4 ester (M+1) 2-Ethyl-5-[4-(4-
S ES so, triflucromethoxy-
R 0-C yield.
Fo I 0 benzyisulfanyl)- } 128 F s—_ is phenyisulfamoyl}- MS: lo} c } 5242 benzoic acid methyl (M-1) ester
Chemical Structure Chemical Name [Data a. 0 I 2-Ethyl-5-2-(4- 20%
FX 0 ° 0=Q trifluoromethoxy- | yield. 129 o~{ = N=8 phenyl>-benzooxazol- | MS:
Ha CH 5-yisulfamoyi]-benzoic | 521.3 acid methyl ester (M+1) 1] o 2] 2-Ethy-5-(4'- 21%
IN | triflucromethoxy- yleld. 130 g J o | biphenyl-4- MS:48
F & yisulfamoyl)-benzoic | 0.0
A acid methyl ester (M+1)
Fo
F : ! 2-|sopropyl-5-{4-(4- o {2 propyl-5-{4-( 62% 7 trifluoromethoxy- .
R 0 yield. ar | F Fo, i CH benzylsutfanyt)- vs:
F 4 ) = henyisutfamoyl]-
NE cH Phenyisutamoy 538.2 benzoic acid methyl (M-1) ester qd 2-Methyl-5-{2-(4- 63%
FF R oi
FX o q trifluoromethoxy- yield. 132 (0) N NS CH.| Phenyl)-benzooxazol | MS: 3
N his 5-yisulfamoyl}-benzoic | 507.2 acid methyl ester {M+1) fo) Je 2-Ethyl-5-[4-(quinolin- | 35% = o O | 2-yimethyisulfanyl)- yield. 133 QQ yw phenylsulfamoyi}- MS:
N H 4 CH benzoic acid methyl | 493.3 ester (M+1) 2-Isopropyl-5-[4- ° - propyt-5-{. 55% d (quinofin-2- od
SN us ot 507.1 © benzoic acid methyl (M+1) ester
Chemical Structure Chemical Name Data od 2-Ethyi5[2-4- 52%
I F [NP o O | trifluoromethyl yield. 135 HOOT, pheryl)-benzooxazol- | MS:
F HS cH 5-yisulfamoylj-benzoic | 505.3 acid methyl ester (M+1)
QJ 2Methyl-52-(4- 93% = 0 ° O | trifluoromethyi- yield. 136 promt 4 gh = CH phenyl)-benzooxazol- | MS:
F N N 0 | 5-ylsulfamoyi}-benzoic | 489.2 acid methyl ester (M-1)
C 1
HO C 5-(4- 79%
NL A Cyclohexyimethylsulfa | yield. 137 3 fe) nyl-phenyisulfamoyl)- | MS:
S L | 2-methyk-benzoic acid | 434.0 methyl ester (M+1)
Cc
HO g 5-(4- 81%
NJ A Cyclobutyimethyisulfa | yield. 138 4 d nyl-phenyisulfamoyl} | MS: [7s { | 2-methyi-benzoic acid | 406.1
C methyl ester (M+1) 0 0 2-Isopropyl-5-[4-(5- 31% 0) methyl-benzooxazol- old yield. 6) ? CH 2-yi)- 139 Pp N—§ henyisulfamoyl] MS: enylsulfamoyl]- he N Ho cH Pens 465.4 3 benzoic acid methyl (M+1) ester 2-Isopropyi-5-{4~(3- fe} _d propyl-5-f4-( 46% 0] trifluoromethoxy- — [eo] CH yield. £ 1 benzylsulfanyl)- 140 S \_7 NR henylisulfamoyf] MS:
Fo © CH P 538.3
F benzoic acid methyl {M-1) : ester
Ex. | Chemical Structure [Chemical Name Date _ | Name [Data fo) i 2-Ethgh-5-4-(3- i 42% i 0-(d trifluoromethoxy- . ? benzylsulfanyl}- yield. 141 F sn zyisultany MS:
F—0 H 4 CH phenytsulfamoyl}- 524.3
F benzoic acid methyl (M-1) ester 0) 46% _A 2-Ethyl-5-(4"-propoxy- . om biphenyi-4- yield iphen ue | moo Hd | sutamog enzo: |S sulfamo nzoic 8 cry Visulfamoyly 452.4 acid methyl ester (M-1) 0 qd , 61% / | 2-isopropyl-5-(4'- .
Oo yield. 143 | n 0 cH propoxy-biphenyl-4- MS: od SH Nuk yisulfamoyl)-benzoic ) = 8 cl 466.4 acid methyl ester (M-1)
Q Va 0] 0 cH 5-2-(4-tert-Butyl- 72% oy phenyl)-benzooxazol- | yield. 144 = o CH 5.yisulfamoyi}-2- MS:
H,C isopropyl-benzoic acid | 505.3 methyl ester (M-1)
HC op, 2-Methyl-5-[2-(5- lo) od yi-5-[2+( 08% q methyl-2-phenyl- old yield. — oxazol-4-yimethyl 145 0 CHa N fi CH, yimethyl)- MS:
A J o benzofuran-5-
N 517.4 lo) yisutfamoyl]-benzoic (M+1) acid methyl ester
Nod ZEthyk5-2-(5-methyl- | 52%
Hq 2-phenyl-oxazol-4- yield. 146 (HE CHy “i | Yimethy)-benzofuran- | MS: “ / 5-yisulfamoyl]-benzoic | 531. 0] acid methyl ester (M+1)
-05-
Ex. | Chemical Structure Chemical Name [Data i a A 2-lsopropyl-5-[2-(4- | 65% i O O | trifluoromethoxy- yield.
Fo § 0 Cc 147 | ; N No phenyl)}-benzooxazol- | MS:
H 0 C| 5-yisulfamoyl]-benzoic | 535.3 i i acid methyl ester (M+1)
CH 79%
CH | ° | 5{4-Bromo- or
P henylsultamoy)2- | oO en -2- 148 0 P y MS:
I methyl-benzoic acid er H—S 531.4 [ I methyl ester © (M-1) 2-Ethyi-5-[4-(2- 0} - yi-5-{4~( 37% trifiuoromethoxy- . ? oO be i yield. 149 5 s—_ it CH. Denzyisuifanyl)- MS
F H henylsulfamoyl]- x © o y y 526.3 nzoic acid me
Fr (M+1) ester
O 5-[4-(5-Cyclohexyl- 95% -N o O-Q [1,3 4joxadiazol-2-yl)- | yield. 150 (HL \ 4 ) n_] CH, | Phenyisuftamoyfl-2- | MS: o H § methyl-benzoic acid | 456.1 methyl ester (M+1) 2-Methyl-5-{4-(4- o yi-5-[4-( 36% trifluoromethoxy-
R (St yield.
Fo 0 benzyloxy)- 151 | J od Hn CH] phenylsulfamoy] MS: enylsulfamoyi]-
Ho pheny! 494.9 benzoic acid methyl . (M-1) ester
EXAMPLE 152: 2,3-Dimethv}-5-[4-(4-trifluoromethoxy-benzyisulfanyi}-phenylsulfamoyl]- benzoic acid methyi ester 0)
R O—CH, oO 9
F sit CH,
O
CH,
41% yield. 'H NMR (400 MHz, CD4Cl): 82.31 (s, 3H), 2.48 (s, 3H), 3.88 (s, 3H), 4.01 (s, 2H), 6.95 (d, 2H), 7.08 (d, 2H), 7.16 (d, 2H), 7.21 (d, 2H), 7.61 (s, 1H), 8.04 (s, 1H).
EXAMPLE 153: 5-[4-(1H-Benzoimidazol-2-yl)-phenvisulfamoylil-2-isopropyl-benzoic acid
E methyl ester fo) ,CHs
H 0] / N—S
N H o . CH, 41% yield. "MH NMR (400 MHz, CD;Cl): $1.16 (d, 6H), 3.67 (m, 1H), 3.83 (s, 3H), 7.11 (d, 2H), 7.23 (c, 2H), 7.42 {(d, 1H), 7.61 (c, 2H), 7.85 (c, 3H), 8.23 (d, 1H).
EXAMPLE 154: 5-(4'-Butyl-biphenyl-4-visulfamoyl)-2-methyi-benzoic acid methyl ester
CH, 03 Is
S
Nn © ? ~~ ,
H,C
A mixture of 4-butylbenzeneboronic acid (174 mg, 0.975 mmol), 5-(4-bromo- phenylsulfamoyl)-2-methyl-benzoic acid methy! ester (150 mg, 0.39 mmol), dichloro(1,1'- bis(diphenylphosphino)ferrocene]palladium(lt) dichloromethane adduct (16 mg, 0.019 mmol), 1,1-bis(diphenylphosphino)ferrocene (11 mg, 0.019 mmol) and potassium carbonate (0.38 mi of a 2M aqueous solution, 0.78 mmol) in 15 mi 1,4-dioxane was heated at reflux under nitrogen for 20 hr. The reaction mixture was cooled to room temperature, diluted with 80 mi water and extracted with 2 X 70 ml ethyl acetate. The combined ethyl acetate extracts were washed with 60 mi brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography {silica gel, 15 g), eluting with 6:1 hexane/ethyl acetate to yield the titte compound as a white solid (109 mg, 64% yield). : MS: 422.1 (M-1)
The title compounds of EXAMPLES 155-173 were prepared using procedures analogous to that of EXAMPLE 154 from appropriate starting materials and the results are presented below.
Chemical Structure Chemica! Name
Chemical Structure Chemical Name [Data : CH, 2-Methyi-5-(4- 50%
HO
NY O | naphthalen-1-yl- yield. 1565 OC) $ ll phenyisulfamoyi)- MS:
O ? benzoic acid methyl | 416.0
CH, ester (M-1) i CH, !
HQ 0 | 543.5"Bis-
F ~s . 80%
F Il trifluoromethyl- . 0 0 . yield. biphenyl-4- 156 | F MS:
CH, | yisulfamoyl)-2- 501.9 methyl-benzoic acid (M-1)
F methyl ester
F F i CH 3 : o
NH N P O | 5-(4'-tert-Butyi- 14% i biphenyl-4- yield. (®] 0) . 157 ] yisulfamoyl)-2- MS:
HC CH3 | methyl-benzoic acid | 422.0
HaC methyl ester (M-1)
CHj;
CH,
HO 2-Methyl-5-(4- 43%
N. 0 .
S naphthalen-2-yi- yield. 158 4 0 phenylsulfamoyl)- MS:
Ly benzoic acid methyl | 416.0 3 ester (M-1)
Chemical Structure Chemical Name
CH,
HO 2-Methyl-5-(4'-
NJ o | ZMety-5{ 78% ) $ = trifluoromethy)- old yield. biphenyl-4- 159 © ? preny MS:
F CH, ylsulfamoyl)- 434.0
F benzoic acid methyl - ester (M1)
F
J i
CH, y Q o 5-(4'-Ethylsulfanyi- 85% 8 biphenyl-4- yield. 160 0] Q yisuifamoyl)-2- MS:
CJ CH, | methyl-benzoic acid | 426.0
He” 8 methyl ester (M-1)
CH, 2-Methyl-5-(3'
HQ Methyh5-(3- 63%
NL SS trifluoromethyi- i
C1 8 omnia yield. iphen 161 © ? . Famoyly MS: amo
CH, ysffamoy! 434.0 benzoic acid methyl
F ester M1)
F F
CHy
HO 5-(4- 70% ig Io Benzojb]thiophen- old 1 2- I yie . 162 x (0) ? y ysufarmoyl-2 MS: enylsulfamoyl)-2-
CH, |© 422.0
CY S 3 | methyl-benzoic acid M1) methyl ester
Ex. | Chemical Structu Chemical Name g
NS 0 | 543 5-Dienloro- 3 biphenyl-4- old jeld. 1163 | Cl 0 0 ylsulfamoyl)-2- y
Ms:436
CH, methyl-benzoic acid (M-1) methyl ester
Cl
CH,
NS x 3 ys Nl O | 5-(4'-Benzyloxy- 17% ~ 3 5 biphenyl-4- yield. 164 in yisulfamoyl)}-2- MS: o * | methyi-benzoic acid | 472.3 methyl ester {M-1)
CH,
HO 5-(2',4'-Dichloro- 95%
NN. 0 ; ;
Ng biphenyl-4- yield. 165 4 N yisulfamoyt)-2- MS:
Na | methyl-benzoic acid | 435.9 _ CH, methyl ester {M-1)
Cl Cl
CH,
HO : 2-Methyl-5-(2- : NL (0) yo 73%
S methylsulfanyl- .
I iohenvl yield. 166 0 0 biphenyl-4- MS: ylsulfamoyl)-
CH 412.3 ® 3 benzoic acid methyl § ester (M1)
CH,
Chemical Structure Chemical Name [Data ! 2-Methyl-5-(4"
RQ SY Pi > 76% ~g trifluoromethoxy- . ¥ yield. 167 bo) 0 biphenyi-4- MS:
F I isulfamoyl i @® CH, | Yisuifamoyl- 450.2
F o benzoic acid methyl M1)
F ester
CH,
H Q 0 2-Methyl-5-(2'- 95%
Ns triftuoromethyl- i ) yield. i 168 oO 0 biphenyl-4- MS:
Ch yisulfamoyl)- 43a 3
F 3 benzoic acid methyl M ;
E ester (M-1)
F
HO CH th 2-Ethyl-5-(4'-
NW 0 ] 5 81%
W trifluoromethyl- yield 169 0 Q biphenyl-4- MS: . F @® CH, yisuifamoyl) 148 3 benzoic acid methyl ™ "
F ester
CH, 72% y A LI 5-4"-Butyl-bipheny}- gield 70 Cd i 4yisufamoy2-
C 2, ethyl-benzoic acid 436 a
H,C s methyl ester ) (M-1)
[Ex] Chemical Structure Chemical Name ! ‘CHa ! 0 i NHI 0 5-(4"-tert-Butyl- 72%
CO] .} 5 biphenyi-4- yield. 171 | yisulfamoyi)}-2- MS:
H4C CHs n j ethyl-benzoic acid 438.2
HC methyl ester (M+1) t CHa
CH,
Ho CH, 2 sopropyhot © | 39%.yiel
NA o uoromethoxy- a
S biphenyl-4- 172 I MS:
E Oo Q yisulfamoyi)- . } 492.0
CH, benzoic acid methyi (M-1)
F E 0 ester 0, oon, 2-Methyi-5- 58% 0) ([1,144',1"terpheny! | yield. 173 Q oH -4-yisulfamoyl)- MS:
N i 3 | benzoic acid methyl | 458.3 ester (M+1)
EXAMPLE 174. 2-Methyi-5-[4-(4-trifluoromethyl-benzylsulfanyi}-phenvisulfamoyll-benzoic acid
Q
EF OH f ae aNa St Yo 0]
A’ solution of 1.0N aqueous sodium hydroxide (9.1 mi, 9.16 mmol) was added to a solution of 2-methyl-5-[4~(4-triflucromethyl-benzylsulfanyl}-phenylsulfamoyl}-benzoic acid methyi ester (1.13 g, 2.29 mmol) in 100 mI methanol and the resulting solution was heated at reflux overnight under nitrogen. The reaction solution was then cooled to room temperature and concentrated under reduced pressure. The residue was stirred in 1.0N aqueous hydrochloric acid solution (25 ml) and filtered to yield the title compound as a white solid (1.03 g, 94%
yield). MS:480.2 (M-1); TH NMR (400 MHz, CD,0D): $2.49 (s, 3H), 4.04 (s, 2H), 6.96 (d, 2H), 7.4 (d, 2H), 7.29 (m, 2H), 7.33 (, 1H), 7.47 (m, 3H), 7.94 (b, 1H).
The title compounds of EXAMPLES 175-258 were prepared using procedures analogous to that of EXAMPLE 174 from appropriate starting materials.
EXAMPLE 175: 5-]4-(Biphenyl-4-vimethyisulfanyl}-phenylsulfamoyl}-2-methyl-benzoic acid
OOH
CH
0. = 3 $50
NO oC 30% yield. MS: 488.2 (M-1); H NMR (400 MHz, CD,OD): 52.48 (s, 3H), 4.15 (s, 2H), 6.99 (d, 2H), 7.22 (m, 2H), 7.32 (m, 3H), 7.43 (m, 3H), 7.52 (m, 2H), 7.61 (m, 2H), 7.70 (m, 1H), 8.18 (d, tH).
EXAMPLE 176; 5-{4-[2-(4-Chioro-phenyi)-thiazol-5-yimethyisulfanvl]-phenylsullamoyl}-2- methyl-benzoic acid
O§-OH
CH
. Or :
Tso ° Oe Lr 1 Js
N
99% yield. MS: 529.0 (M-1); 'H NMR (400 MHz, CD;0D): 52.60 (s, 3H), 4.15 (s, 2H), 6.99 (m, 2H), 7.19 (m, 2H), 7.3-7.5 (c, 5H), 7.87 (d, 2H), 8.27 (d, 1H).
EXAMPLE 177: 2-Methvi-5-[4-{quinolin-2-yimethylsulfanyl)-phenyisulfamoyll-benzoic acid
Oo OH
CH,
ON
70
NH one ~ S co 56% yield. MS: 465.2 (M+1); 'H NMR (400 MHz, CD,0D): $2.59 (s, 3H), 4.29 (s, 2H), 6.95 (d, 2H), 7.18 (d, 2H), 7.29 (d, 1H), 7.41 (d, 1H), 7.56(m, 1H), 7.64 (d, 1H), 7.73 (m, 1H), 7.88 (c, 2H), 8.19 (d, 1H), 8.26 (s, 1H).
EXAMPLE 178; 2-Methvi-5-[4-(§-phenyl-[1.2 4Joxadiaz ol-3-yimethyisulfanvi}-phenylsulfamovyl}- benzoic acid 0)
OH oO Lc ~N J “o
N
AO
85% yield. MS: 481.0 (M-1); 'H NMR (400 MHz, DMSO-D): 82.51 (s, 3H), 4.28 (s, 2H), 7.02 (d, 2H), 7.31 (d, 2H), 7.43 (d, 1H), 7.61 (m, 2H), 7.70 (m, 2H), 8.04 (m, 2H), 8.19 (s, 1H).
EXAMPLE 179: 5-[4-(4-Fluoro-benzylsulfany!}-phenylsuifamoyil-2-methyi-benzoic acid
O
OH
0. CH,
SS
Ne)
Ba: . s 85% yield. MS: 430.0 (M-1); 'H NMR (400 MHz, DMSO-Dg): $2.53 (s, 3H), 4.08(s, 2H), 7.01 (m, 4H), 7.17 (m, 2H), 7.23 (m, 2H), 7.46 (d, 1H), 7.71 (m, 1H), 8.17 (d, 1H).
EXAMPLE 180: 2-Methvi-5-[4-(naphthalen-2-yimethvisulfanyl )-phenyisutfamoyf]-benzoic acid
(e] OH
CH,
Os $=0 job
Ce 82% yield. MS: 462.0 (M-1); 'H NMR (400 MHz, DMSO-Dg): 52.49 (s, 3H), 4.27 (s, 2H), 6.97 (d, 2H), 7.21 (m, 2H), 7.39 (m, 2H), 7.46 (m, 2H), 7.68 (m, 1H), 7.72-7.87 (m, 4H), 8.18 (d, 1H).
EXAMPLE 181: 2-Methyl-5-]4-(3-triflucromethoxy-benzyisulfanyl}-phenylsulfamoyi}-benzoic acid
CH, ]
O OH
P30
F
74% yield. MS: 496.3 (M-1}; 'H NMR (400 MHz, DMSO-Dg): $2.49 (s, 3H), 4.15 (s, 2H), 6.97 (m, 2H), 7.19 (c, 5H), 7.33 (m, 1H), 7.44 (d, 1H), 7.71 (m, 1H), 8.17 (d, 1H).
EXAMPLE 182: 2-Methyl-5-(4-naphthalen-1-vi-phenyisulfamoyl}-benzoic acid
CH,
HQ
1g ) 0) OH 69% yield. MS: 416.0 (M-1); 'H NMR (400 MHz, DMSO-Dg): $2.49 (s, 3H), 7.22 (d, 2H), 7.34 (m, 3H), 7.48 (m, 4H), 7.67 (d, 1H), 7.91 (m, 3H), 8.23 (d, 1H).
EXAMPLE 183: 5-(3'5"-Bis-trifluoromethvi-biphenvi-4-yisulfamowi}-2-methvl-benzoic acid
CH,
H io
F 1 0 OH ay
F
F F
81% vieild. MS: 501.9 (M-1); 'H NMR (400 MHz, CD;0DY): 2.59 (s, 3H), 7.27 {m, 2H), 7.40 (d, 1H), 7.59 (m, 2H), 7.80 (d, 1H), 7.82 (d, 1H), 8.08 (s, 2H), 8.35 (d, 1H).
EXAMPLE 184: 2-Methyl-5-(4-naphthalen-2-yl-phenyisulfamoyl}-benzoic acid
CH,
BH
NL 0 g 65% yield. MS: 416.0 (M-1); 'H NMR (400 MHz, DMSO-Dg): $2.53 (s, 3H), 7.21 (d, 2H), 7.49 {m, 3H), 7.70 (d, 2H), 7.75 (m, 1H), 7.81 (m, 1H), 7.92 (m, 2H), 8.11 (s, 1H), 8.24 (d, 1H).
EXAMPLE 185: 2-Methyl-5-(4"-trifluoromethyl-biphenyl-4-ylsuifamovyl}-benzolc acid
CH,
HO
NW Oo i [ 0) OH
F
3
F
81% yield. MS: 434.0 (M-1); 'H NMR (400 MHz, DMSO-Dg): 52.53 (s, 3H), 7.20 (m, 2H), 7.49 (d. 1H), 7.63 (d, 2H), 7.72-7.84 (m, 5H), 8.24 (d, 1H).
EXAMPLE 186: 5-(4-Ethyisulfanyl-biphenyl-4-yisulfamowi)-2-methyl-benzoic acid
CH,
HQ
NO Oo f 0] OH
HC” Ss . 79% yield. MS: 426.0 (M-1); 'H NMR (400 MHz, DMSO-Dg): 51.22 {t, 3H), 2.53 (s,3H), 2.98 (q, 2H), 7.15 (d, 2H), 7.32 (d, 2H), 7.51 (m, 5H), 7.79 (m, 1H), 8.22 (d, 1H). 5 EXAMPLE 187: 5-[4-(1H-Benzoimidazol-2-yl)-phenyisulfamoyil-2-methvi-benzoic acid 0)
OH
Nl pa i CH = 3
N H i
H
94% yield. MS: 408.2 (M+1); 'H NMR (400 MHz, CD;0D): 52.60 (s, 3H), 7.46 (m, 3H), 7.59 (m, 2H), 7.76 (m, 2H), 7.92 (m,1 H), 8.00 (m, 2H), 8.40 (d, 1H).
EXAMPLE 188: 2-Methyl-5-(3'-trifluoromethyl-biphenvl-4-visulfamoyl}-benzoic acid
CH,
H ig Lc ]
Oy
F
. F F 43% yield. MS: 434.0 (M-1); 'H NMR (400 MHz, DMSO-Dg): $2.53 (s, 3H), 7.19 (d, 2H), 7.48 {d, 1H), 7.64 (c, 4H), 7.81 (m, 1H), 7.88 (c, 2H), 8.23 (d, 1H).
EXAMPLE 189: 5-(4-Benzo[blthiophen-2-vi-phenylisulfamoyl}-2-methvi-benzoic acid
CH,
HO
- O i 4 0 OH ~~
Oa 80% yield. MS: 422.0 (M-1); 'H NMR (400 MHz, DMSO-D): 52.53 (s, 3H), 7.18 (d, 2H), 7.33 (m, 2H), 7.48 (d, 1H), 7.65 (m, 2H), 7.73 (5, 1H), 7.80 (m, 2H), 7.92 (m, 1H), 8.23 (d, 1H).
EXAMPLE 190: 5-(4'-Benzyloxy-biphenyl-4-yisulfamowi)}-2-methyi-benzoic acid
CH,
NR 0 a CT
Oh 74% yield. MS: 472.3 (M-1); H NMR (400 MHz, DMSO-D): 52.52 (s, 3H), 5.11 (s, 2H), 7.03 (m, 2H), 7.12 (d, 2H), 7.28-7.52 (c, 10 H), 7.78 (m, 1H), 8.21 (d, 1H).
EXAMPLE 181: 2-Methyl-5-(4"-propoxy-biphenyl-4-yisulfamoyl }-benzolc acid
CH,
V3 0 i lo} OH
HC o ® 61% yield. 'H NMR (400 MHz, DMSO-Dg): 50.95 (t, 3H), 1.7 (m, 2H), 2.52 (s, 3H), 3.91 {t, 2H), 6.93 (d, 2H), 7.11 (d, 2H), 7.47 (d, 5H), 7.77 (d, 1H), 8.31 (s, 1H).
EXAMPLE 192: 2-Methyl-5-(2'-methyisulfanyl-biphenyi-4-yisulfamoyl)-benzoic acid
CH,
CO
NO Oo
Zz ~~! i OH
N°
ZZ
§
CH, 87% yield. MS: 412.3 (M-1); TH NMR (400 MHz, DMSO-Dg): 52.48 (s 3H), 2.54 {s, 3H), 7.06- . 7.17 (c, 4H), 7.17-7.34 (c, 4H), 7.49 (d, 1H), 7.81 (m, 1H), 8.22 (d, 1H). 5 EXAMPLE 193: 2-Methwvi-5-(4"-trifluoromethoxy-biphenyl-4-yis wilfamoyl}-benzoic acid
CH,
HO
NG (@]
SB hl
LD eA
F
69% yield. MS: 450.2 (M-1); HNMR (400 MHz, DMSO-Dg): 62.48 (s, 3H), 7.17 (d, 2H), 7.38 (d, 2H), 7.48 (d, 1H), 7.56 (d, 2H), 7.68 (d, 2H), 7.80 (m, 1H), 8.22 (d, 1H).
EXAMPLE 194: 2-Methvi-5-(2'-triflucromethyl-biphenyl-4-yvisuifamowi}-benzoic acid
CH,
HO
1g CLs 0) OH (1
FF
64% yield. MS: 434.3 (M-1); "H NMR (400 MHz, DMSO-D): 8300 (s, 3H), 7.11 (d, 2H), 7.17 (d, 2H), 7.30 (d, 1H), 7.48 (d, 1H), 7.55 (m, 1H), 7.65 (m, 1H), 77.78 (m, 2H), 8.20 (d, 1H), 7.78 (d, 2H).
EXAMPLE 195: 2-Ethvi-5-(4"-triflucromethyl-biphenyl-4-visulfamoyi)-benzoic acid
7 C
Ho SC i a ~~ ~~ rT x @] OH
F
F
£ } 90% yield. MS: 448.3 (M-1}; 'H NMR (400 MHz, CD;0D): 1.19 (t, 3H), 3.01 (q, 2H), 7.23 (d, 2H), 7.43 (d, 1H), 7.56 (d, 2H), 7.68 (d, 2H), 7.73 (d, 2H), 7.82 (m, 1H), 8.28 (d, 1H).
EXAMPLE 196: 2-Methy+-5-(2-phenyi-benzooxazol-6-yisulfamovi}-benzoic acid 0
N OH
OID Coe 0 N i 3 85% yield. MS: 409.3 (M+1); 'H NMR (400 MHz, CD;OD): $2.58 (s, 3H), 7.07 (m, 1H), 7.38 (d, 1H), 7.5-7.6 (c, 5H), 7.75 (m, 1H), 8.18 {m, 2H), 8.29 (d, 1H).
EXAMPLE 197; 2-Methvi-5-(2-phenyi-benzothiazol-6-visulfamow)-benzoic acid 0)
N OH
Oy 3 Cron s NTN\_/ oO 93% yield. MS: 425.3 (M+1); 'H NMR (400 MHz, CD,OD): 52.58 (s, 3H), 7.23 (m, 1H), 7.38 (d, 1H), 7.51 (c, 3H), 7.76 (c, 2H), 7.85 (d, 1H), 8.04 (c, 2H), 8.30 (d, 1H).
EXAMPLE 198; 5-[4-(5-tert-Buty|-benzooxazol-2-vi}-phenvisulfamowil-2-methyl-benzoic acid
O
OH
© 0 CH
HC 7 N i 3
HC on, 62 % yiekl. MS: 465.4 (M+1); 'H NMR (400 MHz, CD,0D): 51.38 (s, 9H), 2.59 (s, 3H), 7.31 (m, 2H), 7.42 (d, 1H), 7.46 (d, 1H), 7.49 d, 1H), 7.53 (d, 1H), 7.69 (d, 1H), 7.85 (m, 1H).
EXAMPLE 199: 5-[4-(3 4-Difiuoro-benzyisulfanyl}-phen sulfamoyl]-2—-methyi-benzoic acid 0)
OH
F 9 : F 77% yield. MS: 448.2 (M-1), 'H NMR (400 MHz, CD;0D): 82.61 (s, 3H), 3.98 (s, 2H), 6.89 (c, 1H), 6.97-7.12 (c, 3H), 7.18 (m, 2H), 7.38 (d, 1H),7.69 (m, 1H), 8.27 (d, 1H).
EXAMPLE 200: 5-[4-(3,5-Bis-triflucrome b lsulfan henylsulfamoylf]-2-methyi- benzoic acid
F F 0
F OH
Q os avar
F @]
F F
80% yield. MS: 548.2 (M-1); *H NMR (400 MHz, CD,0D): 52.61 (s, 3H), 7.02 (m, 2H), 7.16 (m, 2H), 7.37 (d, 1H), 7.71 (m, 2H), 8.30 (d, 1H).
EXAMPLE 201: 2-Methw-5-{4-(2-triflucromethyi-benzvisulfanyl}-phenyisulfamowl |-benzoic 16 acid
F F
F oO
OH
?
Oe
Ho 86 % yield. MS: 480.2 (M-1); TH NMR (400 MHz, CD,OD): 82.62 (s, 3H), 4.15 (s, 2H), 7.02 (m,2H), 7.14-7.25 (c, 3H), 7.34-7.42 (c, 3H), 7.61 (m, 1H), 7.73 (m, 1H), 8.29 (d, 1H).
EXAMPLE 202: 5-[4-(3.4-Dimethvi-benzylsulfanyl }-phenyvisulfamoyfl-2-methyl-benzoic acid
0
OH
9
H.C 0]
H,C 85% yield. MS: 439.9 (M-1); "H NMR (400 MHz, CD;0D): 52.15 (s, 3H), 2.19 (3, 3H), 2.61 (s, 3H), 3.94 (s, 2H), 6.83(d, 1H), 6.95 (c, 2H), 6.98 (m, 2H), 7.14 (m, 2H}, 7.38 (d, 1H), 7.70 (m, 1H), 8.28 (d, 1H).
EXAMPLE 203; 5-[4-(2.4-Bis-trifluoromethyi-benzyisulfanyl)-phenylsutfamoyll-2-methyl— benzoic acid
F i 0
OH
F, 0
F § CH
Hd 80% yield. MS: 548.1 (M-1); "H NMR (400 MHz, CD,0OD): §2.61 (s, 3H), 4.21 (s, 2H), 7.04 (m, 2H), 7.19 (m, 2H), 7.39 (m, 2H), 7.67 (d, 1H), 7.74 (m, 1H), 7.87 (s, 1H), 8.28 (d, 1H).
EXAMPLE 204: 5-f4-(2-Chioro-4-fluoro-benzylsulfanyl)-phenyisulfamoyll-2-methyi-ben=zoic acid 0)
Cl OH . Q
Ho 84% yield. MS: 464.0 (M-1)
EXAMPLE 205: 5-[4-{5.6-Difluoro-benzothiazol-2-vimethyisulfanvi)-phenvisulfamoyil-2— methyl-benzoic acid } CH, jog a4 0] OH
No s 9
F
49% yield. MS: 507.0 (M-1); 'H NMR (400 MHz, CDsOD): 82.58 (s, 3H), 4.4-6 (s, 2H), 7.01 (d, 2H), 7.29 (m, 3H), 7.70 (m, 2H), 7.85 (m, 1H), 8.26 (d, 1H).
EXAMPLE 206: 5-[4-{5-Flugro-benzothiazol-2-yimethylsulfan henyisulfa smovil-2-methyl- benzoic acid
F N
Th
Ss )Hp
S$ cH, 0] 0
HO
80% yield. MS: 489.1 (M+1); 'H NMR (400 MHz, CD;0D): 52.58 (s, 3H), 44-7 (s, 2H), 7.02 (m, 2H), 7.21 (m, 1H), 7.28 (c, 3H), 7.55 (m, 1H), 7.65 (m, 1H), 7.89 (m, 1H), 8.27 (d, 1H).
EXAMPLE 207: 5-[4-(3.5-Dimethyl-benzvioxy)-phenyisulfamoyil-2-methyl-be nzoic acid
H,C Q
OH
0 .
Ome ron
H,C Oo 87% yield. MS: 424.2 (M-1); 'H NMR (400 MHz, CD;0OD): 52.28 (s, 6H), 2.6 O (s, 3H), 4.90 (s, 2H), 6.83 (m, 2H), 6.95 (c, 5H), 7.35 (d, 1H), 7.62 (m, 1H), 8.22 (d, 1H).
EXAMPLE 208: 5-[4-(4-Butoxy-benzyloxy}-phenyisulfamovyil-2-methyi-benzoi€ acid 0
OH oy 8
Ores lo) 88% yield. MS: 468.1 (M-1); 'H NMR (400 MHz, CD;0OD): 50.98 (s, 3H), 1.50 (m, 2H), 1.73 (m, 2H), 2.60 (s, 3H), 3.96 (t, 2H), 4.90 (s, 2H), 6.83 (d, 2H), 6.88 (d, 2H), 6.95 (d, 2H), 7.28 (d, 2H), 7.35 (d, 1H), 7.62 (m, 1H), 8.21 (d, 1H).
EXAMPLE 209: 5-[4-(2-Chloro-4-fluoro-benzyloxy}-phenyisulfamoyll-2-methyl-benzoic acid
Cl O
OH
F 9 0 Hn CH,
H 0
84% yield; MS: 448.0 (M-1), TH NMR (400 MHz, CD,0D): $2.60 (s, 3H), 5.05 (s, 2H), 6.86 (m, 2H), 6.98 (m, 2H), 7.08 (m, 1H), 7.25 (m, 1H), 7.36 {d, 1H), 7.53 (m, 1H), 7.64 (m, 1H), 8.21 (d, 1H).
EXAMPLE 210: 5-[4-(2.3-Difluoro-benzyloxy)-phenvisufamoyil-2-methyi-benzoic acid
FF Q
OH a 0) N—3 CH, — Oo 82% yield. MS: 432.2 (M-1); "H NMR (400 MHz, CD,OD): 52.60 (s, 3H), 5.08 (s, 2H), 6.87 (m, 2H), 6.99 (m, 2H), 7.17 (c, 1H), 7.24 (c, 2H), 7.36 (d, 1H), 7.64 (m, 1H), 8.22 (d, 1H).
EXAMPLE 211: 5-{4-(3.5-Diflucro-benzyloxy)-phenyisutfamoyil-2-methvi-benzoic acid
FE QO
OH
? 0 N—S CH,
H I!
F Oo 56% yield. MS: 432.2 (M-1); TH NMR (400 MHz, CD,OD): 82.60 (s, 3H), 5.02 (s, 2H), 6.86 (c, 3H), 6.99 (c, 4H), 7.36 (d, 1H), 7.63 (m, 1H), 8.22 (d, 1H).
EXAMPLE 212: 5-{4-(3,4-Diflucro-benzyloxy}-phenvisulfamoyil-2-methyl-benzoic acid . F (@)
OH
F Q
0] N- CH 73 H i 3 66% yield. MS; 432.2 (M-1); TH NMR (400 MHz, CD30D): 52.60 (s, 3H), 4.97 (s, 2H), 6.85 (c, 2H), 6.97 (c, 2H), 7.17-7.38 (c, 4H), 7.63 (m, 1H), 8.21 (d, 1H).
EXAMPLE 213: 5-[4-(5.7-Difluorg-benzothiazok-2-vimethyisulfanyl}-phenvisulfamoy(l-2- methyi-benzoic acid
CH,
NS O
] i J le) OH
NS
—~
F
19% yield. MS: 507.0 (M+1); HNMR (400 MHz, CD;0D): §2.47 (s, 3H), 4.49 (s, 2H), 7.02 (m, 2H), 7.12 (m, 2H), 7.26 (m, 2H), 7.46 (c, 2H), 7.97 (d, 1H).
EXAMPLE 214: 2-Isopropvi-5-{4-(6-methvi-benzothiazol-2-vi}-phenyisulfamovil-benzoic acid
N
OH = pn
H.C S S le} CH, 0
HO
84% yield. MS: 467.1 (M+1), "HNMR (400 MHz, CD;0D): 81.21 (d, 6H), 2.47 (s, 3H), 3.81 {m, 1H), 7.28 (m, 2H), 7.32 (m, 1H), 7.60 (d, 1H), 7.75 (s, 1H), 7.82 (d, 1H), 7.92 (c, 3H), 8.20 (d, 1H).
EXAMPLE 215; 2-Methvi-5-4-(5-trifluoromethyl-benzothiazol-2-yimsthyisulfanyl)- phenyisulfamovl]-benzoic acid
FF
“Cr! 3
SO)
S CH, (0) 0
HO
17% yield. MS: §39.0 (M+1}; "HNMR (400 MHz, CD50D): 62.55 (s, 3H), 4.52 (s, 2H), 7.01 (d, 2H), 7.27 (c, 4H), 7.64 (m, 2H), 8.12 (d, 1H), 8.22 (b, 1H).
EXAMPLE 216: 2-Ethvi-5-[4-(6-methyi-benzothiazol-2-yl}-phenvisulfamoyil-benzoic acid
N
CO er
H,C S § 0]
HO
83% yield. MS: 453.0 (M+1); 'H NMR (400 MHz, CD,0D): 51.18 (t, 3H), 2.47 (s, 3H), 3.01 (a. 2H), 7.27 (m, 2H), 7.32 (m, 1H), 7.45 (d, 1H), 7.84 (m, 2H), 7.93 (m, 2H), 8.32(d, 1H).
EXAMPLE 217. 2.3-Dimethyl-5-4-(6-methyl-benzothiazol-2-yl}-phenyisulfamoyl-benzoic acid
CH,
CH,
HO
NJ 0 3
Na 0 OH as
H,C 75% yield. MS: 453.0 (M+1); TH NMR (400 MHz, DMSO-D). 52.30 (s, 3H), 2.38 (s, 3H), 2.42 (s, 3H), 7.26 (m, 2H), 7.31 (m, 1H), 7.76 (s, 1H).
EXAMPLE 218: 2,3-Dimethyl-5-[4-(3-trif luoromethyi-benzvisulfanyl }-phenyisulfamovil-benzoic acid
H,
CH, ovr
Ol
S oO H
F
F F
75% yield. MS: 494.2 (M-1}; 4 NMR (400 MHz, CD;0D): $2.32 (s, 3H), 2.48 (s, 3H), 4.07 (s, 2H), 7.0 (m, 2H), 7.14 (d, 2H), 7.34 (c, 2H), 7.46 (c, 2H), 7.63 (s, 1H), 8.0 (s, 1H).
EXAMPLE 219: 5-J4-(4-Ethyl-benzylsutfanyl)-phenvisulfamovil-2,3-dimethyi-benzoic acid
0
RAN SN o ~ ] = Ope 0
CH, 80% yield. MS: 456.3 (M+1); H NMR (400 MHz, CD,0D): $1.17 (t, 3H), 2.33 (s, 3H), 2.49 (s, 3H), 2.57 (q, 2H), 3.97 (s, 2H), 6.96-7.06 (c, 6H), 7.13 (c, 1H), 7.63 (d, 1H), 8.00 (d, 1H).
EXAMPLE 220: 2-isopropyt-5-(4-trifluoromethoxy-biphenyl-4-visutfamovyl}-benzoic acid
Hy
CH
H 3 vd 0 [ 4 0 OH
LC
F E oO . 37%.yield. MS: 480.0 (M+1); "H NMR (400 MHz, CD;0OD): 1.22 (d, 6H), 3.81 (m, 1H), 7.20 (m, 2H), 7.29 (d, 2H), 7.51 (m, 2H), 7.58 (d, 1H), 7.63 (m, 2H), 7.84 (m, 1H), 8.14 (d, 1H).
EXAMPLE 221; 5-[2-{(4-tert-Butyl-phenyl}-benzooxazol-5-yisulfamoyi}-2-methvi-benzoic acid 0
H
Q orien ~ 0]
N
H,C yon
H,C CH, 90% yield. MS: 465.3 (M+1); HNMR (400 MHz, CD,0D): 51.37 (s, 9H), 2.58 (s, 3H), 7.13 (m, 1H), 7.37 (d, 1H), 7.43 (d, 1H), 7.53 (d, 1H), 7.61 (m, 2H), 7.72 (m, 1H), 8.11 (m, 2H), 8.27 (d, 1H).
EXAMPLE 222: 5-[4-(3,5-Dimethyl-benzyisulfanyl}-phenvisulfamovi]-2-methvi-benzoic acid
H,C Q
OH
Q
H,C O 74% yield. MS: 440.2 (M+1), 'H NMR (400 MHz, CD;0D): $2.19 (s, 6H), 2.56 (s, 3H), 3.93 (s, 2H), 6.78 (s, 2H), 6.82 (s, 1H), 6.98 (d, 2H), 7.12 (d, 2H), 7.30 (d, 1H), 7.58 (d, 1H), 8.08 (b, 1H).
EXAMPLE 223: 5-[4-(4-Butoxy-benzyisulfanyl}-phenyisulfamoyil-2-methyl-benzoic acid o}
OH
Heol HN o
Oro 82% yield. MS: 484.2 (M-1); '"H NMR (400 MHz, CD;0D): 80.97 (t, 3H), 1.49 (m, 2H), 1.72 (m, 2H), 2.61 (s, 3H), 3.91 (t, 2H), 3.95 (s, 2H), 6.72 (m, 2H), 6.97 (m, 2H), 7.03 {m, 2H), 7.13 (m, 2H), 7.38 (d, 1H), 7.68 (m, 1H), 8.28 (d, 1H).
EXAMPLE 224: 5-[4-(2 3-Difluoro-benzylsulfanvl}-phenyisutfamovi]-2-methyl-benzoic acid
F F . 0)
OH
0] 81% yield. MS: 448.2 (M-1); 'H NMR (400 MHz, CD,0D): 82.57 (s, 3H), 4.03 (s, 2H), 6.81 (c, 1H), 6.92 (c, 1H), 7.00 (d, 2H), 7.07 (m, 1H), 7.16 (d, 1H), 7.34 (d, 1H), 7.61 (d, 1H), 8.14 (b, 1H).
EXAMPLE 225: 5-[4-(3.5-Difluoro-benzyisulfanyt}-phenylsutfamoy{l-2-methw-benzoic acid
F 0
OH
? s— Hi CH,
H I
F 0 84% yield. MS: 448.2 (M-1); 'H NMR (400 MHz, CD;0D): $2.60 (s, 3H), 4.01 (s, 2H), 6.74 (c, 3H), 7.00 (c, 2H), 7.17 (c, 2K), 7.37, {d, 1H), 7.68 {m, 1H), 8.28 (d, 1H).
IN
EXAMPLE 226: 2-Methyl-5-J4-(4-triflucromethyisulfanyl-benzylsulfan henyisulfamovi}- benzoic acid . 0]
EF OH
FO
F s— Hp- CH,
H li 0 84% yield. MS: 512.2 (M-1); "HNMR {400 MHz, CD,0D); 82.63 (s, 3H), 4.78 (s, 2H), 6.98 tS) (m, 2H), 7.13 (m, 2H), 7.21 (d, 2H), 7.40 (d, 1H), 7.47 (d, 2H), 7.72 (m, 1H), 8,28 (d, 1H).
EXAMPLE 227; 2,3-Dimethyl-5-14-(3-triftuoromethoxy-benzylsuifanyl)-phenyisuifamoyll- benzoic acid
CH,
CH, 0 jo an
Co o] OH
F3-0
F
77% yield. MS: 510.2 (M-1); "HNMR (400 MHz, CD,0D): $2.32 (s, 3H), 2.48 (s, 3H), 4.04 (s, 2H), 6.98 (d, 2H), 7.08 (c, 3H), 7.15 (d, 2H), 7.24 (t, 1H), 7.62 (s, 1H), 7.99 (s, 1H).
EXAMPLE 228; 2,3-Dimethyl-5-(4'-trifluoromethoxy-biphenyi-4-yisulfamoyj}-benzoic acid 3
CH,
NE 0
F . "yO
F
77% yield. MS: 464.2 (M-1); 'H NMR (400 MHz, CD;0D): 52.33 (s, 3H), 2.47 (s, 3H), 7.18 (d, 2H), 7.29 (d, 2H), 7.50 (m, 2H), 7.62 (m, 2H), 7.68 (s, 1H), 8.03 (s, 1H).
EXAMPLE 229: 5-[2-(4-tert-Butyi-phenyl}-benzooxazol-5-ylsulfamoyll-2-ethyl-benzoic acid
0. : CH, 0 OH
H,C \ 7
N NR
84% yield. MS: 479.4 (M+1); TH NMR (400 MHz, CD,0D): 81.17 (t, 3H), 1.37 (s, 9H), 3.00 (q, 2H), 7.13 (m, 1H), 7.42 (m, 2H), 7.53 (d, 1H), 7.61 (m, 2H), 7.75 (m, 1H), 8.11 (m, 2H), 8.23 (d, 1H).
EXAMPLE 230: 2-Ethyl-5-[4-(4-triflucromethoxy-benzyisulfanyi)-phenvisutfamoyi]-benzoic acid 0,
F OH
FO Od
F Ss N-§
Ho CH, 67% yield. MS: 510.3 (M-1); 'H NMR (400 MHz, CD50D): $1.20 (t, 3H), 2.97 (q, 2H), 4.03 (s, 2H), 7.01 (m, 2H), 7.09 (d, 2H}, 7.14 (m, 2H), 7.23 (m, 2H), 7.34 (d, 1H), 7.63 (m, 1H), 8.06 (d, 1H).
EXAMPLE 231: 2,3-Dimethyl-5-[4-(4-trifluoromethoxy-benzylsulfanyl}-phenylsulfamovl}- benzoic acid
F OH
FO od ass a Wat
CH, 49% yield. MS: 510.2 (M-1); 'H NMR (400 MHz, CD30D): 82.32 (s, 3H), 2.48 (s, 3H), 4.02 (s, 2H), 6.99 (m, 2H), 7.06 (d, 2H), 7.14 (m, 2K), 7.21 (m, 2H), 7.62 {t, 1H), 7.96 (d, 1H).
EXAMPLE 232: 2-Ethyl-5-[2-(4-trifluoromethoxy-phenvi)-benzooxazol-5-yisulfamoyi}-benzoic acid lo)
F, F
FX 0 OH
OI
N Ni le} CH, 77% yield. MS: 507.3 (M+1), 'H NMR (400 MHz, CD;0D): 51.17 (t, 3H), 2.97 (gq, 2H), 7.16 (m, 1H), 7.38 (d, 1H), 7.48 (m, 3H), 7.54 (d, 1H), 7.71 (m, 1H), 8.14 (d, 1H), 8.29 (m, 2H).
EXAMPLE 233: 2-Ethyl-5-(4-triflucromethoxy-biphenyl-4-yisulfamovyl)-benzoic acid
CH,
HO
He @ oO OH
LO
A
F 0] 82% yield. MS: 464.2 (M-1), "H NMR (400 MHz, CD50D): §1.19 (t, 3H), 3.0 (q, 2H), 7.20 (m, 2H), 7.29 (d, 2H), 7.43 (d, 1H), 7.50 (m, 2H), 7.62 (m, 2H), 7.81 (m, 1H), 8.27 (d, 1H).
EXAMPLE 234: 2-Isopropyi-5-{4-(4-triflucromethoxy-benzyisulfanvl)-phenvisulfamoyil-benzoic acid 0
F OH
Fo I 1% CH, : sii [o]} CH, 71% yieid. MS: 524.2 (M-1); "TH NMR (400 MHz, CD;0D): $1.23 (d, 6H), 3.75 (m, 1H), 7.02 © (m, 2H), 7.09 (d, 2H), 7.15 (m, 2H), 7.23 (m, 2H), 7.51 (d, 1H), 7.71 (m, 1H), 8.01 (d, 1H).
EXAMPLE 235:2-Methyi-5-[2-{4-trifluoromethoxy-phenyl}-benzooxazol-5-yisulfamoyi]-benzoic acid (0)
F.F
FX o o OH 0 — | Ti
N -$ 4 CH,
H 0 71% yield. MS: 493.2 (M+1); "H NMR (400 MHz, CD;0D): $2.56 (s, 3H), 7.15 (m, 1H), 7.35 (d, 1H), 7.48 (c, 3H), 7.54 (c, 1H), 7.68 (m, 1H), 8.19 (d, 1H), 8.31 (d, 2H).
EXAMPLE 236: 2-Ethyi-5-[4-(quinolin-2-vimethyisulfanwvi}phenvisulfamovi}-benzoic acid (0)
OH
SEP,
N H i CH,
100% vield. MS: 479.4 (M+1); 'H NMR (400 MHz, CD3;0D): $1.20 (t, 3H), 3.03 (qg, 2H), 4.5 (d, 2H), 7.01 (m, 2H), 7.20 (m, 2H), 7.42 (d, 1H), 7.78 (c, 2H), 7.93 (m, 1H), 7.99 (d, 1H), 8.12 (m, 1H), 8.23 (d, 1H), 8.26 (d, 1H), 8.94 (d, 1H).
EXAMPLE 237: 2-| ropyi-5-[4-{quinolin-2-yimethylsulfanyl}-phenvisulfamoyl]-benzoic acid ®)
OH
~ —
N N i CH, 96% yield. MS: 493.3 (M+1), 'H NMR (400 MHz, CD,0DY): $1.23 (d, 6H), 3.82 (m, 1H), 449 (s, 2H), 7.02 (m, 2H), 7.2 (m, 2H), 7.58 (d, 1H),7.76 (d, 1H), 7.82 (m, 1H), 7.95 (m, 1H), 8.04 {m, 1H), 8.11, (c 2H), 8.25 (d, 1H), 8.92 (d, 1H).
EXAMPLE 238: 2-Ethyi-5-{2-(4-trifluoromethyi-phenvyi}-bengooxazol-5-yisulfamoyil-benzoic acid
Oo
F o OH
F) {OY \ Ty! / N
F 5 CH, 85% vield. MS: 491.3 (M+1); "H NMR (400 MHz, CD;0D): §1.17 (t, 3H), 3.00 (q, 2H), 7.19 (m, 1H), 7.41 (d, 1H), 7.51 (d, 1H), 7.58 (d, 1H), 7.76 (m, 1H), 7.87 (d, 2H), B.23 (d, 1H), 8.37 (d, 2H).
EXAMPLE 239: 2-Methyl-5-[2-(4-triflupromethyl-phenyi}-benzooxazol-5-visulfamovyil-benzoic acid (0)
OH
FOS]
NN —- . F N N i Hy 92% vield. MS: 477.3 (M+1); "HNMR (400 MHz, CD30D): 62.58 (s, 3H), 7.18 (m, 1H), 7.38 (d, 1H), 7.50 (d, 1H), 7.38 (d, 1H), 7.50 (d, 1H), 7.58 (d, 1H), 7.73 (m, 1H), 7.88 (d, 2H), 8.27 (d, 1H), 8.38 (d, 2H).
EXAMPLE 240: 5-(4-Cyclohexyimethyisulfanyl-phenylsulfamoyl)-2-methyi-benzoic acid
CH,
HO
0] OH
Oh 74% yield. MS: 418.0 (M-1); 'H NMR (400 MHz, CD;0D): 50.95 (c, 2H), 1.19 {c, 3H), 1.40 (c, 1H), 1.67 (c, 3H), 1.83 (c, 2H), 2.60 (s, 3H), 2.72 (d, 2H), 7.00 (m, 2H), 7.17 (m, 2H), 7.38 (d, 1H), 7.70 (m, 1H), 8.27 (d, 1H).
EXAMPLE 241: 5-(4-Cyclobutyimethyisulfanyl-phenylsulfamoyi)}-2-methyi-benzoic acid
CH,
HO ory
O OH
[gs 83% yield. MS: 390 (M-1); "HNMR (400 MHz, CDCl): $1.70 (c, 2H), 1.85 (c, 2H), 2.06 (c, 2H), 2.47 (m, 1H), 2.68 (s, 3H), 2.93 (d. 2H), 6.99 (m, 2), 7.20 (m, 2H), 7.34 (d, 1H), 7.75 (m, 1H), 8.47 (d, 1H).
EXAMPLE 242: 2-Isopropyt-5-J4-(5-methyl-benzooxazol-2-yl)-phenyisulfamovil-benzoic acid (0)
OH
4 ~%
H.C N id o CH, 89% yield. MS: 451.3 (M+1); 'H NMR (400 MHz, CD30ODY): 51.21 (d, 6H), 2.45 (s, 3H), 3.81 (m, 1H), 7.20 (d, 1H), 7.32 (d, 2H), 7.48 (d, 2H), 7.61 (d, 1H), 7.91 (m, 1H), 8.07 (d, 2H), 8.21 (d, 1H).
EXAMPLE 243: 5-44-(1H-Benzoimidazol-2-yl)-phenyisulfamoyil-2-isopropyl-benzoic acid 0
H OH
N 0 CH,
I — >—N~S
N H oO CH,
94% yield. MS:436.3 (M+1); "HNMR (400 MHz, CD;0D): 81.22 (d, 6H), 3.81 (m, 1H), 7.48 {(m, 2H), 7.61 (c, 3H), 7.77 (c, 2H), 8.00 (c, 3H), 8.23 (d, 1H).
EXAMPLE 244: 2-isopropyi-5-[4-{3-trifiucromethoxy-ben anyl)-phenyisulfamo enzoic acid 0]
OH
OO ? CH,
F——0 h X CH,
F
91% yield. MS: 524.3 (M-1); 'H NMR (400 MHz, CD;0D): 81.23 (d, 6H), 3.82 (m, 1H), 7.00 {m, 2H), 7.08 (c, 3H), 7.16 (m, 2H), 7.25 (m, 1H), 7.55 (d, 1H), 7.76 (m, 1H), 8.11 (d, 1H).
EXAMPLE 245:2-Ethyi-5-[4-(3-triflucromethoxy-benzyisulfanyl}-phenvisulfamovi]-benzoic acid 0] y \ pa ? .
F S -
Fo _/ HN x CH,
F
72% yield. MS: 510.1 (M-1); 'H NMR (400 MHz, CD;0D): 81.20 (t, 3H), 3.03 (q, 2H), 4.04 (s, 2H), 6.99 (m, 2H), 7.08 (c, 3H), 7.16 (m, 2H), 7.25 (m, 1H), 7.40 (d, 1H), 7.73 (m, 1H), 8.24 (d, 1H). 156
EXAMPLE 246: 2-Ethyl-5-(4'-propoxy-biphenyl-4-visulfamowi}-benzoic acid 0,
OH
(e] “moO Or
H
[0] CH, 92% yield. MS:438.3 (M-1); HNMR {400 MHz, CD30OD): $1.04 (t, 3H), 1.18 (t, 3H), 1.79 (m, 2H), 3.02 (q, 2H), 3.94 {t, 2H), 6.92 (m,2H), 7.13 (mM, 2H), 7.43 (c, 5H), 7.78 (m, 1H), 8.26 (d, 1H).
EXAMPLE 247: 2-Isopropyi-5-(4'-propoxy-biphenyi-4-yisulfamovi}-benzoic acid
Q,
OH oO CH,
HC N-S 0} N 3
[0] CH,
93% vield. MS:452.3 (M-1); TH NMR (400 MHz, CD,0D): 61.04 {t, 3H), 1.22 (d, BH), 1.79 (m, 2H), 3.81 (m, 1H), 3.94 (m, 2H), 6.93 (m, 2H), 7.14 (m, 2H), 7.44 (c, 4H), 7.57 (d, 1H), 7.80 (m, 1H), 8.13 (d, 1H).
EXAMPLE 248: 5-[2-(4-tert-Butyl-phenvl)-benzooxazol-5-yisuifamoyl]-2-isopro -benzoic acid @)
OH
Q CH, i y 0 Hy
N
H,C
HC” em, 93% yield. MS: 493.4 (M+1); 'H NMR {400 MHz, CD,0D): 51.20 (d, 6H), 1.37 (s, 9H), 3.80 (c, 1H), 7.13 (m,1H), 7.45 (d, 1H), 7.54 (t, 2H), 7.62 (d, 2H), 7.78 (m, 1H), 8.11 (m, 3H).
EXAMPLE 249: 2-Methyi-5-[4-(5-trifluoromethvi-pyridin-2-ylcarbamoyl}-phenylsulfamoyll- benzoic acid
FF (o)
OH pe N _ I
N N N 5 CH,
Q
2% yield (material lost). MS: 478.0 (M-1); 'H NMR (400 MHz, CD;0D): $2.49 (s, 3H), 7.19 (d, 1H), 7.28 (m, 4H), 7.67 (m, 1H), 7.85 (m, 2H), 8.05 (m, 2H).
EXAMPLE 250: 5-{4-(5-Cyciohexyl-[1,3 4]oxadiazol-2-yi}-phenvisulfamoyil-2-methyl-benzgic acid 0)
OH
N—N
OOH C= 0 NTR (0) 86% vield. MS: 442.0 (M+1); "H NMR (400 MHz, CDCly): 51.15-1.4 (c, 3H), 1.49-1.7 (c, 3H), 1.76 (¢, 2H), 2.02 (c, 2H), 2.53 (s, 3H), 2.86 (c, 1H), 7.20 (m, 3H), 7.73 (m, 3H), 8.39 (d, 1H).
Ex. Chemical Structure [ Chemical Name [Data | Name | Data
WC 2005/092845 PCT/IB2005/000526
Chemical Structure Chemical Name [Data : 2-Methyl-5-[2-(5- ; ; 0 OH y-5-42- 85% ] | 0 methyl-2-phenyl- | jor ; Co - oxazol-4-yimethyi)- 251 0_CH, N $ CH, yimethyi) MS: & J 0 benzofuran-5-
N Isulf benzoic oO ylsulfamoyl}-benzoic (M1) acid 0 2-Ethyl-5-[2-(5-methy+ | 91% o OH | 2-phenyi-oxazok4- yield. i! methyl)}-benzofuran- | MS: 252 0-CH, K $ ; yimethy!)-b
Q 1a Pl 0 CH, | 5- 517.2 ! N 0 yisulfamoyi}-benzoic (M+1) acid i 70% 2-1sopropyl-5-{2-(4- yield.
F ? trifluoromethoxy- 0 OH { 253 ro Q CH, | phenyl)-benzooxazol
F N% cp. | 5-Yisulfamoyil-benzoic 0] 3 fi acid MS: 521.4 (M+1)
RF O | 2-Ethyl-5-4-(2- 50%
Fx trifluoromethoxy- yield. i 254 O ? {| benzyisulfanyl)- MS:
S i C) phenylsulfamoyl)- 511.0
Oo benzoic acid (M+1)
Ex. | Chemical Structure Chemical Name Data 1 | i 94% yield. 0]
OH 5-[4-{5-Cyciohexyl-
N—N — 0 1,3,4]Joxadiazol-2-yl)- 255 I \ a! CH 0 \ // N 0 3 | phenyisulfamoyi]-2- i 0 methyi-benzoic acid | MS: 4420 (M+1)
CH, | o
CH . 75% s | 2-Methyl-5-[(4'- fo) . yield.
Na O | propoxy-biphenyl-4- MS: 256 il i)-pr ifamoyl}- i lo) on | Yirpropytsufamoyl- os x benzoic acid (M+) ! H,
I H.C ~~ o ZZ
Hy Hy 0 CH, | 2-isopropyl-5-[propy}-
Nu Oo (4-trifluoromethoxy- | Y'&' 257 i biphenyl-4-yl)— Ms: 0] OH 5022
F @® sulfamoyl]-benzoic ’
Ag acid (M+1)
F
2-MethyF5-[4-(4- 95%
F R OH trifluoromethoxy- yield. } Fo 0) benzyloxy)- MS: 258 0 -$ CH,
F N a phenyisulfamoyl]- 480.9 benzoic acid {M-1)
EXAMPLE 259: 2-Methyi-5-[(4'-propoxy-biphenyi-4-yl)-propyi-sutfamovil-benzoic acid methyi ester
CHa - % CH, 0] ee:
TTT
Hilo @
A mixture of 5-[(4'-hydroxy-biphenyi-4-yl)-propyl-sulfamoyl}-2-methyl- benzoic acid methyl ester (100 mg, 0.25 mmol), 1-iodopropane (36.7 ul, 0.38 mmol) and potassium carbonate (52 mg, 38 mmol) in 5 ml acetone was heated at 56°C under nitrogen overnight. Additional 1-iodopropane was added (35.7 pl, 0.38 mmol) and the mixture was heated at 56°C under nitrogen overnight. The reaction mixture was then cooled to room temperature and diluted with 40 mi ethyl acetate. The ethyl acetate solution was washed sequentially with 30 ml water and 30 mi brine, dried (anhydrous sodium sulfate} and concentrated under reduced pressure. The residue was purified by preparative thick layer chromatography (silica gel), eluting with 3:1 toluene/ethyl acetate to yield the tiie compound as an off-white solid (21 mg, 17% yield) along with 5-[(4'-hydroxy-biphenyl-4-yl}-propyl- sulfamoyi}-2-methyl-benzoic acid methyl ester (64 mg, 58% yield).
MS:482.2 (M+1) 2-Methyi-5-[(4'-propoxy-biphenyl-4-yl)-propyi-sulfamoyl}-benzoic acid methyl ester
MS: 440.1 (M+1) 5-[(4'-hydroxy-biphenyl-4-yl}-propyl-suifamoyl}-2-methyi-benzoic acid methyl ester
EXAMPLE 260: 2-Isopropyl-5-propyl-{4 -triflucromethoxy-biphenyi-4-yl}-sulfamoyl]-benzoic acid methyl ester
CHs CH,
CH
0] OCHg4
LAC
0 F ()
The title compound was prepared using a procedure analogous to that of EXAMPLE 257 but using 2-isopropyl-5-(4'-trifiucromethoxy-biphenyl-4-yisulfamoyl}-benzoic acid methyl ester in place of 5-[(4"-hydroxy-biphenyl-d-yl)-propytsulfamoyi}-2-methyl-benzoic acid methyl ester. 80% yield. MS: 564.2 (M+1).
EXAMPLE 261: 4-{5-Methyl-benzooxazol-2-yi}-phenylamine .
A mixture of 2-amino-p-cresol (1.5 g, 12 mmol), 4-aminobenzoic acid (1.67 g, 12 mmol) and 40 gq polyphosphoric acid was heated at 190° C under nitrogen for 6 h. The reaction mixture was cooled to room temperature and 300 mi water was added to the viscous liquid. The solid that precipitated was collected by filtration and dissolved in 200 ml ethyl acetate. The ethyl acetate solution was washed sequentially with 100 mi saturated aqueous sodium bicarbonate solution, 100 ml water and 100 m! brine, dried (anhydrous sodium sulfate) and concentrated under reduced pressure to yield the title compound as an off-white solid (2.43 g, 89% yield).
MS: 225.0 (M+1)
The title compounds of EXAMPLES 262-268 were prepared using procedures analogous to that of EXAMPLE 261 from appropriate starting materials.
Ex. Chemical Name Data i . 85% yield. 262 4-Benzooxazol-2-yl-phenylamine
MS: 211.1 (M+1) 92% yield. 263 4-(5-Phenyi-benzooxazol-2-yl)-phenylamine
MS: 287.2 (M+1) 77% yield. 264 4-(5-Chjoro-benzooxazol-2-yl}-phenylamine
MS: 245.1 (M+1) 59% yield. 4-Benzothiazol-2-yl-phenylamine
MS: 227.2 (M+1) 4-(1H-Benzoimidazol-2-y!)-phenylamin 79% yield. -Benzoimidazol-2- nylamine
P MS: 210.2 (M+1) 267 3-(5-Methyt-b 1-2-yl)-phenylami 83% yield. @ enzooxazol-2-yl)-phenylamine yi-pheny MS: 225.1 (M+1) . 39% yield. 268 3-Benzothiazol-2-yl-phenylamine
MS: 227.1 (M+1)
EXAMPLE 269 4-(4-Trifluoromethyl-benzyloxy)-phenylamine - "15 To a solution of p-aminophenol (0.200 g, 1.83 mmol), 4-triflucromethylbenzyl alcohol (025 ml, 1.83 mmol) and triphenylphosphine (0.529 g, 2.02 mmol) in 5 ml anhydrous tetrahydrofuran was added diethyl azodicarboxylate (0.318 ml, 2.02 mmol). The reaction mixture was stirred overnight at room temperature under nitrogen. It was then diluted with 70 ml ethyl acetate and the resulting solution was washed sequentially with 50 ml saturated aqueous sodium bicarbonate solution, 50 ml water and 50 ml brine, dried (anhydrous sodium sulfate) and concentrated under reduced pressure. The solid residue was purified by flash column chromatography (silica gel, 15 g), eluting with 8:2 hexanef/ethyl acetate to yield the title compound as an off-white solid (0.272 g, 55% yield). MS: 284.1 (M+1)
The title compounds of EXAMPLES 270-276 were prepa red using procedures analogous to that of EXAMPLE 269 from appropriate starting materials. [Bx | ChemicalName ~~ fb
MS: 228.3 (M+1 271 4-(4-Butoxy-benzyloxy)-phenylamine 19% vied.
MS: 272.4 (M+1)
MS: 252.2 (M+1)
MS: 236.2 (M+1)
MS: 236.2 (M+1)
MS: 236.2 (M+1)
MS: 284.2 (M+1)
EXAMPLE 277 4-(4-Trifluoromethyt-benzvisulfanyl}phenwlamine
Sodium hydride [0.153 g (50% in mineral oil), 3.2 mmol] wvas added to a solution of 4~ aminothiophenol (0.20 g, 1.6 mmol) in 5 ml anhydrous tetrahydrofuran. The resulting mixture was stirred at room temperature under nitrogen for 15 min, then 4- trifluoromethylbenzyl chloride (0.236 ml, 1.6 mmol) was a dded. The reaction mixture was stirred overnight at room temperature under nitrogen. Water {50 ml ) was then added and the resulting mixture was extracted with 2 X 50 mi ethyl acetate. The combined ethyi acetate extracts were washed sequentially with 60 ml saturated aqueous sodium bicarbonate solution, 60 ml water and 60 ml brine, dried (@nhydrous sodium sulfate) and concentrated under reduced pressure. The solid residue was purified by flash column chromatography (silica gel, 15 g), eluting with 85:15 hexa ne/ethyl acetate to yield the title compound as an off-white solid (0.318 g, 70% yield). MS: 284.1 (M+1)
The title compounds of EXAMPLE 278-304 were prepared using procedures analogous to that of EXAMPLE 277 from appropriate starting materials -
Ex. Chemical Name Data 278 | 3-(4-Trif thyl-benzylsutfanyl}-phenylami 66% yield. -(4-Trifluoromethyl-benzylsulfan enylamine yroensy pheny MS: 284.1 (M+1) 279 | 4(3-Trif thyl-benzylsulfanyl)-phenylami 58% yield. -(3-Trifluoromethyl-benzylsulfanyl)-phenylamine id yore MS: 284.1 (M+1) 0 | 4-(4-t-Butyl-benzylsulfanyl)-phenylamine 42% yield.
MS: 272.2 (M+1 281 4-(4-Isopropyi-benzylsulfanyl)-phenylamine 56% yield.
MS: 268.2 (M+1 == 282 4-(4-Trifluoromethoxy-benzylsulfanyl)-phenylamine 46% yield.
MS: 300.1 (M+1 283 4-(4-Chloro-benzylsulfanyl)-phenylamine 45% yield. 250.1 (M+1 284 | 4-(4-Ethyl-benzyisulfanyl)-phenylamine 45% yield.
MS: 244.1 (M+1 285 4-(4-Phenyl-benzylsulfanyl)-phenylamine 21% yield.
MS: 292.1 (M+1 4-(3-Phenoxy-benzyisulfanyl}-phenylamine 50% yield. - - mi y y MS: 308.1 (M+1) 287 4-{2-{4-Chloro-phenyl)-thiazol-4-yimethylsulfanyl]- 25% yield. phenytamine MS: 333.1 (M+1) 4-(Quinolin-2-yimethylsulfanyl}-phenylamine 53% yield.
MS; 267.1 (M+1 289 4-(5-Phenyl-{1,2,4]oxadiazol-3-ylmethyisuifanyl)- 46% yield. phenylamine MS: 284.2 (M+1) 4-(Naphthalen-2-yimethyisulfany!)-phenylamine 53% vieid.
MS: 266.3 (M+1 291 4-(4-Fluoro-benzylsulfanyl)-phenylamine 41% yield.
MS: 234.3 (M+1 292 4-(3,4-Diflucro-benzylsuifanyl)-phenylamine 66% yield.
MS: 252.2 (M+1) i 45% yield. 293 4-(3,5-Bis-trifluoromethyl-benzylsulfanyl)-phenylamine
MS: 352.2 (M+1 4-(3-Trifluoromethyt-benzylsulfanyl)-phenytamin 22% yield. -{3- - amine
MS: 284.3 (M+1) 295 4-(3,4-Dimethy--benzyisulfany!}-phenylamine 84% yield.
MS: 244.3 (M+1 296 | 4-(2,4-Bis-trifluioromethyi-benzylsulfanyl)-phenylamine 39% yield.
MS: 251.3 (M+1
: 65% yield. ' 297 | 4-(2-Chioro-4-fluoro-benzyisulfanyl)-phenylamine MS: 268.2 (M+1) i phenylamine MS: 309.2 (M+1)
MS:291.1 (M+1 phenylamine MS: 309.0 (M+1) phenylamine MS: 341.2 (M+1)
MS: 300.1 (M+1 303 | 4{4-Cyclohexyimethylsulfanyl)-phenylamine 49% yield. ; MS: 222.1 (M+1
MS: 300.3 (M+1
EXAMPLE 305 4-(3.5-Dimethyl-benzylsuifanyl}-nitrobenzene
To a solution of 4-nitrothiophenol {0.400 g, 2.57 mmol), 3,5-dimethylbenzyl alcohol (0.38 m!, 2.57 mmol) and triphenytphosphine (0.743 g, 2.84 mmol) in 10 mi anhydrous tetrahydrofuran was added diethyl azodicarboxylate (0.446 ml, 2.84 mmol). The reaction mixture was stirred overnight at room temperature under nitrogen. It was then diluted with 90 ml ethyl acetate and the resulting solution was washed sequentially” with 70 ml saturated aqueous sodium bicarbonate solution, 70 ml water and 70 ml brine, dried (anhydrous sodium sulfate) and concentrated under reduced pressure. The solid residue was triturated with 95:5 hexane/ethyl acetate (20 ml) and filtered. The filtrate was co ncentrated under reduced pressure and the residue was purified by column chromatography (silica gel, 15 g), eluting with 95:5 hexane/ethyl acetate to yield title compound as a yellow solid (0.35 g, 50% yield). 'H NMR (400 MHz, CD4CI): $2.30 (s, 6H), 4.18 (s, 2H), 6.92 (s, 1H), 7.0 (s, 2H), 7.33 (d, 2H), 8.10 (d, 2H).
The title compounds of EXAMPLE 306-309 were prepared using procedures analogous to that of EXAMPLE 305 from appropriate starting materials.
EXAMPLE 306 4-(4-Butoxy-benzyisulfanyl}-nitrobenzene 26% yield. 'H NMR (400 MHz, CD3Cl): 80.97 (t, 3H), 1.4-1.53 (c, 2H), 1.7-1.8 (c, 2H), 3.95 {m, 2H), 4.2 (s, 2H), 6.85 (d, 2H), 7.27 (d, 2H), 7.33 (d, 2H), 8.1 (d, 2H).
EXAMPLE 307 4-(2,3-Difluoro-benzyisutfanyl}-nitrobenzene 55% yleid. 'H NMR (400 MHz, CD,CI): 84.28 (s, 2H), 7.0-7.16 (c, 3H), 7.37 (d, 2H). 8.13 (d, 2H).
EXAMPLE 308 4-(3,5-Difluoro-benzylsulfanyl)-nitrobenzene 33% yield. 'H NMR (400 MHz, CDsCl): 54.20 (s, 2H), 6.73 (m, 2H), 6.92 (m, 2H), 7.32 (m, 2H), 8.12 (m, 2H).
EXAMPLE 309 4-(4-Trifluoromethyisulfanyl-benzyisuifanvl)-nitrobenzene 55% yield. MS: 344.1 (M-1).
The title compounds of EXAMPLE 310-312 were prepared using procedures analogous to that of EXAMPLE 305 from appropriate starting materials but using 4- nitrophenot! or 3-nitrophenol in place of 4-nitrothiophenol.
EXAMPLE 310 4-[2-(4-Nitro-phenoxy)-ethyl}-2-(4-trifluoromethoxy-phenvi)-thiazzole 78% yield. MS: 411.1 (M+1)
EXAMPLE 311 4-[2-(4-Nitro-phenoxy)-ethvil-2-(4-trifluoromethyl-phenyl}-thiazo le 70% yield. MS: 395.1 (M+1)
EXAMPLE 312 3-(4-trifluoromethylbenzyloxy)-nitrobenzene 22% yield. MS: 296.1 (M-1)
EXAMPLE 313 4-(4-tert-butylphenoxy)nitrobenzene
Sodium hydride [0.16 g (50% in mineral oil), 3.33 mmol} was added to a solutiors of 4- tert- butyiphenol (0.5 g, 3.33 mmol) in § ml dimethylformamide at room temperature. After 15 min 1-chloro-4-nitrobenzene (0.262 g, 1.66 mmol) was added and the reaction mnixture was ’ heated at 80 °C overnight. The reaction mixture was cooled to room temperature and diluted with 50 mi ethyl acetate. The ethyl acetate solution was washed sequentially with 3
X 40 ml water and 40 ml brine, dried (anhydrous sodium sulfate) and concentrated under reduced pressure. The crude product (0.9 g) was purified by flash column chrornatography (15 g silica gel), eluting with 98:2 hexane/ethyl acetate to yield the title compound as a yellowish solid (0.499 g, quantitative yield). "H NMR (400 MHz, CD;Cl): 81.35 (s, 9H), 7.0 (d, 2H), 7.43 (d, 2H), 8.19 (d, 2H).
EXAMPLE 314 _4-(3.5-Dimethyl-benzylsulfanyl)-phenylamine
A mixture of 4-(3,5-dimethyl-benzylsutfany!)-nitrobenzene (0.35 g, 1.28 mmol) calcium chloride (0.071 g, 0.64 mmol) and iron powder (-325 mesh) (0.573 g, 10.3 mmol) in 4 mi water and 17 ml! ethanol was heated at reflux under nitrogen for 4.5 h. The reaction mixture was then cooled to room temperature, filtered through Celite a nd the filtrate was concentrated under reduced pressure. The residual oil was purified by column chromatography, eluting with 9:1 hexane/ethyl acetate fo yield the title compound as a veilowish oil (0.29 g, 91% yield). MS: 244.3 (M+1)
The title compounds of EXAMPLE 315-327 were prepared using procedures analogous to that of EXAMPLE 314 from appropriate starting materials.
EXAMPLE 315 4-(4-Butoxy-benzvisulfanyl}-phenylamine 80% yield. 'H NMR (400 MHz, CDCI): 50.96 (m, 3H), 1.4-1.52 (c, 2H), 1.7-1.8 (c, 2H), 16 3.85-3.96 (m, 4H), 6.57 (d, 2H), 6.77 (d, 2H), 7.07 (d, 2H), 7.13 (d, 2H).
EL LR
MS: 252.2 (M+1) . 84% yield. 318 4-(4-Trifluoromethylsuifanyl-benzylsulfanyl)-phenytamine
MS: 316.1 (M+1)
MS: 228.3 (M+1)
MS: 244.2 (M+1)
MS: 267.3 (M+1)
MS: 295.3 (M+1)
MS (279.3 (M+1) phenylamine MS: 381.2 (M+1) 205 4-(2-{2-(4-Trifluoromethyl-phenyl)-thiazol-4-yl}-ethoxy}- 70% yield. phenylamine MS:365.2 (M+1)
; ] 80% yield. 326 | 4-(4-tert-Butyl-phenoxy)-phenylamine MS: 242.4 (M+1) 77% yield.
EXAMPLE 328 4'-Triflucromethoxy-biphenyl-4-ylamine
A mixture of 4-trifluoromethoxylbenzeneboronic acid (300 mg, 1.45 mmol), p-bromoaniline {100 mg, 0.58 mmol), dichiorof1,1 "_bis(diphenylphosphino)ferrocene]palladium(ll) dichloromethane adduct (24 mg,0.029 mmol), 1,1"-bis(diphenylphosphino)ferrocene (16 mg, 0.029 mmol) and potassium carbonate (0.58mi of a 2M aqueous solution, 1.16 mmol) in 5 ml 1,4-dioxane was heated at reflux under nitrogen for 20 hr. The reaction mixture was cooled to room temperature, diluted with 40 mi water and extracted with 2 X 40 ml ethyl acetate. The combined ethyl acetate extracts were washed with 40 ml brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 15 g), eluting with 10:1 hexane/ethyi acetate to yield the title compound as a tan solid (70 mg, 48% yield). MS: 254.1 (M+1) 156 EXAMPLE 329 2-Cyclohexyl-5-{4-nitro-phenvi)-{1.3.4loxadiazole
A mixture of 5-(4-nitro-phenyl)-1H-tetrazole (0.5 g, 2.62 mmol) and cyclohexane carbonyl } chloride (0.35 ml, 2.62 mmol) in 3 ml anhydrous pyridine was stirred at room temperature under nitrogen for 20 min, then heated to 60° C for 1 hr and finally heated to 100° C for 2 h.
The reaction mixture was cooled to room temperature then poured onto ice (30 g) and the aqueous mixture was extracted with 30 mi ethyl acetate. The ethyl acetate solution was washed sequentially with 30 ml water, 30 ml 1N aqueous hydrochloric acid solution and 30 mi brine, dried (anhydrous sodium sulfate) and concentrated under reduced pressure. The crude produce was purified by flash column chromatography (silica gel, 40 g), eluting with 4:1 hexane/ethyl acetate to yield the title compound as a yellowish solid (0.5 g, 100% yield).
MS: 274.2 (M+1)
EXAMPLE 330 4-Nitro-4'propoxybiphenyl
To a solution of 4-hydroxy-4'nitrobiphenyl in 5 mi acetone was added potassium carbonate (240 mg, 1.74 mmol) and 1-lodopropane (0.17 ml, 1.74 mmol). The reaction mixture was heated at reflux for 24 h. Additional potassium carbonate (240 mg, 1.74 mmol) and 1- iodopropane (0.17 mi, 1.74 mmol) was added and the reaction mixture was heated at reflux for 24 h. The reaction mixture was cooled to room temperature and diluted with 30 ml ethyl acetate. The ethyl acetate solution was washed sequentially with 25 mi water and 25 mt brine, dried (anhydrous sodium sulfate) and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel), eluting with 14:1 hexane/ethyl acetate to yield the title compound (0.267 g, 89% yield) MS: 258.3 (M-1)
EXAMPLE 331 2-(4-tert-Butyl-phenyl)-5-nitro-benzooxazole 4-tert-Butyl-N-(2-hydroxy-5-nitro-phenyl}-benzamide 4-Dimethylaminopyridine (2.62 g, 21.4 mmol) was added portionwise with stirring to a solution of 4-tert-butylbenzoy! chloride (3.8 ml, 19.5 mmol) and 2-amino-4-nitrophenol (3.0 g, 19.5 mmol) in 60 mi methylene chloride. The resulting solution was stirred overnight at room temperature. The reaction solution was diluted with 60 mi methylene chloride and washed with 3 X 50 ml water. The methylene chloride solution was separated, filtered to remove precipitated solid, dried (anhydrous sodium sulfate) and concentrated to dryness under reduced pressure to yield the title compound as a brownish solid (5.01 g, 82% yield). 2-{4-tert-Butyl-phenyl)-5-nitro-benzooxazole
Diethyl azodicarboxylate (0.275 mi, 1.75 mmol) was added dropwise with stirring to a solution of 4-tert-butyl-N-(2-hydroxy-5-nitro-phenyl)-benzamide (0.5 g, 1.59 mmol) and triphenylphosphine (0.458 g, 1.75 mmol) in 15 ml anhydrous tetrahydrofuran. The reaction mixture was stirred overnight at room temperature, then diluted with 75 mi ethyl acetate.
The ethyl acetate solution was washed sequentially with 50 ml water and 50 ml! brine, dried (anhydrous sodium sulfate) and concentrated to dryness under reduced pressure. The residue was purified by flash column chromatography (40 g silica gel), eluting with 9:1 hexane/ethyl acetate to yield a yellowish solid (0.305 g), which was further purified by column chromatography (15 g silica gel), eluting with 95:5 hexane/ethyl acetate, to yield the title compound as a yellowish solid (0.125 g, 27% yield). MS: 297.3 (M+1)
The title compounds of EXAMPLE 332-333 were prepared using procedures analogous to that of EXAMPLE 331 from appropriate starting materials.
EXAMPLE 332 2-(4-Trifluoromethoxy-phenyi}-5-nitro-benzooxazole 4-Trifluoromethoxy-N-(2-hydroxy-5-nitro-phenyt}-benzamide 100 % yield 2-{4-Trifluoromethoxy-phenvyl}-5-nitro-benzooxazole 66% yield. MS: 325.2 (M+1)
EXAMPLE 333 2-(4-Trifluoromethoxy-phenyl}-5-nitro-benzooxazole 40 4 Triflucromethyl-N-{2-hydroxy-5-nitro-phenyl}-benzamide
83% vield 2:(4-Trifluoromethyi-phenvi)-5-nitro-benzooxazole 93% yield. MS: 309.3 (M+1).
EXAMPLE 334 5-Chiorosulfonyi-2-methyl-benzoic acid
A mixture of o-toluic acid (15 g, 0.11 mol) and chlorosulfonic acid (30 ml) was heated at 100 °C under nitrogen for 2.5 h. The reaction mixture was then poured onto ice (500 ml) and the resuiting precipitate was filtered, yielding the title compound as an off-white solid (20 g, 78% yield). MP 151-1865 °C.
The titie compounds of EXAMPLE 335-337 were prepared using a procedure analogous to that of EXAMPLE 334 from appropriate starting materials.
EXAMPLE 335 3-Chlorosulfonyi-2,6-dimethyl-benzoic acid 28% yield. 'H NMR (400 MHz, CD,0D) § 2.44 (s, 3H), 2.72 (s, 3H), 7.41 (d, 1H), 8.02 (d, 1H),
EXAMPLE 336 5-Chlorosulfonyl-2,3-dimethyi-benzoic acid 77% yield. 'H NMR (400 MHz, CDCls) § 2.49 (s, 3H), 2.66 (s, 3H), 7.98 (s, 1H), 8.47 (s, 1H).
EXAMPLE 337 5-Chiorosulfonyi-2-ethvl-benzoic acid 76% yield. MS: 247.0 (M-1).
EXAMPLE 338 5-Chlorosulfonyl-2-methyi-benzoic acid methyl ester
Chlorosulfonic acid (106.2 ml) was carefully added over 1 min with stirring under nitrogen to 2-methyl-benzoic acid methyl ester (55.9 ml, 0.4 mol). The reaction mixture was placed in an oil bath preheated to 100 °C for 15 min, then poured onto ice (1000 mi). The resulting precipitate was filtered and dissolved in ethyl acetate (400 ml). The ethyl acetate solution was washed sequentially with 10X 300 ml saturated aqueous sodium bicarbonate, 30 0 ml water and 300 mi brine, dried (anhydrous sodium sulfate) and concentrated under reduced pressure to yield the title compound as a yellowish oil (37.3 g, 37% yield). 'H NMR (4-00
MHz, CDCI3) §, 2.74 (s, 3H), 3.96 (s, 3H), 7.52 (d, 1H), 8.04 (m, 1H), 8.58 (d, 1H).
The title compounds of EXAMPLE 339-343 were prepared using procedures analogous to that of EXAMPLE 338 from appropriate starting materials. 25
EXAMPLE 339 5-Chiorosulfonyi-2-ethyl-benzoic acid methyl ester
42% yield. "H NMR (400 MHz, CDCly) § 1.29 (t, 3H), 3.11 (a, 2H), 3.96 (s, 3H), 7.54 (d, 1H), 8.06 (m, 1H), 8.53 (d, 1H).
EXAMPLE 340 5-Chiorosutfonyi-2-isopropyl-benzoic acid methyl ester 47% yield. 'H NMR (400 MHz, CDCl;)5 1.3 (d, 6H), 3.87 (m, 1H), 3.96 (s, 3H), 7.67 (d, 1H), 8.08 (m, 1H), 8.41 (d, 1H).
EXAMPLE 341_5-Chlorosuifonyl-2,3-dimethyl-benzoic acid methyl ester 41% yield. 'H NMR (400 MHz, CDCly) § 2.45 (s, 3H), 2.58 (s, 3H), 3.95 (s, 3H), 7.92 (d, 1H), 8.31 (d, 1H).
EXAMPLE 342 5-Chlorosutfonyi-2-ethoxy-benzoic acid ethyl ester 10% yield. 1H NMR (400 MHz, CDCI3) d 1.43 (t, 3H), 1.52 (t, 3H), 4.24 (a, 2H), 4.40 (q, 2H), 7.10 (d, 1H), 8.09 (m, 1H), 8.43 (d, 1H). 18 y
EXAMPLE 343 5-Chiorosuifonyl-2-methyisulfanyl-benzoic acid methyl ester 58% yield. 1H NMR (400 MHz, CDCI3) d 2.55 (s, 3H), 3.98 (s, 3H), 7.47 (d, 1H), 8.05 (m, 1H), 8.64 (d, 1H).
Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application for all purposes. it will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. Itis intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
Claims (1)
- What is claimed is:1. A compound having a Formula Hae (J)g——ArP—B—Ar'——— N——5§ \ Pi I X Formula or a pharmaceutically acceptable salt of said compound, wherein Q is carbon; each R'is independently hydrogen, halo, (C+-Cs)alkyl optionally substituted with one or more halo or with (C,-Cs)alkoxy, (C,-Cs)alkoxy optionally substituted with one to eleven halo, (C,-Cs)alkyithio optionally substituted with one or more halo, or R' in conjunction with the two adjacent carbon atoms forms a Cs-Cs fused fully saturated, partially unsaturated or fully unsaturated carbocyclic ring wherein each carbon in the carbon chain may optionally be replaced with one heteroatom selected from oxygen and sulfur; R? is hydrogen or (C1-Cs)alkyl optionally substituted with C,-Cs alkoxy; X is -COOR*; R*is H, (Cs-Cy)alkyl; benzyl or p-nitrobenzyl; Ar' is phenyl or phenyl fused to either oxazolyl or thiazolyl;; wherein Ar' is optionally mono- or di-substituted: independently with: halo, (C,-Cj)alkyl optionally substituted with one to nine halo, ef (C4-Cs)alkoxy optionally substituted with one to nine halo, or (C,-Cs)alkylthio optionally substituted with one to nine halo; Bis a bond, -L-(CY2),- or -(CYz).-L-, and Lis O or S, each Y is independently hydrogen or (C,-C5) alkyl, and nis 0, 1 or 2; Ar is phenyl or phenyl fused to a ring selected from the group consisting of: phenyl, pyridinyl, thienyl, thiazolyl, oxazoly!, and imidazolyl; each J is independently hydrogen, hydroxy, halo, (C,-Cg)alkyl optionally substituted with one to eleven halo. (C,-Cg)alkoxy optionally substituted with one to eleven halo, (C,-Cg)alkylthio optionally substituted with one to eleven halo, (Cs- C;)cycloalkyl, (C3-C)cycloalkoxy, (C5-Cr)cycloalkylthio. or phenyl optionally substituted 138 AMCNDED SHEET with one to four substituents from the group consisting of: halo, (C,-C,)alkyl optionally substituted with one to five halo, (C.-Cs)alkoxy optionally substituted with one to five halo, and (C;-C;)alkylthio optionally substituted with one to five halo; p and q are each independently 0, 1, 2 or 3: and with the provisos: d) if Ar' is phenyl, Bis a bond, Ar? is a bond or phenyl, and X is <COOH then q is other than 0 and J is other than hydrogen, halo, (C4-Cg)alkyl or unsubstituted phenyl; e) if Ar' is phenyl, Bis not a bond, Ar? is phenyl and X is -COOR® then B is attached to Ar' para to NR? and f) ifBisO, S, SO, NH, CO, CH, or SO, then R' is not H.2. A compound according to claim 1, wherein N HO HOO HOO HC, Aris : N , or ; and N N Sha “CH =3t i ~~ J Aris — As 7 : , or ° $ (e— ++3. A compound according to claim 2, wherein gis 1or2and each Jis independently halo, (C,-C;)alkyl optionally substituted with one to three halo, or (C;- Cs)alkoxy optionally substituted with one to three halo. 4, A compound according to claim 3 wherein pis 1 and R*is H or (C;- Cj)alkyl.5. A compound according to any of claims 1-4, wherein L is S,nis 1, and halo is fluoro. 139 AMUNOEU SHEET11. A free acid compound of a compound having the following structure OH 0 fo] XN / Xx 8 S NH or a pharmaceutically acceptable salt of the compound.12. A pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 11 or 16, further comprising a pharmaceutically acceptable carrier, vehicle or diluent. 141 AMLNDEU SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55211404P | 2004-03-10 | 2004-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200606597B true ZA200606597B (en) | 2007-10-31 |
Family
ID=37859499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200606597A ZA200606597B (en) | 2004-03-10 | 2006-08-08 | Substituted heteroaryl-and phenylsulfamoyl compounds |
Country Status (5)
Country | Link |
---|---|
CN (1) | CN1930121A (en) |
CR (1) | CR8567A (en) |
GT (1) | GT200500042A (en) |
TN (1) | TNSN06269A1 (en) |
ZA (1) | ZA200606597B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109384694B (en) * | 2017-08-10 | 2022-04-05 | 上海爱乐维生物科技有限公司 | SIRT6 small-molecule agonist and application thereof |
US20220220069A1 (en) * | 2017-08-10 | 2022-07-14 | Shanghai Jiaotong University School Of Medicine | Compound used as sirt6 small-molecule allosteric activator and pharmaceutical composition thereof |
-
2005
- 2005-02-28 CN CN 200580007622 patent/CN1930121A/en active Pending
- 2005-03-09 GT GT200500042A patent/GT200500042A/en unknown
-
2006
- 2006-08-08 ZA ZA200606597A patent/ZA200606597B/en unknown
- 2006-08-24 CR CR8567A patent/CR8567A/en not_active Application Discontinuation
- 2006-09-08 TN TNP2006000269A patent/TNSN06269A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CR8567A (en) | 2006-10-17 |
TNSN06269A1 (en) | 2007-12-03 |
CN1930121A (en) | 2007-03-14 |
GT200500042A (en) | 2005-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005225628B2 (en) | Substituted heteroaryl- and phenylsulfamoyl compounds | |
US20060229363A1 (en) | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | |
US6699904B2 (en) | PPAR agonists | |
CA2918365C (en) | Sulfonamides as modulators of sodium channels | |
US20070088027A1 (en) | Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient | |
JP2006515838A (en) | Farnesoid X receptor agonist | |
US20060100460A1 (en) | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | |
KR20040022238A (en) | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | |
MX2007006137A (en) | Dibenzyl amine compounds and derivatives. | |
MX2007002391A (en) | 4-aminomethyl benzamidine derivatives and their use as factor viiia inhibitors. | |
US20050075377A1 (en) | PPAR compounds | |
JP4488732B2 (en) | Benzoxazole compound and pharmaceutical composition containing the same | |
WO2002020462A1 (en) | Benzoic acid derivatives and drugs containing the same as the active ingredient | |
WO2007091140A1 (en) | Substituted phenylsulfamoyl compounds as ppar agonists | |
KR20070045346A (en) | 4-amino-substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds | |
ZA200606597B (en) | Substituted heteroaryl-and phenylsulfamoyl compounds | |
TW200918509A (en) | Pharmaceutical compounds and derivatives | |
SG176418A1 (en) | Dibenzyl amine compounds and derivatives | |
MXPA06010261A (en) | Substituted heteroaryl- and phenylsulfamoyl compounds | |
WO2009136375A1 (en) | Treatment of interstitial cystitis | |
JP2007314534A (en) | Salt suitable for medicine and animal drug |